<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">94755</article-id><article-id pub-id-type="doi">10.7554/eLife.94755</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.94755.3</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group></article-categories><title-group><article-title>Impact of protein and small molecule interactions on kinase conformations</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Kugler</surname><given-names>Valentina</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0001-1238-9530</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Schwaighofer</surname><given-names>Selina</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0001-3273-7715</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Feichtner</surname><given-names>Andreas</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Enzler</surname><given-names>Florian</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Fleischmann</surname><given-names>Jakob</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Strich</surname><given-names>Sophie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Schwarz</surname><given-names>Sarah</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Wilson</surname><given-names>Rebecca</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Tschaikner</surname><given-names>Philipp</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Troppmair</surname><given-names>Jakob</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Sexl</surname><given-names>Veronika</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Meier</surname><given-names>Pascal</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2760-6523</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Kaserer</surname><given-names>Teresa</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0372-1885</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Stefan</surname><given-names>Eduard</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3650-4713</contrib-id><email>Eduard.Stefan@uibk.ac.at</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/054pv6659</institution-id><institution>Institute for Molecular Biology and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck</institution></institution-wrap><addr-line><named-content content-type="city">Innsbruck</named-content></addr-line><country>Austria</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/016sds817</institution-id><institution>Tyrolean Cancer Research Institute (TKFI)</institution></institution-wrap><addr-line><named-content content-type="city">Innsbruck</named-content></addr-line><country>Austria</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/054pv6659</institution-id><institution>Daniel Swarovski Research Laboratory, Department of Visceral, Transplant and Thoracic Surgery, Medical University of Innsbruck</institution></institution-wrap><addr-line><named-content content-type="city">Innsbruck</named-content></addr-line><country>Austria</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043jzw605</institution-id><institution>The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research</institution></institution-wrap><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff5"><label>5</label><institution>KinCon biolabs GmbH</institution><addr-line><named-content content-type="city">Innsbruck</named-content></addr-line><country>Austria</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/054pv6659</institution-id><institution>University of Innsbruck</institution></institution-wrap><addr-line><named-content content-type="city">Innsbruck</named-content></addr-line><country>Austria</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/054pv6659</institution-id><institution>Institute of Pharmacy/Pharmaceutical Chemistry and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck</institution></institution-wrap><addr-line><named-content content-type="city">Innsbruck</named-content></addr-line><country>Austria</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Dötsch</surname><given-names>Volker</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04cvxnb49</institution-id><institution>Goethe University</institution></institution-wrap><country>Germany</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Dötsch</surname><given-names>Volker</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04cvxnb49</institution-id><institution>Goethe University</institution></institution-wrap><country>Germany</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>01</day><month>08</month><year>2024</year></pub-date><volume>13</volume><elocation-id>RP94755</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2023-12-04"><day>04</day><month>12</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-01-18"><day>18</day><month>01</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.01.11.575270"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-02-20"><day>20</day><month>02</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.94755.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-06-19"><day>19</day><month>06</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.94755.2"/></event></pub-history><permissions><copyright-statement>© 2024, Kugler, Schwaighofer et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Kugler, Schwaighofer et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-94755-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-94755-figures-v1.pdf"/><abstract><p>Protein kinases act as central molecular switches in the control of cellular functions. Alterations in the regulation and function of protein kinases may provoke diseases including cancer. In this study we investigate the conformational states of such disease-associated kinases using the high sensitivity of the kinase conformation (KinCon) reporter system. We first track BRAF kinase activity conformational changes upon melanoma drug binding. Second, we also use the KinCon reporter technology to examine the impact of regulatory protein interactions on LKB1 kinase tumor suppressor functions. Third, we explore the conformational dynamics of RIP kinases in response to TNF pathway activation and small molecule interactions. Finally, we show that CDK4/6 interactions with regulatory proteins alter conformations which remain unaffected in the presence of clinically applied inhibitors. Apart from its predictive value, the KinCon technology helps to identify cellular factors that impact drug efficacies. The understanding of the structural dynamics of full-length protein kinases when interacting with small molecule inhibitors or regulatory proteins is crucial for designing more effective therapeutic strategies.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>kinase conformation</kwd><kwd>target engagement</kwd><kwd>drug interactions</kwd><kwd>kinase scaffolding function</kwd><kwd>kinase complex formation</kwd><kwd>cell-based reporter assay</kwd><kwd>pseudo enzymes</kwd><kwd>hard-to-target enzymes</kwd><kwd>enzyme reactivation</kwd><kwd>dark kinome</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>None</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100012163</institution-id><institution>Universität Innsbruck</institution></institution-wrap></funding-source><award-id>WS104004</award-id><principal-award-recipient><name><surname>Schwaighofer</surname><given-names>Selina</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100012163</institution-id><institution>Universität Innsbruck</institution></institution-wrap></funding-source><award-id>WS104005</award-id><principal-award-recipient><name><surname>Fleischmann</surname><given-names>Jakob</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010661</institution-id><institution>Horizon 2020 Framework Programme</institution></institution-wrap></funding-source><award-id>cONCReTE (872391)</award-id><principal-award-recipient><name><surname>Stefan</surname><given-names>Eduard</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002428</institution-id><institution>Austrian Science Fund</institution></institution-wrap></funding-source><award-id award-id-type="doi">10.55776/P30441</award-id><principal-award-recipient><name><surname>Stefan</surname><given-names>Eduard</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002428</institution-id><institution>Austrian Science Fund</institution></institution-wrap></funding-source><award-id award-id-type="doi">10.55776/P32960</award-id><principal-award-recipient><name><surname>Stefan</surname><given-names>Eduard</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002428</institution-id><institution>Austrian Science Fund</institution></institution-wrap></funding-source><award-id award-id-type="doi">10.55776/P35159</award-id><principal-award-recipient><name><surname>Stefan</surname><given-names>Eduard</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002428</institution-id><institution>Austrian Science Fund</institution></institution-wrap></funding-source><award-id award-id-type="doi">10.55776/I5406</award-id><principal-award-recipient><name><surname>Stefan</surname><given-names>Eduard</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004955</institution-id><institution>Österreichische Forschungsförderungsgesellschaft</institution></institution-wrap></funding-source><award-id>877163</award-id><principal-award-recipient><name><surname>Stefan</surname><given-names>Eduard</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Kinase conformation reporters reveal how protein kinase activity conformations are influenced by regulatory protein interactions, patient mutations, and cellular drug binding, aiding in systematically anticipating treatment efficacy and designing patient-tailored therapies.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The human kinome is encoded by more than 500 genes which lead to the synthesis of functionally diverse kinases. Kinases are different in their domain composition but all contain a structurally conserved phosphotransferase domain (<xref ref-type="bibr" rid="bib73">Manning, 2009</xref>, <xref ref-type="bibr" rid="bib56">Kornev and Taylor, 2010</xref>). Conventionally, protein kinases function as enzymes that enable the transfer of a phosphate group from ATP to defined amino acids of a target protein. Protein kinases regulate various aspects of cellular functions including cell survival, apoptosis, cell division, and metabolism via reversible and tightly regulated phosphorylations (<xref ref-type="fig" rid="fig1">Figure 1A</xref>; <xref ref-type="bibr" rid="bib8">Bhullar et al., 2018</xref>, <xref ref-type="bibr" rid="bib9">Blume-Jensen and Hunter, 2001</xref>, <xref ref-type="bibr" rid="bib72">Manning et al., 2002</xref>). In addition to kinase phosphotransferase activities, kinase domains display scaffolding functions (<xref ref-type="bibr" rid="bib117">Shrestha et al., 2020</xref>, <xref ref-type="bibr" rid="bib103">Reiterer et al., 2014</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Kinase regulation and kinase conformation (KinCon) reporter technology features.</title><p>(<bold>A</bold>) Impact of indicated factors/features (e.g. protein-protein interactions [PPIs], post-translational modifications [PTM], cis-regulatory elements [CRE]) on the switch-like behavior of kinases. (<bold>B</bold>) Schematic representation of the KinCon reporter technology using the <italic>Renilla</italic> luciferase (<italic>R</italic>Luc) protein-fragment complementation assay (PCA) as it applies to kinases such as BRAF which contain auto-inhibitory modules (AIM); <italic>R</italic>Luc fragments 1 and 2 are N and C terminally fused to the kinase of interest (with interjacent linker in red) and are labeled with F[1] and F[2]. PPIs, drug (candidate) or small molecule binding, mutations and/or PTMs may convert the KinCon reporter into different conformation states. Protein movements are quantified through measuring alterations of bioluminescence signals upon <italic>R</italic>Luc substrate addition. (<bold>C</bold>) Shown is the workflow for the KinCon reporter construct engineering and analyses using KinCon technology. The kinase gene of interest is inserted into the multiple cloning site of a mammalian expression vector which is flanked by respective PCA fragments (F[1]-, -F[2]; KD, kinase domain) and separated with interjacent flexible linkers. Expression of the genetically encoded reporter in indicated multi-well formats allows to vary expression levels and define a coherent drug treatment plan. Moreover, it is possible to alter the kinase sequence (mutations) or to co-express or knock down the respective endogenous kinase, interlinked kinases, or proteinogenic regulators of the respective pathway. After systematic administration of pathway modulating drugs or drug candidates, analyses of KinCon structure dynamics may reveal alterations in potency, efficacy, and potential synergistic effects of the tested bioactive small molecules (schematic dose-response curves are depicted). (<bold>D</bold>) Simplfied schematic representation of the activation mechanisms of BRAF, LKB1, RIPK1, and CDK6 complexes (with indication of selected regulators or complex components) engaged in altering OFF (top) or ON (bottom) kinase states. (<bold>E</bold>) Representative KinCon experiments of time-dependent expressions of indicated KinCon reporter constructs in HEK293T cells are shown (mean ± SEM). Indicated KinCon reporters were transiently over-expressed in 24-well format in HEK293T cells for 10 hr, 16 hr, 24 hr, and 48 hr each. Immunoblotting show expression levels of endogenous kinases and over-expressed KinCon reporters. (<bold>F</bold>) Impact of 1 μM PLX8394 exposure (for 1 hr) on BRAF and BRAF-V600E KinCon reporters (HEK293T cells) is shown. Representative experiment of n=4 independent is presented. (<bold>G</bold>) <italic>R</italic>Luc PCA values have been normalized on the untreated conditions. The mean ± SEM of PLX8394 exposure on BRAF conformation opening and closing of n=4 experiments is shown. RLU, relative light units. Statistical significance for G: one-sample t-test (*p&lt;0.05, **p&lt;0.01, ***p&lt;0.001).</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Raw unedited western blots shown in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-94755-fig1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>Uncropped and labelled western blots shown in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-94755-fig1-data2-v1.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-94755-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Time-dependent kinase conformation (KinCon) expression.</title><p>(<bold>A</bold>) Summary of n=4 independent experiments of time-dependent expressions of indicated KinCon reporter constructs in HEK293T cells is shown (mean ± SEM). BRAF-V600E, LKB1, RIPK1, and CDK6 KinCon reporters were transiently over-expressed in 24-well format in HEK293T cells for 10 hr, 16 hr, 24 hr, and 48 hr each. (<bold>B</bold>) Impact of 1 μM PLX8394 exposure for 1 hr on BRAF and BRAF-V600E KinCon reporters transiently over-expressed for indicated time frames in HEK293T cells is shown. Mean of n=4 independent experiments with ± SEM is presented.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-94755-fig1-figsupp1-v1.tif"/></fig></fig-group><p>On the cellular level, kinases act as molecular switches, adopting conformational states that align with an active (ON) or inactive (OFF) kinase state (<xref ref-type="bibr" rid="bib43">Huse and Kuriyan, 2002</xref>, <xref ref-type="bibr" rid="bib139">Yamaguchi and Hendrickson, 1996</xref>, <xref ref-type="bibr" rid="bib70">Lopez et al., 2020</xref>, <xref ref-type="bibr" rid="bib33">Feichtner et al., 2022</xref>). These ON and OFF states of protein kinases signify a switch-like behavior which is governed by a collection of molecular mechanisms (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Kinases integrate, amplify and relay a wide variety of input signals, underscoring their pivotal role in numerous signaling pathways that often involve interconnected kinase regulation. Thus, one kinase directly modulates the activity level and role of the subsequent kinase in a cascade-like structure (<xref ref-type="bibr" rid="bib42">Guo et al., 2020</xref>, <xref ref-type="bibr" rid="bib4">Avruch et al., 2001</xref>). This regulation is facilitated by the formation of multi-protein complexes to spatiotemporally control and amplify signal transmission (<xref ref-type="bibr" rid="bib80">Morrison, 2001</xref>, <xref ref-type="bibr" rid="bib95">Pouysségur et al., 2002</xref>). <xref ref-type="fig" rid="fig1">Figure 1A</xref> highlights several factors affecting kinase functions. Selected modes of kinase regulation which are of relevance for the presented study are listed below.</p><p>First, the activity of a kinase can be altered by post-translational modifications (PTMs) of selected amino acids. PTMs alter kinase characteristics like its activity status, its location within the cell, rate of degradation, and its associations with other proteins (<xref ref-type="bibr" rid="bib19">Chou, 2020</xref>, <xref ref-type="bibr" rid="bib23">Cohen, 2000</xref>, <xref ref-type="bibr" rid="bib27">Deribe et al., 2010</xref>).</p><p>Second, the scaffolding functions of kinase domains accompany the process of phosphotransferase reactions. These play central roles in the activation and deactivation process of interacting kinase protomers. This feature is key for pseudokinase activities, for relaying signaling inputs without catalytic functions (<xref ref-type="bibr" rid="bib133">Weinlich and Green, 2014</xref>, <xref ref-type="bibr" rid="bib81">Morrison and Davis, 2003</xref>, <xref ref-type="bibr" rid="bib13">Boudeau et al., 2006</xref>).</p><p>Third, kinase functions depend on decisive regulatory protein interactions or movements for which several modes of regulation have been described. Intramolecular auto-inhibitory modules (AIMs) alter kinase activity states by reducing the accessibility of the substrate protein for the subsequent kiss-and-run phosphotransferase reaction (<xref ref-type="bibr" rid="bib75">Mayrhofer et al., 2020</xref>, <xref ref-type="bibr" rid="bib96">Pufall and Graves, 2002</xref>, <xref ref-type="bibr" rid="bib136">Xu et al., 2002</xref>). In some cases, kinase domain activities are controlled through inter- or intramolecular interactions with substrate-like sequences. Pseudo-substrate stretches bind to the catalytic cleft of the kinase and hinder the phosphorylation of the substrate. This binding to the catalytic site is altered in response to input signals and manifested in kinase conformational changes, which in turn coordinate protein kinase activation cycles (<xref ref-type="bibr" rid="bib112">Schmitt et al., 2022</xref>, <xref ref-type="bibr" rid="bib50">Kemp et al., 1994</xref>). Besides intramolecular inhibition both activating and inactivating regulatory protein interactions exist and have been described for prototypical kinases such as PKA and CDKs (<xref ref-type="bibr" rid="bib11">Boudeau et al., 2003</xref>, <xref ref-type="bibr" rid="bib124">Taylor et al., 2005</xref>).</p><p>Fourth, kinase regulation is strongly dependent on the expression pattern and how the protein is stabilized in regard to the cell fate within the respective cell system or compartment (<xref ref-type="bibr" rid="bib14">Capra et al., 2006</xref>).</p><p>Fifth, regulatory protein interactions of kinases depend on small molecule interactions. Besides different types of second messengers (e.g. Ca<sup>2+</sup>, IP3, cAMP) (<xref ref-type="bibr" rid="bib87">Newton et al., 2016</xref>, <xref ref-type="bibr" rid="bib48">Kasai and Petersen, 1994</xref>) a collection of metabolites and ions contribute in orchestrating cellular kinase functions (<xref ref-type="bibr" rid="bib102">Ramms et al., 2021</xref>).</p><p>Alterations of the ON and OFF states of kinases are also pertinent to kinase-related disorders. Deregulation of kinase functions is associated with the development of numerous diseases, such as cancer, inflammatory, infectious, and degenerative conditions (<xref ref-type="bibr" rid="bib116">Shchemelinin et al., 2006</xref>, <xref ref-type="bibr" rid="bib57">Köstler and Zielinski, 2015</xref>, <xref ref-type="bibr" rid="bib34">Ferguson and Gray, 2018</xref>). Kinase malfunctions result from gene mutations, deletions, fusions, or increased or aberrant expressions. These mechanisms result in gain or loss of function of the involved kinase pathways, thus driving disease etiology and progression (<xref ref-type="bibr" rid="bib88">Ochoa et al., 2018</xref>, <xref ref-type="bibr" rid="bib129">Van et al., 2021</xref>, <xref ref-type="bibr" rid="bib21">Cicenas et al., 2018</xref>).</p><p>For this technical report, we have incorporated disease-relevant full-length phosphotransferases which exhibit different modes of regulation into the kinase conformation (KinCon) reporter system. The KinCon reporter platform is a <italic>Renilla</italic> luciferase (<italic>R</italic>Luc) based protein-fragment complementation assay, which is based on the fusion of two fragments of <italic>R</italic>Luc to the N and the C terminus of a full-length kinase. This reporter can be used to track dynamic changes of kinases conformations due to mutations, PTMs, protein:protein interactions (PPIs), or binding of bioactive small molecules. We discuss the KinCon reporter principle at the beginning of the Results section. The kinases listed below are characterized by distinctive modes of regulation, are viable targets for inhibition, or are difficult to assess directly through traditional biochemical measurements: the liver kinase B1 (LKB1, STK11), the receptor-interacting serine/threonine-protein kinase 1 (RIPK1), and the cyclin-dependent kinases 4 and 6 (CDK4/6).</p><p>LKB1 is active as trimeric cytoplasmic protein complex. It is the upstream regulator of the AMP-activated protein kinase (AMPK) (<xref ref-type="bibr" rid="bib105">Rodríguez et al., 2021</xref>). LKB1 promotes AMPK signaling by forming an heterotrimeric complex with the pseudokinase STE20-related adaptor alpha (STRADα) and the scaffolding protein Mouse protein-25 (MO25) through phosphorylation and thus activation of cytoplasmic AMPK (<xref ref-type="bibr" rid="bib12">Boudeau et al., 2004</xref>, <xref ref-type="bibr" rid="bib83">Narbonne et al., 2010</xref>). Mutations in LKB1 can lead to the autosomal dominant disease Peutz-Jeghers syndrome (PJS) (<xref ref-type="bibr" rid="bib77">Mehenni et al., 1998</xref>, <xref ref-type="bibr" rid="bib6">Beggs et al., 2010</xref>). Inactivating mutations of LKB1 are frequently observed in non-small-cell lung cancer (NSCLC), cervical carcinoma, and malignant melanoma (<xref ref-type="bibr" rid="bib134">Wingo et al., 2009</xref>, <xref ref-type="bibr" rid="bib84">Ndembe et al., 2022</xref>).</p><p>RIPK1 acts as a central stress sensor to control cell survival, inflammation, and cell death signaling (<xref ref-type="bibr" rid="bib22">Clucas and Meier, 2023</xref>). Deregulation of RIPK1- and RIPK3-involved signaling cascades have been linked to inflammatory bowel disease, rheumatoid arthritis, autoimmune conditions, and neuroinflammatory diseases such as Alzheimer’s and Parkinson’s disease (<xref ref-type="bibr" rid="bib74">Martens et al., 2020</xref>, <xref ref-type="bibr" rid="bib65">Li et al., 2019</xref>, <xref ref-type="bibr" rid="bib121">Speir et al., 2021</xref>, <xref ref-type="bibr" rid="bib22">Clucas and Meier, 2023</xref>). This is believed to be related to deregulations of both catalytic and kinase scaffolding functions. Thus, a collection of small molecule blockers has been identified to interfere with RIPK1 signaling and function. It’s intriguing to note that RIPK1 and RIPK3 may share a similar mechanism of action with BRAF, as their structural arrangements and the dimerization of their kinase domains bear resemblance (<xref ref-type="bibr" rid="bib101">Raju et al., 2018</xref>). In addition to this, auto-phosphorylation of RIPK1 and RIPK3 represents a central regulatory element, overall showing some similar molecular ties to BRAF (<xref ref-type="bibr" rid="bib62">Laurien et al., 2020</xref>).</p><p>Unlike the auto-inhibitory mechanisms of kinase regulation, some kinases dynamically engage with activating and deactivating polypeptides (<xref ref-type="bibr" rid="bib150">Zhang et al., 2021</xref>). One of the best studied examples is the interaction of regulatory proteins with the catalytic subunits of the cAMP-controlled serine/ threonine protein kinase A (PKA) (<xref ref-type="bibr" rid="bib125">Taylor et al., 2012</xref>, <xref ref-type="bibr" rid="bib149">Zhang et al., 2020</xref>). In a similar manner CDKs form active and inactive protein complexes to directly promote the cell cycle (<xref ref-type="bibr" rid="bib40">Goel et al., 2018</xref>). The central role of CDK4/6 lies in regulating cell cycle progression by phosphorylating and activating the key substrate retinoblastoma protein (Rb) that promotes G1 to S phase transition. On the molecular level this is controlled by complex formation of CDK4 and CDK6 with regulatory polypeptides (<xref ref-type="bibr" rid="bib46">James et al., 2008</xref>). Binding to p16<sup>INK4a</sup>, one of the most frequently mutated tumor suppressor proteins, blocks CDK4/6 functions (<xref ref-type="bibr" rid="bib99">Quelle et al., 1997</xref>). Cancer mutations in p16<sup>INK4a</sup> counteract this. As a result, kinase activating cyclinD proteins bind to CDK4/6 to promote carcinogenesis (<xref ref-type="bibr" rid="bib130">VanArsdale et al., 2015</xref>). Thus, CDK4/6 inhibitors (CDK4/6i) found the way into the clinic, in particular for treating breast cancer patients (<xref ref-type="bibr" rid="bib85">Nebenfuehr et al., 2020</xref>; <xref ref-type="bibr" rid="bib145">Yu et al., 2006</xref>). The development of drug resistance upon CDK4/6 inhibitor therapies underscores the need for personalized treatments that consider the patient’s genetic profile and the underlying alterations of CDK4/6 complexes present in their cancer cells (<xref ref-type="bibr" rid="bib2">Álvarez-Fernández and Malumbres, 2020</xref>, <xref ref-type="bibr" rid="bib53">Knudsen and Witkiewicz, 2017</xref>).</p><p>Various cellular mechanisms are employed to control the molecular switch-like behavior of protein kinases to temporally lock them into either an active or inactive conformation. These mechanisms include the PTMs of specific residues, the binding of regulatory proteins or co-factors, and allosteric changes induced by ligands (<xref ref-type="bibr" rid="bib8">Bhullar et al., 2018</xref>, <xref ref-type="bibr" rid="bib127">Taylor et al., 2021</xref>, <xref ref-type="bibr" rid="bib86">Newton, 2001</xref>). This precisely controlled mode of action can be hindered, among others by patient-specific mutations or modified by bioactive small molecules (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Conventional methods often fall short in capturing the dynamics of kinase phosphotransferase and scaffolding activities which occur in their native cellular environments (<xref ref-type="bibr" rid="bib52">Klaeger et al., 2017</xref>, <xref ref-type="bibr" rid="bib24">Croce et al., 2019</xref>). This underscores the importance of advanced biotechnology-centered strategies for a comprehensive understanding of drug target engagement and protein binding in the intact cell. Here, we show that genetically encoded KinCon reporters are extendable to many more kinases, to enable systematic monitoring of cellular kinase activity states in living cells. In addition to its predictive capabilities, the KinCon technology serves as a valuable tool for uncovering cellular factors influencing drug efficacy (<xref ref-type="bibr" rid="bib75">Mayrhofer et al., 2020</xref>, <xref ref-type="bibr" rid="bib37">Fleischmann et al., 2023</xref>, <xref ref-type="bibr" rid="bib104">Röck et al., 2019</xref>). Such insights into the molecular structure dynamics of kinases in intact cells upon interactions with small molecule inhibitors or regulatory proteins is necessary for the design of more effective therapeutic strategies.</p></sec><sec id="s2" sec-type="results"><title>Results</title><p>Kinases act as molecular switches to integrate, amplify, restrict, and/or relay signal propagation in spatiotemporal fashion and in cell-type-specific manner. The precise coordination of usually oscillating kinase activities is a prerequisite for proper signal transmission (<xref ref-type="bibr" rid="bib125">Taylor et al., 2012</xref>, <xref ref-type="bibr" rid="bib91">Pan and Heitman, 2002</xref>). When investigating pathological kinase functions for therapeutic purposes, it is crucial to take the cellular elements that influence kinase activities into account. In <xref ref-type="fig" rid="fig1">Figure 1A</xref> we list a collection of factors which affect kinase activity states. It is thus essential to closely monitor the physiological and pathophysiological kinase functions of activation and deactivation in intact cell settings in the presence and absence of patient mutation and drug exposure.</p><p>One cell-based technology for studying cellular kinase activity states is the KinCon reporter technology (<xref ref-type="bibr" rid="bib104">Röck et al., 2019</xref>, <xref ref-type="bibr" rid="bib75">Mayrhofer et al., 2020</xref>, <xref ref-type="bibr" rid="bib37">Fleischmann et al., 2023</xref>). It is a highly sensitive assay for tracking kinase activities which is mirrored by the alterations of full-length kinase structures in cells. With in silico predictions it was projected that more than 200 protein kinases of the human kinome contain cis-regulatory elements. In many cases these sequence stretches act as auto-inhibitory modules, so called AIMs (<xref ref-type="bibr" rid="bib75">Mayrhofer et al., 2020</xref>, <xref ref-type="bibr" rid="bib144">Yeon et al., 2016</xref>). In <xref ref-type="fig" rid="fig1">Figure 1B</xref> we depict exemplary how underlying kinase ON and OFF states can be tracked using KinCon reporter technology (<xref ref-type="bibr" rid="bib30">Enzler et al., 2020</xref>). The readout is based on the molecular motion of the full-length kinase containing diverse cis-regulatory elements / AIMs. Cell-type-specific KinCon measurement allows the testing of the influence of mutations, signaling pathway activation, binary protein interactions, and drug binding on the respective reporter reflecting conformational changes of full-length kinases. We have previously applied the technology to gain insights into the functioning of two kinases that belong to the MAPK pathway. In these proof-of-concept studies, we showed that BRAF and MEK1 KinCon reporters are direct real-time readouts for kinase activities in intact cell settings caused or altered by mutation and drug treatments (<xref ref-type="bibr" rid="bib104">Röck et al., 2019</xref>, <xref ref-type="bibr" rid="bib75">Mayrhofer et al., 2020</xref>, <xref ref-type="bibr" rid="bib36">Fleischmann et al., 2021</xref>, <xref ref-type="bibr" rid="bib37">Fleischmann et al., 2023</xref>).</p><p>The construction principle of the KinCon reporter is modular. For the generation of the genetically encoded KinCon reporter the sequence of the kinase of choice is inserted into the multiple cloning site (MCS) of a mammalian expression construct. The MCS is flanked by the coding regions of a split luminescent protein for cellular over-expression experiments of the encoded hybrid reporter protein (see the KinCon reporter protein domain structure at the top of <xref ref-type="fig" rid="fig1">Figure 1C</xref>). In many cases it is sufficient to fuse to the N and C terminus of the full-length kinase sequence the two fragments of the respective reporter protein (with intervening flexible linker stretches shown in red, <xref ref-type="fig" rid="fig1">Figure 1B and C</xref>).</p><p>In this study we used the protein-fragment complementation fragments (PCA, F[1]- and -F[2]) of the <italic>Renilla</italic> luciferase (<italic>R</italic>Luc-PCA) (<xref ref-type="bibr" rid="bib122">Stefan et al., 2007</xref>). The KinCon reporters are constructed to facilitate the intramolecular complementation of appended RLuc PCA fragments. Transient expression offers the flexibility to analyze different time frames for KinCon reporter expression and drug candidate exposures, in either low- or high-throughput format in intact cells (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Besides applying wild-type (wt) reporters it allows for the ‘personalization’ of the sensor setup by integrating patient-specific mutations, co-expressing regulatory proteins, or making systematic changes to PTM sites.</p><p>Following KinCon reporter expression along with co-expression of interacting molecules in the appropriate cell plate format, systematic perturbations can be applied. Following addition of the luciferase substrate to cells grown in a mono-layer or in suspension, cellular bioluminescence signals are emanating from complemented <italic>R</italic>Luc PCA fragments (<xref ref-type="fig" rid="fig1">Figure 1B and C</xref>; <xref ref-type="bibr" rid="bib104">Röck et al., 2019</xref>, <xref ref-type="bibr" rid="bib75">Mayrhofer et al., 2020</xref>). Light recordings and subsequent calculations of time-dependent dosage variations of bioluminescence signatures of parallel implemented KinCon reporter configurations aid in establishing dose-response curves. These curves are used for discerning pharmacological characteristics such as drug potency, effectiveness of drug candidates, and potential drug synergies (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). In order to enhance our understanding of kinase structure dynamics we selected a group of kinases which activities are altered in different pathological settings. These examples emphasize how mutations, PTMs, PPIs, or kinase drugs induce context-dependent effects on the conformation states of kinases. In <xref ref-type="fig" rid="fig1">Figure 1D</xref> we present a schematic and simplified depiction of the kinase’s ON and OFF conditions for complexes emanating from the kinases BRAF, LKB1, RIPK1, and CDK6. Exemplary, we show how protein complex formation and patient mutations contribute or perturb kinase activation cycles. As a starting point, we illustrated the high sensitivity of the reporter system for tracking basal activity conformations of the kinases BRAF-V600E, LKB1, RIPK1, and CDK6 respectively. We showed that transient over-expression of these KinCon reporters for a time frame of 10 hr, 16 hr, 24 hr, or 48 hr in HEK293T cells delivers consistently increasing signals for all KinCon reporters (<xref ref-type="fig" rid="fig1">Figure 1E</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). Immunoblotting of cell lysates following luminescence measurements showed expression levels of the reporters in the range and below the endogenous expressed kinases (<xref ref-type="fig" rid="fig1">Figure 1E</xref>).</p><p>Next, we analyzed the BRAF kinase activity conformations using wild type (wt) and mutated KinCon BRAF reporters. The V600E mutation, found primarily in melanoma patients, effectively immobilized the respective BRAF KinCon reporter in its opened and active conformation (<xref ref-type="bibr" rid="bib25">Davies et al., 2002</xref>, <xref ref-type="bibr" rid="bib63">Lavoie et al., 2020</xref>, <xref ref-type="bibr" rid="bib47">Karoulia et al., 2017</xref>, <xref ref-type="bibr" rid="bib68">Lito et al., 2013</xref>, <xref ref-type="bibr" rid="bib104">Röck et al., 2019</xref>). Previously we have shown that FDA-approved melanoma drugs (Vemurafenib, Encorafenib, Dabrafenib) and one drug candidate from clinical studies (PLX8394) converted the opened BRAF-V600E reporter back to the more closed and thus inactive conformation (<xref ref-type="bibr" rid="bib104">Röck et al., 2019</xref>, <xref ref-type="bibr" rid="bib75">Mayrhofer et al., 2020</xref>, <xref ref-type="bibr" rid="bib142">Yao et al., 2019</xref>). Using this readout, we showed that at expression levels of the BRAF KinCon reporter below the immunoblotting detection limit, 1 hr of drug exposure exclusively converted BRAF-V600E to the more closed conformation (<xref ref-type="fig" rid="fig1">Figure 1F and G</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>). These data underline that at expression levels far below the endogenous kinase, protein activity conformations can be tracked in intact cells. This may represent the more authentic (patho)physiological context and takes the molecular interactions with endogenous factors into consideration.</p><p>Next, we adapted the KinCon biosensor technology to investigate the correlation between conformation and activity regulation of key kinase pathways. We analyzed three different kinase pathways displaying different modes of kinase ON-OFF regulation.</p><sec id="s2-1"><title>Trimeric LKB1 complexes</title><p>Upon heterotrimeric complex formation with the pseudokinase STRADα and the scaffolding protein MO25, the kinase LKB1 contributes to the activation of AMPK by phosphorylation at the position Thr172 (<xref ref-type="fig" rid="fig2">Figure 2A</xref>; <xref ref-type="bibr" rid="bib115">Shackelford and Shaw, 2009</xref>, <xref ref-type="bibr" rid="bib12">Boudeau et al., 2004</xref>, <xref ref-type="bibr" rid="bib5">Baas et al., 2003</xref>). The pseudokinase domain of STRADα directly interacts with the kinase domain of LKB1, thus triggering the activation of LKB1’s tumor-suppressing phosphotransferase functions (<xref ref-type="fig" rid="fig2">Figure 2B and C</xref>). It is assumed that upon ATP-binding STRADα occupies an active conformation. In this scenario LKB1 affinities for binding rise and it binds as a pseudo-substrate. MO25 acts as scaffold for the kinase dimer to promote the activated LKB1 conformation state (<xref ref-type="bibr" rid="bib146">Zeqiraj et al., 2009a</xref>, <xref ref-type="bibr" rid="bib147">Zeqiraj et al., 2009b</xref>). Further, MO25 binding stabilizes this trimeric cytoplasmic complex (<xref ref-type="fig" rid="fig2">Figure 2A and B</xref>; <xref ref-type="bibr" rid="bib11">Boudeau et al., 2003</xref>, <xref ref-type="bibr" rid="bib5">Baas et al., 2003</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>LKB1 emanating complexes and mutation-related kinase activity conformations in intact cells.</title><p>(<bold>A</bold>) Simplified representation of the LKB1-complex composition which promotes AMPKα signaling via phosphorylation at position Thr172. (<bold>B</bold>) Crystal structure of the LKB1-STRADα-MO25 complex (PDB code 2WTK, <xref ref-type="bibr" rid="bib146">Zeqiraj et al., 2009a</xref>) representing a snapshot of trimeric complex assembly. The missense mutations we have analyzed are indicated in blue (STRADα) and pale yellow and rose (LKB1). The ATP analogue AMP-PNP is depicted in light green sticks. (<bold>C</bold>) Domain organization of human LKB1, STRADα, and MO25 (accession numbers: Q15831, Q7RTN6, Q9Y376) with indication of the kinase and pseudokinase domains (KD). Shown in red are tested missense mutations. These are summarized in the table together with their origin and assumed functions (<xref ref-type="bibr" rid="bib151">Zubiete-Franco et al., 2019</xref>, <xref ref-type="bibr" rid="bib98">Qing et al., 2022</xref>, <xref ref-type="bibr" rid="bib141">Yang et al., 2019</xref>, <xref ref-type="bibr" rid="bib128">Ui et al., 2014</xref>, <xref ref-type="bibr" rid="bib1">Al Bakir et al., 2023</xref>, <xref ref-type="bibr" rid="bib44">Islam et al., 2019</xref>, <xref ref-type="bibr" rid="bib12">Boudeau et al., 2004</xref>). (<bold>D</bold>) Effect of co-expressions of indicated kinase complex components on AMPK phosphorylation (HeLa cells, 48 hr post transfection) (mean ± SEM, n=4 ind. experiments; 3x-Flag is indicated as flag). (<bold>E</bold>) Illustration of the kinase conformation (KinCon) reporter setup for STRADα KinCon measurements: Effect of LKB1-STRADα-MO25 complex formation on the STRADα KinCon reporter opening and closing (HEK293T cells, 48 hr post transfection). Expression corrected signals (STRADα-KinCon) are shown (mean ± SEM, n=4 ind. experiments). (<bold>F</bold>) KinCon reporter setup for LKB1 KinCon measurements: Effect of LKB1-STRADα-MO25 complex formation on the LKB1 KinCon reporter conformation. Expression corrected signals are shown (LKB1-KinCon; HEK293T cells, 48 hr post transfection) (mean ± SEM, n=5 ind. experiments). (<bold>G</bold>) LKB1-KinCon measurements upon co-expression of indicated proteins displaying the binding deﬁcient STRADα mutations H231A/F233A (HF; see binding interface in B and H). Expression corrected signals are displayed (HEK293T cells, 48 hr post transfection) (mean ± SEM, n=4 ind. experiments). (<bold>H</bold>) Structure depiction highlights the localization of mutations conferring altered LKB1 functions. LKB1 residues K78, D176, and D194 (pale yellow sticks) are located within the catalytic cleft and in close proximity to AMP-PNP (light green sticks). (<bold>I</bold>) Impact of LKB1 missense mutations (three patient mutations D176N, D194N, and W308C and three ‘non-patient’ mutations K48R, R74A, K78I) on KinCon conformational changes upon co-expression of interactors. Expression corrected signals are displayed (HEK293T cells, 48 hr post transfection) (mean ± SEM, n=4 ind. experiments). Statistical significance for D, E, F, G, and I: one-sample t-test (*p&lt;0.05, **p&lt;0.01, ***p&lt;0.001).</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Raw unedited western blots shown in <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-94755-fig2-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Uncropped and labelled western blots shown in <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-94755-fig2-data2-v1.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-94755-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Complex formation of LKB1/STRADα/MO25 in HeLa and SW480 cells.</title><p>(<bold>A</bold>) Effect of LKB1-STRADα-MO25 complex formation on the LKB1 kinase conformation (KinCon) reporter (HeLa and SW480 cells). Bioluminescence signals were compared to the LKB1-KinCon signal (mean ± SEM, n=3–4). Representative western blots are shown below. (<bold>B</bold>) Effect of LKB1-STRADα-MO25 complex formation on the STRADα KinCon reporter (HeLa and SW480 cells). Bioluminescence signals were compared to the STRADα-KinCon signal (mean ± SEM, n=4 (HeLa) and n=3 (SW480)). Representative western blots are shown below. Statistical significance for A and B: one-sample t-test (*p&lt;0.05, **p&lt;0.01, ***p&lt;0.001).</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Raw unedited western blots shown in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-94755-fig2-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata2"><label>Figure 2—figure supplement 1—source data 2.</label><caption><title>Uncropped and labelled western blots shown in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-94755-fig2-figsupp1-data2-v1.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-94755-fig2-figsupp1-v1.tif"/></fig></fig-group><p>The capacity of STRADα for allosterically modulating LKB1 functions through direct interaction underlines that pseudokinases are more than inert scaffolds. They are involved in modulating interacting enzyme entities (<xref ref-type="bibr" rid="bib100">Rajakulendran and Sicheri, 2010</xref>, <xref ref-type="bibr" rid="bib103">Reiterer et al., 2014</xref>). This is in line with the common belief that pseudokinases can employ switch-like transitions to regulate signaling networks (<xref ref-type="bibr" rid="bib58">Kung and Jura, 2019</xref>, <xref ref-type="bibr" rid="bib117">Shrestha et al., 2020</xref>). Given the discovery of LKB1 inactivating mutations in diseases like PJS, NSCLC, and colorectal cancer, there is a growing interest in exploring strategies to therapeutically restore the function of mutated LKB1 (<xref ref-type="bibr" rid="bib109">Sanchez-Cespedes, 2007</xref>, <xref ref-type="bibr" rid="bib61">Launonen, 2005</xref>, <xref ref-type="bibr" rid="bib51">Kitajima et al., 2019</xref>).</p><p>In contrast to blockers of kinase functions it is more challenging to identify activator molecules for promoting reactivation of the LKB1-AMPK axis. Thus, we investigated the impact of trimeric complex formation of LKB1:STRADα:MO25 on downstream activity of LKB1. We adopted the KinCon technology for measuring involved kinase conformation states. First, we transiently over-expressed the three flag-tagged polypeptides LKB1, STRADα, and MO25 in HeLa cells. Next, we employed the pT172-AMPK/AMPK ratio as a measure of cellular LKB1 activity, observing the highest increase of LKB1-mediated downstream phosphorylation of AMPKα-T172 following co-expression of both, MO25 and STRADα, respectively. Using the chosen cellular setting and transfection protocol with a 1:1:1 ratio of transfected expression constructs, a similar effect was observed when solely over-expressing STRADα. No impact on AMPK phosphorylation was observed when MO25 was coexpressed alone (<xref ref-type="fig" rid="fig2">Figure 2D</xref>).</p><p>Next, we started to investigate the impact of LKB1 and MO25 co-expression on STRADα conformation changes. Notable is the fact that only faint STRADα KinCon signals were detected in the absence of MO25 and LKB1 co-expression. To our surprise we have observed a more than 10-fold elevation of the reporter signals following co-expression of both interacting partners in HEK293T cells (48 hr of expression, <xref ref-type="fig" rid="fig2">Figure 2E</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). This data supports the notion that STRADα engages an opened conformation, where C and N termini are separated and thus almost no bioluminescence signals can be detected under basal conditions. Upon interaction with LKB1 this conformation shifts to a partially closed intermediate state. The trimeric complex further promotes structure closing. We have observed the same tendency – but to a lower extent – using LKB1 KinCon readouts in the presence and absence of both interacting proteins (<xref ref-type="fig" rid="fig2">Figure 2F</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>).</p><p>To validate these findings, we then tested the impact of the LKB1-binding deficient STRADα-H231A/ F233A (HF) mutant proteins (<xref ref-type="bibr" rid="bib12">Boudeau et al., 2004</xref>) in co-expression experiments with the LKB1 KinCon reporter. It has previously been reported that these mutations prevent STRADα-LKB1 dimer and greatly hinders STRADα-MO25-LKB1 trimer formation and thereby AMPK activation (<xref ref-type="bibr" rid="bib146">Zeqiraj et al., 2009a</xref>). We observed that the so-called HF double mutation of STRADα is sufficient to abolish the elevating effect of trimer complex formation (<xref ref-type="fig" rid="fig2">Figure 2G</xref>). Indeed both mutations are located in the LKB1/STRADα binding interface, thereby preventing complex formation (<xref ref-type="bibr" rid="bib98">Qing et al., 2022</xref>, <xref ref-type="bibr" rid="bib146">Zeqiraj et al., 2009a</xref>; <xref ref-type="fig" rid="fig2">Figure 2H</xref>). These findings underline that trimeric complex formation alters the opening and closing of the tested full-length kinase structures using the applied KinCon reporter readout. With this reporter technology we monitored the interaction controlled activities of LKB1 directly in a living cell setting.</p><p>LKB1 loss-of-function mutations have been identified in a plethora of pathological conditions including autosomal diseases and many different forms of cancers (<xref ref-type="bibr" rid="bib109">Sanchez-Cespedes, 2007</xref>, <xref ref-type="bibr" rid="bib61">Launonen, 2005</xref>, <xref ref-type="bibr" rid="bib79">Molaei et al., 2022</xref>). Thus, we set out to analyze the impact of patient mutations on alterations of LKB1 kinase conformations.</p><p>In <xref ref-type="fig" rid="fig2">Figure 2C</xref> we have listed the proposed functions of the tested mutations. Three ‘tool’ mutations (K48R, R74A, and K78I) (<xref ref-type="bibr" rid="bib151">Zubiete-Franco et al., 2019</xref>, <xref ref-type="bibr" rid="bib98">Qing et al., 2022</xref>, <xref ref-type="bibr" rid="bib141">Yang et al., 2019</xref>) and three patient mutations (D176N, D194N, and W308C, in red) (<xref ref-type="bibr" rid="bib128">Ui et al., 2014</xref>, <xref ref-type="bibr" rid="bib1">Al Bakir et al., 2023</xref>, <xref ref-type="bibr" rid="bib44">Islam et al., 2019</xref>) were analyzed.</p><p><xref ref-type="fig" rid="fig2">Figure 2H</xref> highlights the location of these mutations within LKB1. K78, D176, and D194 are highly conserved residues within the ATP-binding pocket and are critical for kinase activity: K78 forms a salt bridge with E98 on the αC-helix which stabilizes a functional active conformation, the catalytic D176 is crucial for phosphoryl transfer, and D194 is part of the DFG motif involved in binding of the Mg<sup>2+</sup> ion (<xref ref-type="bibr" rid="bib31">Fabbro et al., 2015</xref>, <xref ref-type="bibr" rid="bib76">Meharena et al., 2016</xref>). The residue W308 is part of a hydrophobic cluster and thus surrounded by lipophilic residues (<xref ref-type="bibr" rid="bib146">Zeqiraj et al., 2009a</xref>). R74 is located within the STRADα binding interface, and has been reported to interact with STRADα-Q251 (<xref ref-type="bibr" rid="bib146">Zeqiraj et al., 2009a</xref>), and K48 is a solvent-exposed acetylation site (<xref ref-type="bibr" rid="bib151">Zubiete-Franco et al., 2019</xref>, <xref ref-type="bibr" rid="bib146">Zeqiraj et al., 2009a</xref>) located on the back of the N-lobe. Among these mutations, only the W308C mutation prevented significant closing of the LKB1 conformation when co-expressed with STRADα and MO25 (<xref ref-type="fig" rid="fig2">Figure 2I</xref>). This indicates that the catalytic site residues are critical for enzymatic activity, but play a less important role in maintaining the active LKB1 conformation in the presence of both STRADα and MO25. The W308C mutation has previously been identified to cause a reduction in LKB1 stability when compared to the wt variant (<xref ref-type="bibr" rid="bib44">Islam et al., 2019</xref>), suggesting the polar side chain of cysteine likely disrupts the interaction network within the hydrophobic cluster. Additionally, the LKB1 mutant W308C diminishes its catalytic activity (<xref ref-type="bibr" rid="bib44">Islam et al., 2019</xref>, <xref ref-type="bibr" rid="bib12">Boudeau et al., 2004</xref>, <xref ref-type="bibr" rid="bib77">Mehenni et al., 1998</xref>), consistent with the observed prevention of the PPI-directed closing of the LKB1 KinCon reporter conformation (<xref ref-type="fig" rid="fig2">Figure 2I</xref>). These findings suggest that LKB1-W308C lost its ability to form the heterotrimeric complex, with implications on hindering downstream activation and thus affecting its tumor suppressor functions. Overall these findings underline that the KinCon technology can be extended to track the impact of binary protein complexes and related cancer mutations on kinase activity dynamics. Moreover, this data demonstrated that in contrast to the previously published MEK1 and BRAF KinCon reporter (<xref ref-type="bibr" rid="bib36">Fleischmann et al., 2021</xref>, <xref ref-type="bibr" rid="bib37">Fleischmann et al., 2023</xref>, <xref ref-type="bibr" rid="bib104">Röck et al., 2019</xref>, <xref ref-type="bibr" rid="bib75">Mayrhofer et al., 2020</xref>), the more closed STRADα and LKB1 KinCon reporter conformations represent the more active full-length kinase states.</p></sec><sec id="s2-2"><title>Mutations and inhibitors induce RIPK1 conformational changes</title><p>RIPK1 is a multi-functional protein and central regulator of cell death, inflammatory processes, and immune responses (<xref ref-type="fig" rid="fig3">Figure 3A</xref>; <xref ref-type="bibr" rid="bib26">Degterev et al., 2019</xref>, <xref ref-type="bibr" rid="bib22">Clucas and Meier, 2023</xref>, <xref ref-type="bibr" rid="bib119">Silke and Meier, 2013</xref>). Genetic alterations of RIPK1 are linked to immune and autoinflammatory diseases (<xref ref-type="bibr" rid="bib60">Lalaoui et al., 2020</xref>, <xref ref-type="bibr" rid="bib123">Tao et al., 2020</xref>). Small molecule-mediated inhibition of RIPK1 kinase activity was shown to counteract the necroptotic phenotype in disease models (<xref ref-type="bibr" rid="bib123">Tao et al., 2020</xref>). This exemplifies the potential of RIPK1 targeting drugs for the treatment of certain inflammatory diseases.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>RIPK1 conformation dynamics.</title><p>(<bold>A</bold>) Simplified schematic representations of the activation pathways for apoptosis and necroptosis. Highlighted in black is the combination treatment termed TBZ (10 pg/ml TNFα, 10 nM BV-6, and 20 nM zVAD-FMK) that induces necroptosis. (<bold>B</bold>) Domain organization of human RIPK1 (accession number: Q13546), RIPK2 (accession number: O43353), RIPK3 (accession number: Q9Y572), and MLKL (accession number: Q8NB16). (<bold>C</bold>) Basal signals of indicated kinase conformation (KinCon) reporters following transient over-expression in HEK293T cells. Bars represent the RLU fold change relative to RIPK1 (mean ± SD, n=5 ind. experiments). (<bold>D</bold>) Time-dependent treatments using TBZ of HEK293T cells transiently expressing wild-type (wt) RIPK1 (left) and wt RIPK3 (right) KinCon reporters (expression corrected) (mean ± SD, n=3 ind. experiments). (<bold>E</bold>) Domain organization of RIPK1 displaying missense mutation sites. (<bold>F</bold>) 3D structure of RIPK1 dimers with functional mutations highlighted (PDB code: 6HHO, <xref ref-type="bibr" rid="bib131">Wang et al., 2018</xref>). GSK547 is depicted as brown sticks. (<bold>G</bold>) KinCon reporter signals with/without mutations (S14/15/166A, S14/15/166E, K45A) were measured in a HEK293T RIPK1 knock-out (KO) cell line (expression corrected) (mean ± SEM, n=5 ind. experiments). (<bold>H</bold>) KinCon reporter signals of RIPK1 (patient loci: D324A, D324E, D324H, C601Y) were measured in HEK293T RIPK1 KO cells (expression corrected) (mean ± SD, n=5 ind. experiments). (<bold>I</bold>) 3D structure of RIPK1 with the inhibitor GSK547, which binds to an allosteric site in close proximity to the ATP-binding site (PDB code: 6HHO, <xref ref-type="bibr" rid="bib131">Wang et al., 2018</xref>). (<bold>J</bold>) RIPK1 reporter signals with indicated mutations (described in G) upon exposure to GSK547 and Necrostatin 1 μM, and the MEKi Cobimetinib (1 μM, control experiment) or DMSO for 1 hr (mean ± SD, n=6 ind. experiments, HEK293T RIPK1 KO). Statistical signiﬁcance for C–J: one-sample t-test (*p&lt;0.05, **p&lt;0.01, ***p&lt;0.001).</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Raw unedited western blots underlying <xref ref-type="fig" rid="fig3">Figure 3</xref> and shown in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-94755-fig3-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><label>Figure 3—source data 2.</label><caption><title>Uncropped and labelled western blots <xref ref-type="fig" rid="fig3">Figure 3</xref> and shown in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-94755-fig3-data2-v1.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-94755-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Small molecule effects on RIPK1.</title><p>(<bold>A</bold>) Representative western blots of RIPK1 and RIPK3 kinase conformation (KinCon) expressions after TBZ treatment for indicated time points. HEK293T cells were transfected with KinCon constructs and subjected to bioluminescence measurements after 48 hr. (<bold>B</bold>) 3D structure of RIPK1 with the inhibitor GSK547 (PDB code: 6HHO, <xref ref-type="bibr" rid="bib131">Wang et al., 2018</xref>), which binds to an allosteric site in close proximity to ATP. For comparison, the structure of RIPK2 (light gray) in complex with the ATP analogue AMP-PCP (green sticks) is aligned (PDB code: 5NG0, <xref ref-type="bibr" rid="bib93">Pellegrini et al., 2017</xref>). (<bold>C</bold>) Time-dependent treatment of RIPK1-K45A KinCon with two RIPK1i (GSK547 and Necrostatin, 1 μM each). The KinCon reporter was over-expressed in HEK293T RIPK1 KO cells for 48 hr. Points represent the mean RLU fold change relative to time point zero for n=3 independent experiments with ± SEM.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-94755-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Conformation and phosphorylation of RIPK1.</title><p>(<bold>A</bold>) Conformation dynamics of indicated RIPK1 KinCon reporter upon exposure to the two RIPK1i (GSK547 and Necrostatin 1 μM), and the MEKi Cobimetinib (1 μM, control experiment) or DMSO for 1 hr. Bars represent the RLU fold change relative to the DMSO control of wild-type (wt) RIPK1 (mean ± SEM, n=6 ind. experiments, HEK293T RIPK1 KO). (<bold>B</bold>) RIPK1 KinCon auto-phosphorylation with co-expressed Flag-tagged RIPK1 constructs following expression in HEK293T RIPK1 KO cells. Indicated RIPK1 wt or mutant constructs were co-expressed for 48 hr and subjected to western blotting. KinCon RIPK1 constructs are annotated with single asterisk and Flag-tagged RIPK1 with double asterisks.</p><p><supplementary-material id="fig3s2sdata1"><label>Figure 3—figure supplement 2—source data 1.</label><caption><title>Raw unedited western blots shown in <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-94755-fig3-figsupp2-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3s2sdata2"><label>Figure 3—figure supplement 2—source data 2.</label><caption><title>Uncropped and labelled western blots shown in <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-94755-fig3-figsupp2-data2-v1.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-94755-fig3-figsupp2-v1.tif"/></fig></fig-group><p>We established a KinCon reporter platform for monitoring the conformational changes of central kinases and pseudokinases involved in the necroptosis signaling pathway. Additionally, we examined the effects of binding of allosteric kinase blockers to both wt and mutant RIPK1 reporters. We depict the domain organization of RIPK1, RIPK3, and MLKL. We also included analyses of RIPK2, which is not part of the necroptosis pathway (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). We cloned the human versions of these kinase genes into KinCon reporter expression constructs. After transient over-expression of these kinases in HEK293T cells, we quantified the basal <italic>R</italic>Luc PCA signals and compared these to the basal signal of the BRAF KinCon reporter (<xref ref-type="fig" rid="fig3">Figure 3C</xref>).</p><p>As starting point, we evaluated whether RIP kinases 1 and 3 activation would display conformational changes. We promoted necroptosis introducing stimuli by activating the TNFα pathway with TNFα (<xref ref-type="bibr" rid="bib20">Christofferson et al., 2012</xref>), while preventing repressive RIPK1 ubiquitylation with the SMAC mimetic BV-6 (<xref ref-type="bibr" rid="bib64">Li et al., 2011</xref>). To prevent the onset of apoptosis and instead induce activation of RIPK3, we blocked caspase 8 activation with the caspase inhibitor zVAD-FMK (<xref ref-type="bibr" rid="bib35">Festjens et al., 2007</xref>) (as illustrated in <xref ref-type="fig" rid="fig3">Figure 3A</xref>).</p><p>We used HEK293T cells and transiently expressed the RIPK1 and RIPK3 KinCon reporters for 48 hr. Bioluminescence readouts of the KinCon reporters were quantified after indicated timings of TNFα, BV-6, and zVAD-FMK (TBZ) treatments. We observed successive accumulation of the respective KinCon reporter protein levels over the treatment time course (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). We assume that this is caused by blocking of caspase 8, thus preventing the cleavage of both RIPK KinCon biosensors. As consequence we normalized the obtained <italic>R</italic>Luc PCA signals on reporter expression levels. We showed that both KinCon reporters exhibit markedly reduced bioluminescence in the necroptotic cellular environment (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). These results support the notion that both kinases shift to a more opened ON state of the full-length protein upon pathway activation.</p><p>Conformational modulation of the RIPK1 KinCon following TNFα pathway activation suggests that the reporter is incorporated into complex I. We were interested to test the degree to which the RIPK1 KinCon represents a functional RIPK1 entity. For this purpose, we conducted co-expression experiments of various RIPK1 KinCon and flag-tagged RIPK1 variants in RIPK1-deficient HEK293T cells. We used auto-phosphorylation at S166 as the primary readout for RIPK1 catalytic activity. Our results showed that the RIPK1 KinCon reporter was not capable of auto-phosphorylation. In the presence of active flag-tagged RIPK1 however, trans-phosphorylation of the KinCon reporter hybrid proteins was evident (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2B</xref>).</p><p>To further deepen our understanding of the modes of RIPK1 activation we integrated a collection of missense mutations into the KinCon reporter. Their assumed functions have been listed in <xref ref-type="fig" rid="fig3">Figure 3E</xref>. At the kinase N terminus a stretch of phosphorylation sites are attributed to kinase activation. Auto-phosphorylations at the positions S14, S15, and S166 have been shown to trigger downstream activation (<xref ref-type="bibr" rid="bib62">Laurien et al., 2020</xref>, <xref ref-type="bibr" rid="bib131">Wang et al., 2018</xref>). The localizations are highlighted in the domain organization and the structure depiction of RIPK1 dimers (<xref ref-type="fig" rid="fig3">Figure 3E and F</xref>). It needs to be noted that additional kinases have been linked to control the phosphorylation and activity state of RIPK1 (<xref ref-type="bibr" rid="bib28">Dondelinger et al., 2019</xref>, <xref ref-type="bibr" rid="bib137">Xu et al., 2018</xref>, <xref ref-type="bibr" rid="bib45">Jaco et al., 2017</xref>).</p><p>Auto-phosphorylation events have been described for the positions S14/S15/S166 (referred to as S14/15/166) and are critical for RIPK1 activation (<xref ref-type="bibr" rid="bib132">Wang et al., 2021</xref>). Thus, we integrated mutations that mimic protein phosphorylation (S to E amino acid substitutions) and those that are deficient of phosphorylation (S to A amino acid substitutions), aiming to track their impact on molecular motions of RIPK1 to simulate the more activate kinase status. In addition, the kinase-deﬁcient mutant K45A was investigated (<xref ref-type="bibr" rid="bib118">Shutinoski et al., 2016</xref>). Interestingly, K45 in RIPK1 corresponds to K78 in LKB1, highlighting the importance of this lysine residue in the functionality of various kinases. Our KinCon findings unexpectedly demonstrated for RIPK1 that in addition to the kinase-deficient mutant (K45A) all the phosphorylation mimetic (S14/15/166E) and phosphorylation preventing (S14/15/166A) mutations tested led to an opening of RIPK1 conformations (<xref ref-type="fig" rid="fig3">Figure 3G</xref>).</p><p>We also incorporated prevalent patient mutations of RIPK1, observed in distinct inflammatory diseases, into the KinCon biosensor. Besides the patient mutations of the regulatory caspase 8 cleavage site in RIPK1 (D324A/E/H) we integrated the C601Y missense mutation, which causes immunodeficiency and inflammatory bowel disease, into the reporter (<xref ref-type="bibr" rid="bib65">Li et al., 2019</xref>). Again, we observed an opening of RIPK1 conformations with all mutations tested (<xref ref-type="fig" rid="fig3">Figure 3H</xref>). This data supports the notion that in addition to preventing caspase 8 cleavage the mutations at position 324 affect the activity conformation of RIPK1. The C601Y substitution promotes RIPK1 opening as well.</p><p>We next tested all RIPK1 KinCon settings with the allosteric RIPK1 modulators GSK547 and Necrostatin (<xref ref-type="bibr" rid="bib97">Puylaert et al., 2022</xref>, <xref ref-type="bibr" rid="bib17">Cho et al., 2011</xref>). When bound to RIPK1, both of these compounds occupy a pocket located behind the ATP-binding site (<xref ref-type="fig" rid="fig3">Figure 3I</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). The kinase-deficient mutation (K45A) of the KinCon biosensor displayed the strongest opening of the enzyme conformation. We used the RIPK1-K45A KinCon to benchmark the time-dependent effects of Necrostation and GSK547 on the conformational changes (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). Application of both compounds showed engagement with all the tested RIPK1 KinCon reporters tested. An increase of bioluminescence for all RIPK1 inhibitors was evident reflecting the closing of the full-length kinase conformation. Even the phosphorylation mimetic (S14/15/166E) and phosphorylation preventing (S14/15/166A) KinCon reporters showed these phenomena of promoting a more closed conﬁguration when compared to the unrelated small molecule control, the MEK1 kinase inhibitor Cobimetinib (<xref ref-type="fig" rid="fig3">Figure 3J</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>, <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A</xref>). This data underlines that application of both allosteric kinase blockers alters the RIPK1 conformations and we assume scaffolding functions of active and inactive RIPK1 protomers.</p></sec><sec id="s2-3"><title>CDK4 and CDK6 interactions and conformations</title><p>CDK4 and CDK6 exhibit proto-oncogenic properties that rely on the presence and interaction with regulatory proteins (<xref ref-type="bibr" rid="bib110">Scheiblecker et al., 2020</xref>, <xref ref-type="bibr" rid="bib29">Eferl and Wagner, 2003</xref>). Further, CDK6 functions as a chromatin-bound factor and transcriptional regulator, thereby promoting the initiation of tumorigenesis (<xref ref-type="bibr" rid="bib54">Kollmann et al., 2013</xref>, <xref ref-type="bibr" rid="bib114">Semczuk and Jakowicki, 2004</xref>, <xref ref-type="bibr" rid="bib111">Scheicher et al., 2015</xref>; <xref ref-type="bibr" rid="bib55">Kollmann and Sexl, 2013</xref>). These activities are modulated by its molecular interaction partners, particularly cyclins and proteinogenic inhibitors (<xref ref-type="bibr" rid="bib40">Goel et al., 2018</xref>, <xref ref-type="bibr" rid="bib39">Giacinti and Giordano, 2006</xref>, <xref ref-type="bibr" rid="bib89">Ortega et al., 2002</xref>). CDK4/6 deregulation is caused by alterations of protein expression levels and/or by mutations within regulatory proteins. Prime example is the tumor suppressor protein p16<sup>INK4a</sup> which is one of the most frequently mutated genes in human cancers (<xref ref-type="bibr" rid="bib107">Romagosa et al., 2011</xref>, <xref ref-type="bibr" rid="bib66">Liggett and Sidransky, 1998</xref>).</p><p>The CDK4/6-cyclinD protein complex has been found to be hyperactivated in many cancers and therefore promote tumor growth (<xref ref-type="bibr" rid="bib18">Choi et al., 2012</xref>). This implies that CDK4/6 serves as a significant therapeutic target, and chemical inhibitors have been developed to target CDK4/6 phosphotransferase activities. Efficient CDK4/6 inhibitors such as Palbocilicb, Ribociclib, and Abemaciclib are currently in clinical use against breast cancer (<xref ref-type="bibr" rid="bib90">Otto and Sicinski, 2017</xref>). A major drawback of these therapies is the emergence of drug resistance (<xref ref-type="bibr" rid="bib32">Fassl et al., 2022</xref>). The development of precision medicine oriented polypharmacology therapies is one strategy to avoid the early advent of resistance (<xref ref-type="bibr" rid="bib2">Álvarez-Fernández and Malumbres, 2020</xref>, <xref ref-type="bibr" rid="bib140">Yang et al., 2017</xref>).</p><p>On the molecular level CDK4/6 activity states depend on the formation of PPIs with cyclinD or p16<sup>INK4a</sup>, wherein cyclinD activates them, while p16<sup>INK4a</sup> inhibits kinase activity cycles of promoting Rb phosphorylation (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Distinct to the other kinases tested here, the CDK protein coding sequences are composed almost exclusively of the kinase domain with short additional stretches at the N and C termini (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). In contrast to BRAF and RIPK1, the regulatory protein motifs are encoded by separate polypeptides. In the following, we tested the binary interaction of p16<sup>INK4a</sup> with CDK4 and CDK6. Structures of these complexes have been described. It is evident that substitution of arginine at the position 31 of CDK6 with cysteine (R31C) alters the binding affinities for p16<sup>INK4a</sup>. It forms two ionic interactions with p16<sup>INK4a</sup> residues D74 and D84, which are lost in the R31C mutant (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Experimental data further supports this notion (<xref ref-type="bibr" rid="bib106">Rodríguez-Díez et al., 2014</xref>). We included the respective mutations by generating CDK6-R31C and also the corresponding R24C mutated expression construct of CDK4 (CDK4-R24C). We conceived a work program with PPI and KinCon reporters to elucidate any relations of dimerization and drug binding.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>CDK4/6 interactions and conformations.</title><p>(<bold>A</bold>) Illustration of regulatory CDK4/6 interactions and Rb activation. (<bold>B</bold>) Domain organization of CDK4, CDK6, and p16<sup>INK4a</sup>; tested point mutations are listed. (<bold>C</bold>) 3D structure of CDK6 in complex with p16<sup>INK4a</sup>. Crucial amino acids involved in the interaction of the two proteins are highlighted. The R31C mutant is depicted in orange (PDB code: 1BI7, <xref ref-type="bibr" rid="bib108">Russo et al., 1998</xref>). (<bold>D</bold>) Protein:protein interaction (PPI) reporter analyses of the kinases CDK4 and CDK6 with p16<sup>INK4a</sup>. Scheme illustrates CDK4/6 hetero-dimer formation with p16<sup>INK4a</sup> analyzed using a PCA <italic>R</italic>Luc PPI reporter system. PPI induces the complementation of <italic>R</italic>Luc PCA fragments promoting an increase in bioluminescence (HEK293T cells, 48 hr of transient reporter expression). Bars represent the RLU fold change of PPI in relation to wild-type CDK4/6:p16<sup>INK4a</sup> complex (mean ± SEM, n=7 ind. experiments). (<bold>E</bold>) Basal signal of CDK4/6 KinCon reporters with indicated mutations are shown (expressed for 48 hr in HEK293T cells) (mean ± SEM, n=6 ind. experiments). (<bold>F</bold>) Quantification of alterations of CDK4/6 KinCon reporter bioluminescence signals (HEK293T, expression for 48 hr) upon exposure to indicated CDK4/6i (1 μM) or DMSO for 3 hr (mean ± SEM, n=4 ind. experiments). Statistical significance for D–F: one-sample t-test (*p&lt;0.05, **p&lt;0.01, ***p&lt;0.001).</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Raw unedited western blots shown in <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-94755-fig4-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Uncropped and labelled western blots shown in <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-94755-fig4-data2-v1.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-94755-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Expression of CDK4/6:p16<sup>INK4a</sup> PPI reporter constructs.</title><p>Exemplary western blot of CDK4/6 :p16<sup>INK4a</sup> PPI PCA. Immunoblot with respective antibodies show expression levels of RLuc PCA F[1] and RLuc PCA F[2] tagged expression constructs.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Raw unedited western blots shown in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-94755-fig4-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata2"><label>Figure 4—figure supplement 1—source data 2.</label><caption><title>Uncropped and labelled western blots shown in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-94755-fig4-figsupp1-data2-v1.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-94755-fig4-figsupp1-v1.tif"/></fig></fig-group><p>We started analyzing binary protein interaction of p16<sup>INK4a</sup> with CDK4 and CDK6. We fused the two <italic>R</italic>Luc fragments that are used in the KinCon reporter to two different proteins, in this case CDK4/CDK6 and p16<sup>ink4a</sup>. When two proteins interact, the two <italic>R</italic>Luc PCA fragments form a complemented luciferase and an increased light signal can be detected (<xref ref-type="fig" rid="fig4">Figure 4D</xref>, left). Originally the underlying technology had been developed for the dynamic measurements of regulatory kinase interactions of PKA (<xref ref-type="bibr" rid="bib122">Stefan et al., 2007</xref>). Besides testing the kinase mutations CDK6-R31C and CDK4-R24C we generated the murine homolog of p16<sup>INK4a</sup> displaying the cancer mutation P40L. P40L showed reduced affinities for the tested CDKs and thus no longer inhibits phosphotransferase functions of CDK4/6 (<xref ref-type="bibr" rid="bib143">Yarbrough et al., 1999</xref>). Upon complex formation of CDKs with p16<sup>INK4a</sup> the C terminal fused <italic>R</italic>Luc PCA reporter fragments complement and bioluminescence signals can be detected directly in intact cells transiently expressing the hybrid proteins. Using this cell-based PPI reporter we observed a significant reduction of p16<sup>INK4a</sup>:CDK4/6 complex formation when the respective R residues are mutated to C. Integration of the P40L mutation in p16<sup>INK4a</sup> prevented complex formation as expected and further validates the reporter system applied (<xref ref-type="fig" rid="fig4">Figure 4D</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>).</p><p>Next, we set out to test the impact of these CDK mutations on kinase conformations. We have previously shown that basal CDK4/6 KinCon conformation states can be tracked using the KinCon reporter technology (<xref ref-type="bibr" rid="bib75">Mayrhofer et al., 2020</xref>). Thus, we evaluated if a reduction of interaction with inhibitory proteins such as p16<sup>INK4a</sup> alters CDK full-length conformations. We transiently over-expressed the wt and mutant CDK4/6 KinCon reporter in HEK293T cells. After 48 hr of expression the cells were subjected to bioluminescence measurements. The results showed that the reduced affinity for p16<sup>INK4a</sup> binding alters the conformations of both CDKs. P16<sup>INK4a</sup> binding deficient CDK4 and CDK6 mutants exhibited a more opened conformation, as indicated by a decrease in bioluminescence (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). In the following, all KinCon reporters have been subjected to analyses upon CDK4/6 inhibitor exposure (<xref ref-type="bibr" rid="bib138">Yam et al., 2018</xref>). Again we used HEK293T cells and transiently expressed the wt and mutated KinCon reporters for 48 hr. We then exposed the cells to three clinically applied CDK4/6 inhibitors (CDK4/6i) at a concentration of 1 μM for 3 hr. Overall we could not detect any major effects of drug exposure on the dynamics of the four CDK KinCon reporters which showed different affinities for p16<sup>INK4a</sup> binding (<xref ref-type="fig" rid="fig4">Figure 4F</xref>). This data underlines that these breast cancer drugs which should bind to the active protein kinase did not induce full-length CDK4 and CDK6 conformational changes in the tested cell culture settings.</p></sec><sec id="s2-4"><title>Effect of different kinase inhibitor types on the KinCon reporter system</title><p>The inhibitors used in this study fall into different inhibitor categories (type I, type I 1/2, type II, and type III). The classification of inhibitors is determined by the activation state of the protein kinase, particularly the positioning of the DFG-Asp (active in, inactive out) and the αC-helix (active in, inactive out) (<xref ref-type="bibr" rid="bib148">Zhang et al., 2009</xref>). However, type III (allosteric) inhibitors deviate from this pattern. They bind adjacent to the ATP-binding pocket, enabling simultaneous binding of ATP and the inhibitor (<xref ref-type="bibr" rid="bib135">Wu et al., 2015</xref>). Type I inhibitors selectively bind to the active conformation of the kinase, characterized by DFG in and αC in. Type I 1/2 inhibitors, on the other hand, bind to the inactive state of the kinase, represented by DFG in and αC out. Type II inhibitors bind to the inactive kinase, where DFG is out and αC can be either in or out (<xref ref-type="bibr" rid="bib3">Arter et al., 2022</xref>; <xref ref-type="fig" rid="fig5">Figure 5A and B</xref>). In this study we have observed alterations of KinCon activity conformations upon changes of protein interactions and through type I 1/2 and type III inhibitor binding (<xref ref-type="fig" rid="fig5">Figure 5A–C</xref>), but not type I inhibitors. We provide a summary of the changes in KinCon activity conformations. We have previously shown that for both kinases of the MAPK pathway, MEK1 and BRAF, the respective inhibitors affect primarily the active kinase conformation (<xref ref-type="bibr" rid="bib104">Röck et al., 2019</xref>, <xref ref-type="bibr" rid="bib75">Mayrhofer et al., 2020</xref>, <xref ref-type="bibr" rid="bib36">Fleischmann et al., 2021</xref>, <xref ref-type="bibr" rid="bib37">Fleischmann et al., 2023</xref>). Exemplarily we illustrate that both kinases which are activated through cancer patient mutations (BRAF-V600E and MEK1-K57E) bind the respective kinase inhibitor, resulting in a change in the activity conformations (<xref ref-type="fig" rid="fig5">Figure 5A and B</xref>). The same observation was made with the MEK1 KinCon upon activation through BRAF-mediated phosphorylation of the reporter (<xref ref-type="bibr" rid="bib37">Fleischmann et al., 2023</xref>). In contrast, it was of interest that for all tested RIPK1 activity conformations we observed that the binding of allosteric RIPK1i promoted a closing of the RIPK1 conformation. In <xref ref-type="fig" rid="fig5">Figure 5B</xref> we exemplarily illustrate the impact of inhibitor binding on the kinase-dead version RIPK1-K45A. This observation underlines that also inactive RIPK1 complexes are target of drug binding with feasible consequences on kinase scaffolding functions. Kinase activities of CDK4/6 are regulated via defined PPIs (<xref ref-type="bibr" rid="bib85">Nebenfuehr et al., 2020</xref>). We showed that reducing binding affinities for p16<sup>INK4a</sup> and related inhibitory proteins triggers the opening of the KinCon (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). However, using the applied standard protocols we have chosen for all CDK4/6 KinCon reporter we have not observed that any of the three clinically applied CDK4/6i tested (such as Abemaciclib) altered the kinase conformation significantly.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Impact of small molecules and protein interactions on kinase activity conformations.</title><p>(<bold>A+B</bold>) Depiction of molecular interactions of a type I 1/2 and type III kinase inhibitors with a kinase domain (N and C lobe). Impact of PLX8394, Cobimetinib and GSK547 on wild-type (wt) and mutated versions of BRAF, RIPK1, and MEK1 kinase conformation (KinCon) reporters. 48 hr post transfection HEK293T cells expressing respective reporter constructs were treated with indicated inhibitors for 1 hr (1 μM) followed by RLuc PCA analyses (mean ± SEM, n=4/5 ind. experiments). (<bold>C</bold>) Depiction of molecular interactions of a type I kinase inhibitor with a kinase domain (N and C lobe). Impact of Abemaciclib on indicated CDK6 kinase conformations (wt and p16<sup>INK4a</sup> binding deficient). 48 hr post transfection HEK293T cells expressing respective reporter constructs were treated with indicated inhibitors for 3 hr (1 μM) followed by RLuc PCA analyses (mean ± SEM, n=4 ind. experiments). (<bold>D</bold>) Bioluminescence measurement of PKAc wt and L206R KinCon reporters. HEK293T cells expressing the reporter were treated with 20 μM of Forskolin for 15 min followed by RLuc PCA analyses (mean ± SEM, n=4 ind. experiments). (<bold>E</bold>) Kinome tree displays kinases for which KinCon reporters have been generated (red dots). The blue squares highlight the kinases for which approved drugs are available. Generated with <ext-link ext-link-type="uri" xlink:href="https://kinhub.org/kinmap/">https://kinhub.org/kinmap/</ext-link>. Statistical significance for A–D: one-sample t-test (*p&lt;0.05, **p&lt;0.01, ***p&lt;0.001).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-94755-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Subcellular localization of kinase conformation (KinCon) reporters.</title><p>BRAF and PKAc wild-type (wt) and mutated (BRAF-V600E, PKAc-L206R) reporters were over-expressed in HEK293T cells. (<bold>A</bold>) Representative western blot from the cytoplasmic (<bold>C</bold>) and nuclear (N) fractions. (B+C) Quantifications of the signals from n=3 ind. experiments (mean ± SEM).</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Raw unedited western blots shown in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-94755-fig5-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5s1sdata2"><label>Figure 5—figure supplement 1—source data 2.</label><caption><title>Uncropped and labelled western blots shown in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-94755-fig5-figsupp1-data2-v1.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-94755-fig5-figsupp1-v1.tif"/></fig></fig-group><p>In this context we would like to introduce another kinase example displaying regulatory PPI controlling the catalytic kinase protomer. When the regulatory (R) and the catalytic (C/PKAc) subunit interact, the tetrameric PKA holoenzyme complex (R2:C2) is inactive. When second messenger cAMP molecules bind to the R dimer, the complex dissociates and catalytic PKA subunits are activated (<xref ref-type="bibr" rid="bib126">Taylor et al., 2013</xref>). Mutations such as L206R lock the catalytic subunit (PKAc) in its active state. Thus, interactions of regulatory subunits are significantly reduced (<xref ref-type="bibr" rid="bib75">Mayrhofer et al., 2020</xref>, <xref ref-type="bibr" rid="bib10">Bolger, 2022</xref>). Reduction of binding affinities through the use of the general cAMP elevating agent Forskolin triggers conformational changes to the more opened state, mechanistically similar to CDK6-R31C. The PKAc-L206R KinCon mutant already engages this opened activity conformation state (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). Based on these two examples we assume that binary protein interactions are the prime factors for altering CDK4/6 and PKAc activity conformations.</p><p>In the context of kinase compartmentalization and activating kinase mutations we showed that using PKAc and BRAF KinCon reporters as example we could not track alterations of cytoplasmic and nuclear localization (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). Furthermore, subcellular localization of PKAc KinCon reporters did not change when the L206R mutation was introduced (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). As a control BRAF wt and V600E KinCon reporters were used and no changes in localization were observed.</p><p>In this study we focused on a collection of well-studied kinase pathways. In this regard it is important to note that only a limited number of human kinases are targeted by approved drugs. We have illustrated this by using a phylogenetic kinome tree to represent kinase relationships within the human kinome (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). The blue squares indicate the kinase branches displaying approved kinase blockers. It is evident that numerous protein kinases lack drug candidates. Many of these miss suitable tools/readouts for basic research analyses of physiological and pathological kinase functions. Such kinases have been referred to be part of the so-called ‘dark kinome’ (<xref ref-type="bibr" rid="bib7">Berginski et al., 2021</xref>, <xref ref-type="bibr" rid="bib120">Southekal et al., 2021</xref>). In the kinome tree illustration we have integrated our growing catalog of KinCon reporters (red dots, <xref ref-type="fig" rid="fig5">Figure 5E</xref>). These conformation reporters represent an extendable toolbox for gaining first and also deeper insights into alterations of kinase activity-related conformation states induced by different means of inhibitors, activators, binders, or mutations. Systematic implementation of this technology in kinase research programs would assist in advancing our understanding of kinase and pseudokinase regulations and functions.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In the field of kinase-related diseases, mutations of different kinds and at different stages of kinase pathways have prompted the development of kinase-specific and small molecule-based inhibitors as primary therapeutic approach (<xref ref-type="bibr" rid="bib34">Ferguson and Gray, 2018</xref>). Despite significant efforts in this direction, only a small fraction of the entire kinome has been successfully targeted by FDA-approved kinase blockers so far (<xref ref-type="bibr" rid="bib59">Lahiry et al., 2010</xref>, <xref ref-type="bibr" rid="bib94">Politi et al., 2015</xref>). Moreover, once a kinase inhibitor is introduced into clinical use, it often encounters the development of drug resistance mechanisms over time (<xref ref-type="bibr" rid="bib69">Longley and Johnston, 2005</xref>). Especially in cancer therapy, these facts pose a significant challenge for identifying and applying efficient small molecule-based therapies. Hence, it is crucial to gain more extensive insights into the cellular drug-target engagement, the molecular consequences of kinase patient mutations, and the evolving patterns of drug resistance mechanisms. For both endeavors new technologies are indispensable for identifying, accurately monitoring, and targeting the dysregulated functions of kinases on the cellular level.</p><p>Anticipating and unveiling the cellular mechanism of drug actions may help to develop new treatment concepts with the hope of reducing the diminishing of drug efficacies (<xref ref-type="bibr" rid="bib15">Chan and Ginsburg, 2011</xref>, <xref ref-type="bibr" rid="bib41">Goetz and Schork, 2018</xref>). The KinCon technology, introduced here, seeks to address the previously mentioned challenges. It has the potential to track kinase functions in living cells effectively, providing assistance in measuring difficult-to-assess processes that may include or go beyond phosphotransferase activities. Overall, it offers an innovative solution for understanding kinase activity conformations, which could pave the way for new intervention strategies for kinase entities that have so far not been addressable for drug screenings. So far, this relates to the tracking of kinase scaffold and pseudokinase functions.</p><p>Key advantages of the KinCon reporter technology is the robustness of the system to track kinase conformations at varying expression levels. However, in contrast to fluorescence-based reporter readouts, subcellular analyses and cell sorting are still challenging due to comparably low levels of light emission.</p><p>At the beginning of our studies, we underlined the exceptional sensitivity of the KinCon reporter system for tracking kinase activity conformations. We demonstrated that at expression levels far below the endogenous kinase of interest we tracked kinase conformations and their alterations upon drug exposure (<xref ref-type="fig" rid="fig1">Figure 1E–G</xref>). Tracking enzyme activities at low expression levels is paramount for understanding the details of cellular functions, as many regulatory and spatiotemporal controlled kinase interactions occur under such settings. Such precise measurements are essential for unraveling and targeting pathological kinases functions.</p><p>So far, KinCon reporters have been used to assess different conformational states of kinases which are altered by phosphotransferase-activating patient mutations and/or kinase drug binding (<xref ref-type="bibr" rid="bib104">Röck et al., 2019</xref>, <xref ref-type="bibr" rid="bib75">Mayrhofer et al., 2020</xref>, <xref ref-type="bibr" rid="bib36">Fleischmann et al., 2021</xref>, <xref ref-type="bibr" rid="bib37">Fleischmann et al., 2023</xref>). Here, we set out to evaluate consequences of inactivating patient mutations on the complex formation emanating from the kinase LKB1. We aimed to broaden the application spectrum of this reporter technology for investigating how regulatory protein interactions influence the tumor suppressor functions of the kinase LKB1 (<xref ref-type="bibr" rid="bib92">Partanen et al., 2012</xref>). This holds particular implication for inactivated LKB1, as it suggests that activator compounds could potentially counteract its loss-of-function mutations in cancer. In order to screen or test such reactivator molecules, bioluminescence measurements in living cells would be advantageous, since the complex cellular environment needs to be taken into account. In in vitro assays, which mostly focus on kinase domain activities, regulatory protein interactions are neglected. We have confirmed the notion that the formation of the trimeric complex between STRADα-LKB1-MO25 was necessary for signal propagation to AMPK. In line with this, the LKB1 and STRADα KinCon bioluminescence signals increased upon complex formation and vice versa were reduced back to the baseline signal when a complex breaking mutation in the pseudokinase STRADα was introduced (<xref ref-type="fig" rid="fig2">Figure 2G</xref>). Further, we showed that tracking structural rearrangements induced by diverse types of mutations can be quantified using KinCon technology (<xref ref-type="fig" rid="fig2">Figure 2I</xref>). In this setting KinCon measurements of either the kinase (LKB1) or pseudokinase (STRADα) report trimeric complex formation which is pivotal for cytoplasmic kinase pathway activation (<xref ref-type="fig" rid="fig2">Figure 2E and F</xref>). In contrast to MEK1 and BRAF KinCon reporters, the closed STRADα and LKB1 KinCon conformations seem to represent the active kinase state.</p><p>In the next step, we expanded the application of the KinCon reporter to RIPK. Examining the molecular mechanisms that regulate RIPK1 activity poses a challenge because of the intricate nature of the pathway. Functioning as a molecular scaffold, RIPK1 orchestrates signal transduction by coordinating multiple kinases participating in the NFκB pathway (<xref ref-type="bibr" rid="bib82">Moynagh, 2005</xref>, <xref ref-type="bibr" rid="bib78">Meylan et al., 2004</xref>). Moreover, as a regulator of cell death, RIPK1 forms a substantial amyloid-like signalosome in conjunction with RIPK3 and various other factors (<xref ref-type="bibr" rid="bib26">Degterev et al., 2019</xref>). We have shown that indeed pathway activation at different levels of the cascade can be tracked. Further, all tested mutations converted RIPK1 to the more opened conformation (<xref ref-type="fig" rid="fig3">Figure 3G and H</xref>). Both tested and allosterically acting RIPK1i converted the KinCon reporter back to a more closed conformation (<xref ref-type="fig" rid="fig3">Figures 3J</xref> and <xref ref-type="fig" rid="fig5">5B</xref>). This consistent impact on the opened kinase conformation indicates a uniform response in altering the enzymes structural state. We assume that this unexpected drug-driven transition of inactive and active RIPK1 complexes to more closed kinase conformation may have relevance for scaffold functions of RIPK1. Additionally, we hypothesize that it could potentially impact the effectiveness of drug binding.</p><p>The proto-oncogenic characteristics of CDK4 and CDK6 depend on expression levels and their interactions with a collection of regulatory proteins (<xref ref-type="bibr" rid="bib67">Lin et al., 2001</xref>). We applied the KinCon technology for tracking activity states of both kinases. We demonstrated that regulatory CDK4/6 interactions induce conformational changes that remain unaltered when clinically used type I inhibitors bind to them in the tested cell setting (<xref ref-type="fig" rid="fig4">Figure 4F</xref>).</p><p>In summary, we have extended the KinCon reporter scope of applications. Besides monitoring conformational changes induced by drugs and drug candidates, the reporter system can be applied to accurately track the formation of activated and kinase centered protein complexes. Besides its predictive value in assessing drug effectiveness, the KinCon technology helps consider or identify cellular factors that impact drug candidate binding. KinCon reporters provide unique insights into the molecular dynamics of kinase structure rearrangements. Understanding the molecular motion of kinases as they interact with small molecule inhibitors or regulatory proteins is crucial for designing more effective therapeutic strategies, especially considering that many kinase pathways have so far remained untargeted. The KinCon technology offers a potential avenue to change this.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Kidney; Embryo</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CRL-3216</td><td align="left" valign="bottom">HEK293T</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Uterus; Cervix,<break/>Adenocarcinoma</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CCL-2</td><td align="left" valign="bottom">HeLa</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Large intestine; Colon <break/>Adenocarcinoma</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CCL-228</td><td align="left" valign="bottom">SW480</td></tr><tr><td align="left" valign="bottom">Transfected construct <italic>human</italic></td><td align="left" valign="bottom">MA-T-gRNA-RIP1</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">48138</td><td align="left" valign="bottom">RIPK1-KO<break/></td></tr><tr><td align="left" valign="bottom">Transfected construct <italic>human</italic></td><td align="left" valign="bottom">Cas9-GFP pSp<break/>Cas9(BB)–2A-GFP</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">RIPK1-KO</td></tr><tr><td align="left" valign="bottom">Transfected construct <italic>human</italic></td><td align="left" valign="bottom">pcDNA3.1-F[1]<break/>-LKB1-F[2]</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">LKB1-KinCon</td></tr><tr><td align="left" valign="bottom">Transfected construct <italic>human</italic></td><td align="left" valign="bottom">pcDNA3.1-<break/>F[1]-LKB1-K78I-F[2]</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">LKB1-KinCon (K78I)</td></tr><tr><td align="left" valign="bottom">Transfected construct <italic>human</italic></td><td align="left" valign="bottom">pcDNA3.1-F[1]<break/>-LKB1-D176N-F[2]</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">LKB1-KinCon (D176N)</td></tr><tr><td align="left" valign="bottom">Transfected construct <italic>human</italic></td><td align="left" valign="bottom">pcDNA3.1-F[1]<break/>-LKB1-D194N-F[2]</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">LKB1-KinCon (D194N)</td></tr><tr><td align="left" valign="bottom">Transfected construct <italic>human</italic></td><td align="left" valign="bottom">pcDNA3.1-F[1]-LKB1-R74A-F[2]</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">LKB1-KinCon (R74A)</td></tr><tr><td align="left" valign="bottom">Transfected construct <italic>human</italic></td><td align="left" valign="bottom">pcDNA3.1-F[1]-LKB1-W308C-F[2]</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">LKB1-KinCon (W308C)</td></tr><tr><td align="left" valign="bottom">Transfected construct <italic>human</italic></td><td align="left" valign="bottom">pcDNA3.1-F[1]<break/>-LKB1-K48R-F[2]</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">LKB1-KinCon (K48R)</td></tr><tr><td align="left" valign="bottom">Transfected construct <italic>human</italic></td><td align="left" valign="bottom">pcDNA3.1-F[1]<break/>-STRADα-F[2]</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">STRADα-KinCon<break/></td></tr><tr><td align="left" valign="bottom">Transfected construct <italic>human</italic></td><td align="left" valign="bottom">pcDNA3.1-LKB1-3xFlag</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">LKB1-3xFlag<break/></td></tr><tr><td align="left" valign="bottom">Transfected construct <italic>human</italic></td><td align="left" valign="bottom">pcDNA3.1-<break/>STRADα–3xFlag</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">STRADα–3x<break/>Flag</td></tr><tr><td align="left" valign="bottom">Transfected construct <italic>human</italic></td><td align="left" valign="bottom">pcDNA3.1-<break/>STRADα- H231A/F233A-3xFlag</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">STRADα–3xFlag (H231A /F233A)</td></tr><tr><td align="left" valign="bottom">Transfected construct <italic>human</italic></td><td align="left" valign="bottom">pcDNA3.1-<break/>F[1]-MLKL-F[2]</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">MLKL-<break/>KinCon</td></tr><tr><td align="left" valign="bottom">Transfected construct <italic>human</italic></td><td align="left" valign="bottom">pcDNA3.1-<break/>F[1]-RIPK1- S14/S15/S166A-F[2]</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">RIPK1-KinCon (S14A/S15A/S166A)</td></tr><tr><td align="left" valign="bottom">Transfected construct <italic>human</italic></td><td align="left" valign="bottom">pcDNA3.1-<break/>F[1]-RIPK1- S14/S15/S166E-F[2]</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">RIPK1-KinCon (S14E/S15E/S166E)</td></tr><tr><td align="left" valign="bottom">Transfected construct <italic>human</italic></td><td align="left" valign="bottom">pcDNA3.1-<break/>F[1]-RIPK1-K45A-F[2]</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">RIPK1-KinCon<break/> (K45A)</td></tr><tr><td align="left" valign="bottom">Transfected construct <italic>human</italic></td><td align="left" valign="bottom">pcDNA3.1-F[1]-RIPK1-D324H-F[2]</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">RIPK1-KinCon (D324H)</td></tr><tr><td align="left" valign="bottom">Transfected construct <italic>human</italic></td><td align="left" valign="bottom">pcDNA3.1-<break/>F[1]-RIPK1-D324A-F[2]</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">RIPK1-KinCon<break/> (D324A)</td></tr><tr><td align="left" valign="bottom">Transfected construct <italic>human</italic></td><td align="left" valign="bottom">pcDNA3.1-<break/>F[1]-RIPK1-D324E-F[2]</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">RIPK1-KinCon (D324E)</td></tr><tr><td align="left" valign="bottom">Transfected construct <italic>human</italic></td><td align="left" valign="bottom">pcDNA3.1-<break/>F[1]-RIPK1-C601Y-F[2]</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">RIPK1-KinCon<break/> (C601Y)</td></tr><tr><td align="left" valign="bottom">Transfected construct <italic>mouse</italic></td><td align="left" valign="bottom">pcDNA3.1-<break/>F[1]-CDK6-F[2]</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">CDK6-KinCon</td></tr><tr><td align="left" valign="bottom">Transfected construct <italic>mouse</italic></td><td align="left" valign="bottom">pcDNA3.1-<break/>F[1]-CDK6-R31C-F[2]</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">CDK6-KinCon<break/> (R31C)</td></tr><tr><td align="left" valign="bottom">Transfected construct <italic>mouse</italic></td><td align="left" valign="bottom">pcDNA3.1-<break/>F[1]-CDK4-F[2]</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">CDK4-KinCon</td></tr><tr><td align="left" valign="bottom">Transfected construct <italic>mouse</italic></td><td align="left" valign="bottom">pcDNA3.1-<break/>CDK6-F[1]</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">CDK6-PPI reporter</td></tr><tr><td align="left" valign="bottom">Transfected construct <italic>mouse</italic></td><td align="left" valign="bottom">pcDNA3.1-<break/>CDK6-R31C-F[1]</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">CDK6-PPI reporter <break/>(R31C)</td></tr><tr><td align="left" valign="bottom">Transfected construct <italic>mouse</italic></td><td align="left" valign="bottom">pcDNA3.1-<break/>CDK4-F[1]</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">CDK4-PPI reporter</td></tr><tr><td align="left" valign="bottom">Transfected construct <italic>mouse</italic></td><td align="left" valign="bottom">pcDNA3.1- <break/>CDK4-R24C-F[1]</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">CDK4-PPI reporter<break/> (R24C)</td></tr><tr><td align="left" valign="bottom">Transfected construct <italic>mouse</italic></td><td align="left" valign="bottom">pcDNA3.1-<break/>p16<sup>INK4a</sup>-F[2]</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">p16<sup>INK4a</sup>-PPI reporter</td></tr><tr><td align="left" valign="bottom">Transfected construct <italic>mouse</italic></td><td align="left" valign="bottom">pcDNA3.1- p16<sup>INK4a</sup>-P40L-F[2]</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">p16<sup>INK4a</sup>-PPI reporter <break/>(P40L)</td></tr><tr><td align="left" valign="bottom">Transfected construct <italic>human</italic></td><td align="left" valign="bottom">pcDNA3.1-<break/>F[1]-MEK1-F[2]</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">MEK1-KinCon</td></tr><tr><td align="left" valign="bottom">Transfected construct <italic>human</italic></td><td align="left" valign="bottom">pcDNA3.1- F[1]-MEK1-K57E-F[2]</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">MEK-KinCon<break/> (K57E)</td></tr><tr><td align="left" valign="bottom">Transfected construct <italic>human</italic></td><td align="left" valign="bottom">pcDNA3.1-<break/>F[1]-PKAc-F[2]</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">PKAc-KinCon</td></tr><tr><td align="left" valign="bottom">Transfected construct <italic>human</italic></td><td align="left" valign="bottom">pcDNA3.1-<break/>F[1]-PKAc-L206R-F[2]</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">PKAc-KinCon<break/> (L206R)</td></tr><tr><td align="left" valign="bottom">Transfected construct <italic>human</italic></td><td align="left" valign="bottom">pcDNA3.1-<break/>MO25-3xFlag</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">MO25-3xFlag</td></tr><tr><td align="left" valign="bottom">Transfected construct <italic>human</italic></td><td align="left" valign="bottom">pcDNA3.1-<break/>F[1]-BRAF-F[2]</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">BRAF-KinCon</td></tr><tr><td align="left" valign="bottom">Transfected construct <italic>human</italic></td><td align="left" valign="bottom">pcDNA3.1-<break/>F[1]-BRAF-V600E-F[2]</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">BRAF-KinCon<break/> (V600E)</td></tr><tr><td align="left" valign="bottom">Transfected construct <italic>human</italic></td><td align="left" valign="bottom">pcDNA3.1-<break/>F[1]-RIPK1-F[2]</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">RIPK1-KinCon</td></tr><tr><td align="left" valign="bottom">Transfected construct <italic>human</italic></td><td align="left" valign="bottom">pcDNA3.1-<break/>F[1]-RIPK2-F[2]</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">RIPK2-KinCon</td></tr><tr><td align="left" valign="bottom">Transfected construct <italic>human</italic></td><td align="left" valign="bottom">pcDNA3.1-<break/>F[1]-RIPK3-F[2]</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">RIPK3-KinCon</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">GAPDH <break/>Rabbit monoclonal</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">2118</td><td align="left" valign="bottom">1:10000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">AMPKα Rabbit <break/>monoclonal</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">2532</td><td align="left" valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Phospho-<break/>AMPKα(Thr172) <break/>Rabbit monoclonal</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">2535</td><td align="left" valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">LKB1 Rabbit <break/>monoclonal</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">3047</td><td align="left" valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Vinculin Rabbit <break/>monoclonal</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">4650</td><td align="left" valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">RIP XP Rabbit<break/> monoclonal</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">3493</td><td align="left" valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">RIP3 Rabbit<break/> monoclonal</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">13526</td><td align="left" valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CDK6 Mouse<break/> monoclonal</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">3136</td><td align="left" valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">FLAG-M2 Mouse <break/>monoclonal</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">F3165</td><td align="left" valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Renilla Luciferase<break/> Rabbit monoclonal</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Ab185926 [EPR17792]</td><td align="left" valign="bottom">1:10000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Renilla Luciferase<break/> clone 1D5.2 <break/>Mouse monoclonal</td><td align="left" valign="bottom">Millipore</td><td align="left" valign="bottom">MAB4410</td><td align="left" valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">Drug, chemical compound</td><td align="left" valign="bottom">Inhibitor</td><td align="left" valign="bottom">MCE Med Chem Express</td><td align="left" valign="bottom">HY-50767</td><td align="left" valign="bottom">Palbociclib <break/>PD 0332991</td></tr><tr><td align="left" valign="bottom">Drug, chemical compound</td><td align="left" valign="bottom">Inhibitor</td><td align="left" valign="bottom">MCE Med Chem Express</td><td align="left" valign="bottom">HY-16297A</td><td align="left" valign="bottom">Abemaciclib<break/> LY2835219</td></tr><tr><td align="left" valign="bottom">Drug, chemical compound</td><td align="left" valign="bottom">Inhibitor</td><td align="left" valign="bottom">MCE Med Chem Express</td><td align="left" valign="bottom">HY-15777</td><td align="left" valign="bottom">Ribociclib<break/> LEE011</td></tr><tr><td align="left" valign="bottom">Drug, chemical compound</td><td align="left" valign="bottom">Inhibitor</td><td align="left" valign="bottom">MCE Med Chem Express</td><td align="left" valign="bottom">HY-18972</td><td align="left" valign="bottom">PLX8394</td></tr><tr><td align="left" valign="bottom">Drug, chemical compound</td><td align="left" valign="bottom">Inhibitor</td><td align="left" valign="bottom">MCE Med Chem Express</td><td align="left" valign="bottom">HY-114492</td><td align="left" valign="bottom">GSK-547</td></tr><tr><td align="left" valign="bottom">Drug, chemical compound</td><td align="left" valign="bottom">Inhibitor</td><td align="left" valign="bottom">MCE Med Chem Express</td><td align="left" valign="bottom">HY-14622A</td><td align="left" valign="bottom">Necrostatin<break/> 1 S</td></tr><tr><td align="left" valign="bottom">Drug, chemical compound</td><td align="left" valign="bottom">Inhibitor</td><td align="left" valign="bottom">MCE Med Chem Express</td><td align="left" valign="bottom">HY-13064</td><td align="left" valign="bottom">Cobimetinib</td></tr><tr><td align="left" valign="bottom">Drug, chemical compound</td><td align="left" valign="bottom">Inhibitor</td><td align="left" valign="bottom">MCE Med Chem Express</td><td align="left" valign="bottom">HY-P7090A</td><td align="left" valign="bottom">TNFα</td></tr><tr><td align="left" valign="bottom">Drug, chemical compound</td><td align="left" valign="bottom">Inhibitor</td><td align="left" valign="bottom">MCE</td><td align="left" valign="bottom">HY-16658</td><td align="left" valign="bottom">z-VAD(OMe)-FMK</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Expression constructs</title><p>All constructs were cloned into the pcDNA3.1 expression vector containing the sequences of Rluc PCA fragments F[1] and F[2] as previously described (<xref ref-type="bibr" rid="bib75">Mayrhofer et al., 2020</xref>, <xref ref-type="bibr" rid="bib37">Fleischmann et al., 2023</xref>, <xref ref-type="bibr" rid="bib104">Röck et al., 2019</xref>). Linear DNA fragments were produced by PCR using Q5 DNA Polymerase. After removing the PCR overhangs with AgeI and HpaI (NEB) respectively and subsequent DNA fragment gel extraction, the PCR insert fragments were isolated using the innuPREP DOUBLEpure Kit (Analytik Jena). The DNA fragments were ligated using T4 DNA ligase (NEB) and amplified using XL10-gold ultracompetent cells. Plasmids were purified by mini- or midiprep (QIAGEN) and verified by Sanger sequencing (Microsynth/Eurofins).</p></sec><sec id="s4-2"><title>Cell culture</title><p>HEK293T cells were obtained from ATCC (CRL-11268). HEK293T cells were grown in DMEM supplemented with 10% FBS. Transient transfections were performed with Transfectin reagent (Bio-Rad, 1703352). HeLa cells were obtained from ATCC (CCL-2). HeLa cells were grown in DMEM supplemented with 10% FBS. Transient transfections were performed with JetPRIME DNA and siRNA transfection reagent (Polyplus supplied by VWR, 101000046). SW480 cells were obtained from ATCC (CCL-228). SW480 cells were grown in DMEM supplemented with 10% FBS. Transient transfections were performed with JetPRIME DNA and siRNA transfection reagent (Polyplus supplied by VWR, 101000046).</p><p>For the HEK293 RIPK1 KO cells HEK293T parental cells were transfected with pMA-T-gRNA-RIP1 targeting (synthetic construct expressing the guide) and Cas9-GFP (pSpCas9(BB)-2A-GFP-Addgene 48138). Both plasmids (one expressing the guide and the other cas9) were transfected with Lipofectamine LTX (Thermo Fisher Scientific). Cells were FACS (BD FACSymphony S6) sorted into single cell clones and analyzed for RIPK1 expression by western blot analysis.</p><p>All cells are tested regularly for mycoplasma by PCR using suitable primers and/or Universal Mycoplasma Detection Kit (ATCC, 30-1012K).</p></sec><sec id="s4-3"><title>Immunoblotting</title><p>Cells were lysed in ice-cold RIPA buffer (50 mM Tris-HCl pH 7.4, 1% NP-40, 0.25% Na-deoxycholate, 120 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1 μg/mL leupeptine/aprotinin/pepstatin, 1 mM Na<sub>3</sub>VO<sub>4</sub>/Na<sub>4</sub>P<sub>2</sub>O<sub>7</sub>/NAF) and mixed with 5× Laemmli Buffer. After heating to 95°C for 10 min, the samples were loaded on 10% acrylamide SDS gels for subsequent electrophoresis. Gels were transferred to a PVDF membrane (Roth) using either the Trans-Blot SD Semi-Dry Transfer Cell (Bio-Rad) or the Mini Trans-Blot Cell (Bio-Rad), blocked in TBS-T with 2.5% BSA for 30 min at room temperature and incubated in the primary antibody overnight at 4°C. Blots were incubated with secondary antibodies for 1 hr at room temperature and washed with TBS-T before imaging. Imaging was performed with a FUSION FX (Vilber). Immunoblot images were analyzed using ImageJ (NHI). The signal of the target protein was then normalized on the indicated loading control (e.g. GAPDH or Vinculin). To normalize AMPK phosphorylation (pAMPK) levels to those of total AMPK, GAPDH-normalized pAMPK levels were divided by their respective GAPDH-normalized total AMPK levels from the same experiment. Primary antibodies used were the rabbit anti-GAPDH (14C10) (Cell Signaling, 2118), rabbit anti-AMPKα (Thr172) (40H9) (Cell Signaling, 2532), rabbit-anti-Phospho-AMPKα (Thr172) (40H9) (Cell Signaling, 2535), rabbit-anti-LKB1 (D60C5) (Cell Signaling, 3047), rabbit-anti-Vinculin (Cell Signaling, 4650), rabbit-anti-RIP (D94C12) XP (Cell Signaling, 3493), rabbit-anti RIP3 (E1Z1D) (Cell Signaling, 13526), anti-CDK6 (DCS83) mouse (Cell Signaling 3136S), mouse-anti-FLAG M2 (Sigma-Aldrich F3165-1MG), rabbit-anti-Renilla Luciferase (EPR17792) (Abcam ab185926), mouse-anti-Renilla Luciferase clone 1D5.2 (Millipore MAB4410).</p></sec><sec id="s4-4"><title>Luciferase PPI assay</title><p>PCA was performed by growing HEK293T cells in DMEM supplemented with 10% FBS in a 24-well plate format. PCA analyses was performed similarly as previously described in <xref ref-type="bibr" rid="bib104">Röck et al., 2019</xref>. HEK293T cells were grown in DMEM supplemented with 10% FBS. The indicated <italic>R</italic>Luc-tagged constructs, one with <italic>R</italic>Luc-F[1] and one with <italic>R</italic>Luc-F[2], were transiently over-expressed following transfection with TransFectin reagent (Bio-Rad, 1703352) in a 24-well plate format. Fourty-eight hours after transfection the medium was carefully aspirated, the cells were washed once with PBS (1 mM sodium phosphate pH 7.2; 15 mM NaCl) and after addition of 150 μL of PBS to each well, transferred to a 96-well plate (Grainer 96 F-Bottom). Bioluminescence was measured after addition of 20 μL (50 ng) h-coelenterazine (Nanolight Technology) using the PHERAstar FSX (BMG Labtech) (measurement start time [s]: 0.2; measurement interval time [s]: 10.00; optic module LUM plus; gain: 3600; focal height [mm] 12.5). Data were evaluated using the MARS Data evaluation Software (BMG Labtech).</p></sec><sec id="s4-5"><title>Luciferase PCA assay (KinCon assay)</title><p>HEK293T cells, cultured in StableCell DMEM (Sigma-Aldrich), were split into 24-well plates at 90.000 cells /well and after 24 hr the indicated plasmids were transfected using TransFectin Lipid reagent (Bio-Rad 1703352) at a total of 50–66 ng/well. After 48 hr of protein expression cells were washed once with PBS (1 mM sodium phosphate pH 7.2; 15 mM NaCl) and after addition of 150 μL of PBS to each well, transferred to a 96-well plate (Grainer 96 F-Bottom). Bioluminescence was measured after addition of 20 μL (50 ng) h-coelenterazine (Nanolight Technology) using the PHERAstar FSX (BMG Labtech) (measurement start time [s]: 0.2; measurement interval time [s]: 10.00; optic module LUM plus; gain: 3600; focal height [mm] 12.5). Data was evaluated using the MARS Data Evaluation Software (BMG Labtech).</p></sec><sec id="s4-6"><title>Inhibitors</title><p>Inhibitors used were Palbociclib (PD 0332991) (MCE Med Chem Express, HY-50767), Abemaciclib (LY2835219) (MCE Med Chem Express, HY-16297A), Ribociclib (LEE011) (MCE Med Chem Express, HY-15777), PLX8394 (MCE Med Chem Express, HY-18972), GSK-547 (MCE Med Chem Express, HY-114492), Necrostatin 2 racemate (1S; Nec-1S; 7-Cl-O-Nec1) (MCE Med Chem Express, HY-14622A), Cobimetinib (GDC-0973; XL518) (MCE Med Chem Express HY13064), TNFα (MCE Med Chem Express, HY-P7090A), z-VAD(OMe)-FMK (MCE Med Chem Express, HY-16658), BV6 (MCE Med Chem Express, HY-16701).</p></sec><sec id="s4-7"><title>Representation of data</title><p>In <xref ref-type="fig" rid="fig1">Figure 1E and F</xref>, representative experiments of n=4 independent experiments are shown. In these cases absolute bioluminescence values without any normalization are presented. Otherwise, data was indicated as RLU fold change. Data was normalized on the indicated control condition (through normalization of expression levels determined by the western blotting).</p></sec><sec id="s4-8"><title>Statistical analyses</title><p>The data were analyzed using GraphPad Prism 8.0. If not indicated otherwise, one-sample t-tests were used to evaluate statistical significance. Values are expressed as the mean ± SEM as indicated. Significance was set at the 95% confidence level and ranked as *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001.</p></sec><sec id="s4-9"><title>Preparation of structures</title><p>The LKB1-STRADα-MO25α (PDB code 2WTK, <xref ref-type="bibr" rid="bib146">Zeqiraj et al., 2009a</xref>) and CDK6-p16<sup>INK4a</sup> (PDB code: 1BI7, <xref ref-type="bibr" rid="bib108">Russo et al., 1998</xref>) complex structures were prepared using the default setting of the Protein Preparation Wizard <xref ref-type="bibr" rid="bib71">Madhavi Sastry et al., 2013</xref>, <xref ref-type="bibr" rid="bib113">Schrödinger, 2019</xref> in Maestro Schrödinger release 2019-4 (Schrödinger Release 2019-4:<xref ref-type="bibr" rid="bib113">Schrödinger, 2019</xref>). The construct used to generate the LKB1 structure contained the inactivating mutation D194A, intended to prevent Mg<sup>2+</sup> binding (<xref ref-type="bibr" rid="bib146">Zeqiraj et al., 2009a</xref>). This mutation was converted back to the wt Asp residue using MOE version v2022.02 (Molecular Operating Environment [MOE], 2022.02; Chemical Computing Group ULC, 1010 Sherbrooke St. West, Suite 910, Montreal, QC, Canada, H3A 2R7, 2022). For the calculation of the CDK6 R31C mutant, only the CDK6 residues within 12 Å of p16<sup>INK4a</sup> were retained. The mutation was then generated using Osprey v2.2beta (<xref ref-type="bibr" rid="bib16">Chen et al., 2009</xref>, <xref ref-type="bibr" rid="bib38">Gainza et al., 2013</xref>) as described before (<xref ref-type="bibr" rid="bib49">Kaserer and Blagg, 2018</xref>). Figures were generated using PyMOL version 2.5.0 (The PyMOL Molecular Graphics System, version 2.5.0 Schrödinger, LLC).</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>ES and PT are co-founders of KinCon biolabs; KinCon-reporters are subject of patents (WO2018060415A1)</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Data curation, Formal analysis, Validation, Investigation, Visualization, Writing – original draft</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Funding acquisition, Validation, Investigation, Visualization, Writing – original draft</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Validation, Investigation</p></fn><fn fn-type="con" id="con4"><p>Data curation, Formal analysis, Validation, Investigation</p></fn><fn fn-type="con" id="con5"><p>Data curation, Formal analysis, Validation, Investigation</p></fn><fn fn-type="con" id="con6"><p>Data curation, Formal analysis, Validation, Investigation</p></fn><fn fn-type="con" id="con7"><p>Visualization</p></fn><fn fn-type="con" id="con8"><p>Resources, Data curation</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Conceptualization</p></fn><fn fn-type="con" id="con11"><p>Conceptualization</p></fn><fn fn-type="con" id="con12"><p>Conceptualization</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Data curation, Software, Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Resources, Supervision, Funding acquisition, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-94755-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Data supporting the findings of this study are available within the article and the corresponding raw data is freely available as a PDF-File on Zenodo (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5281/zenodo.12073536">https://doi.org/10.5281/zenodo.12073536</ext-link>).</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Kugler</surname><given-names>V</given-names></name><name><surname>Schwaighofer</surname><given-names>S</given-names></name><name><surname>Feichtner</surname><given-names>A</given-names></name><name><surname>Enzler</surname><given-names>F</given-names></name><name><surname>Fleischmann</surname><given-names>J</given-names></name><name><surname>Strich</surname><given-names>S</given-names></name><name><surname>Schwarz</surname><given-names>S</given-names></name><name><surname>Wilson</surname><given-names>R</given-names></name><name><surname>Tschaikner</surname><given-names>P</given-names></name><name><surname>Troppmair</surname><given-names>J</given-names></name><name><surname>Sexl</surname><given-names>V</given-names></name><name><surname>Meier</surname><given-names>P</given-names></name><name><surname>Kaserer</surname><given-names>T</given-names></name><name><surname>Stefan</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>Kinases in motion: impact of protein and small molecule interactions on kinase conformations</data-title><source>Zenodo</source><pub-id pub-id-type="doi">10.5281/zenodo.12073536</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Thomas Nuener for technical, and Erika Lentner and Gabriele Reiter for management support. We thank Alexandra Fritz for her contributions to advance the KinCon technology. Further we would like to thank the Dr. Martin Steinmeyer Foundation for support.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al Bakir</surname><given-names>M</given-names></name><name><surname>Huebner</surname><given-names>A</given-names></name><name><surname>Martínez-Ruiz</surname><given-names>C</given-names></name><name><surname>Grigoriadis</surname><given-names>K</given-names></name><name><surname>Watkins</surname><given-names>TBK</given-names></name><name><surname>Pich</surname><given-names>O</given-names></name><name><surname>Moore</surname><given-names>DA</given-names></name><name><surname>Veeriah</surname><given-names>S</given-names></name><name><surname>Ward</surname><given-names>S</given-names></name><name><surname>Laycock</surname><given-names>J</given-names></name><name><surname>Johnson</surname><given-names>D</given-names></name><name><surname>Rowan</surname><given-names>A</given-names></name><name><surname>Razaq</surname><given-names>M</given-names></name><name><surname>Akther</surname><given-names>M</given-names></name><name><surname>Naceur-Lombardelli</surname><given-names>C</given-names></name><name><surname>Prymas</surname><given-names>P</given-names></name><name><surname>Toncheva</surname><given-names>A</given-names></name><name><surname>Hessey</surname><given-names>S</given-names></name><name><surname>Dietzen</surname><given-names>M</given-names></name><name><surname>Colliver</surname><given-names>E</given-names></name><name><surname>Frankell</surname><given-names>AM</given-names></name><name><surname>Bunkum</surname><given-names>A</given-names></name><name><surname>Lim</surname><given-names>EL</given-names></name><name><surname>Karasaki</surname><given-names>T</given-names></name><name><surname>Abbosh</surname><given-names>C</given-names></name><name><surname>Hiley</surname><given-names>CT</given-names></name><name><surname>Hill</surname><given-names>MS</given-names></name><name><surname>Cook</surname><given-names>DE</given-names></name><name><surname>Wilson</surname><given-names>GA</given-names></name><name><surname>Salgado</surname><given-names>R</given-names></name><name><surname>Nye</surname><given-names>E</given-names></name><name><surname>Stone</surname><given-names>RK</given-names></name><name><surname>Fennell</surname><given-names>DA</given-names></name><name><surname>Price</surname><given-names>G</given-names></name><name><surname>Kerr</surname><given-names>KM</given-names></name><name><surname>Naidu</surname><given-names>B</given-names></name><name><surname>Middleton</surname><given-names>G</given-names></name><name><surname>Summers</surname><given-names>Y</given-names></name><name><surname>Lindsay</surname><given-names>CR</given-names></name><name><surname>Blackhall</surname><given-names>FH</given-names></name><name><surname>Cave</surname><given-names>J</given-names></name><name><surname>Blyth</surname><given-names>KG</given-names></name><name><surname>Nair</surname><given-names>A</given-names></name><name><surname>Ahmed</surname><given-names>A</given-names></name><name><surname>Taylor</surname><given-names>MN</given-names></name><name><surname>Procter</surname><given-names>AJ</given-names></name><name><surname>Falzon</surname><given-names>M</given-names></name><name><surname>Lawrence</surname><given-names>D</given-names></name><name><surname>Navani</surname><given-names>N</given-names></name><name><surname>Thakrar</surname><given-names>RM</given-names></name><name><surname>Janes</surname><given-names>SM</given-names></name><name><surname>Papadatos-Pastos</surname><given-names>D</given-names></name><name><surname>Forster</surname><given-names>MD</given-names></name><name><surname>Lee</surname><given-names>SM</given-names></name><name><surname>Ahmad</surname><given-names>T</given-names></name><name><surname>Quezada</surname><given-names>SA</given-names></name><name><surname>Peggs</surname><given-names>KS</given-names></name><name><surname>Van Loo</surname><given-names>P</given-names></name><name><surname>Dive</surname><given-names>C</given-names></name><name><surname>Hackshaw</surname><given-names>A</given-names></name><name><surname>Birkbak</surname><given-names>NJ</given-names></name><name><surname>Zaccaria</surname><given-names>S</given-names></name><name><surname>Jamal-Hanjani</surname><given-names>M</given-names></name><name><surname>McGranahan</surname><given-names>N</given-names></name><name><surname>Swanton</surname><given-names>C</given-names></name><collab>TRACERx Consortium</collab></person-group><year iso-8601-date="2023">2023</year><article-title>The evolution of non-small cell lung cancer metastases in TRACERx</article-title><source>Nature</source><volume>616</volume><fpage>534</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-05729-x</pub-id><pub-id pub-id-type="pmid">37046095</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Álvarez-Fernández</surname><given-names>M</given-names></name><name><surname>Malumbres</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mechanisms of sensitivity and resistance to CDK4/6 inhibition</article-title><source>Cancer Cell</source><volume>37</volume><fpage>514</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2020.03.010</pub-id><pub-id pub-id-type="pmid">32289274</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arter</surname><given-names>C</given-names></name><name><surname>Trask</surname><given-names>L</given-names></name><name><surname>Ward</surname><given-names>S</given-names></name><name><surname>Yeoh</surname><given-names>S</given-names></name><name><surname>Bayliss</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Structural features of the protein kinase domain and targeted binding by small-molecule inhibitors</article-title><source>The Journal of Biological Chemistry</source><volume>298</volume><elocation-id>102247</elocation-id><pub-id pub-id-type="doi">10.1016/j.jbc.2022.102247</pub-id><pub-id pub-id-type="pmid">35830914</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avruch</surname><given-names>J</given-names></name><name><surname>Khokhlatchev</surname><given-names>A</given-names></name><name><surname>Kyriakis</surname><given-names>JM</given-names></name><name><surname>Luo</surname><given-names>Z</given-names></name><name><surname>Tzivion</surname><given-names>G</given-names></name><name><surname>Vavvas</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>XF</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade</article-title><source>Recent Progress in Hormone Research</source><volume>56</volume><fpage>127</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1210/rp.56.1.127</pub-id><pub-id pub-id-type="pmid">11237210</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baas</surname><given-names>AF</given-names></name><name><surname>Boudeau</surname><given-names>J</given-names></name><name><surname>Sapkota</surname><given-names>GP</given-names></name><name><surname>Smit</surname><given-names>L</given-names></name><name><surname>Medema</surname><given-names>R</given-names></name><name><surname>Morrice</surname><given-names>NA</given-names></name><name><surname>Alessi</surname><given-names>DR</given-names></name><name><surname>Clevers</surname><given-names>HC</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Activation of the tumour suppressor kinase LKB1 by the STE20-like pseudokinase STRAD</article-title><source>The EMBO Journal</source><volume>22</volume><fpage>3062</fpage><lpage>3072</lpage><pub-id pub-id-type="doi">10.1093/emboj/cdg292</pub-id><pub-id pub-id-type="pmid">12805220</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beggs</surname><given-names>AD</given-names></name><name><surname>Latchford</surname><given-names>AR</given-names></name><name><surname>Vasen</surname><given-names>HFA</given-names></name><name><surname>Moslein</surname><given-names>G</given-names></name><name><surname>Alonso</surname><given-names>A</given-names></name><name><surname>Aretz</surname><given-names>S</given-names></name><name><surname>Bertario</surname><given-names>L</given-names></name><name><surname>Blanco</surname><given-names>I</given-names></name><name><surname>Bülow</surname><given-names>S</given-names></name><name><surname>Burn</surname><given-names>J</given-names></name><name><surname>Capella</surname><given-names>G</given-names></name><name><surname>Colas</surname><given-names>C</given-names></name><name><surname>Friedl</surname><given-names>W</given-names></name><name><surname>Møller</surname><given-names>P</given-names></name><name><surname>Hes</surname><given-names>FJ</given-names></name><name><surname>Järvinen</surname><given-names>H</given-names></name><name><surname>Mecklin</surname><given-names>J-P</given-names></name><name><surname>Nagengast</surname><given-names>FM</given-names></name><name><surname>Parc</surname><given-names>Y</given-names></name><name><surname>Phillips</surname><given-names>RKS</given-names></name><name><surname>Hyer</surname><given-names>W</given-names></name><name><surname>Ponz de Leon</surname><given-names>M</given-names></name><name><surname>Renkonen-Sinisalo</surname><given-names>L</given-names></name><name><surname>Sampson</surname><given-names>JR</given-names></name><name><surname>Stormorken</surname><given-names>A</given-names></name><name><surname>Tejpar</surname><given-names>S</given-names></name><name><surname>Thomas</surname><given-names>HJW</given-names></name><name><surname>Wijnen</surname><given-names>JT</given-names></name><name><surname>Clark</surname><given-names>SK</given-names></name><name><surname>Hodgson</surname><given-names>SV</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Peutz-Jeghers syndrome: a systematic review and recommendations for management</article-title><source>Gut</source><volume>59</volume><fpage>975</fpage><lpage>986</lpage><pub-id pub-id-type="doi">10.1136/gut.2009.198499</pub-id><pub-id pub-id-type="pmid">20581245</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berginski</surname><given-names>ME</given-names></name><name><surname>Moret</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Goldfarb</surname><given-names>D</given-names></name><name><surname>Sorger</surname><given-names>PK</given-names></name><name><surname>Gomez</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The dark kinase knowledgebase: an online compendium of knowledge and experimental results of understudied kinases</article-title><source>Nucleic Acids Research</source><volume>49</volume><fpage>D529</fpage><lpage>D535</lpage><pub-id pub-id-type="doi">10.1093/nar/gkaa853</pub-id><pub-id pub-id-type="pmid">33079988</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhullar</surname><given-names>KS</given-names></name><name><surname>Lagarón</surname><given-names>NO</given-names></name><name><surname>McGowan</surname><given-names>EM</given-names></name><name><surname>Parmar</surname><given-names>I</given-names></name><name><surname>Jha</surname><given-names>A</given-names></name><name><surname>Hubbard</surname><given-names>BP</given-names></name><name><surname>Rupasinghe</surname><given-names>HPV</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Kinase-targeted cancer therapies: progress, challenges and future directions</article-title><source>Molecular Cancer</source><volume>17</volume><elocation-id>48</elocation-id><pub-id pub-id-type="doi">10.1186/s12943-018-0804-2</pub-id><pub-id pub-id-type="pmid">29455673</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blume-Jensen</surname><given-names>P</given-names></name><name><surname>Hunter</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Oncogenic kinase signalling</article-title><source>Nature</source><volume>411</volume><fpage>355</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1038/35077225</pub-id><pub-id pub-id-type="pmid">11357143</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolger</surname><given-names>GB</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The cAMP-signaling cancers: clinically-divergent disorders with a common central pathway</article-title><source>Frontiers in Endocrinology</source><volume>13</volume><elocation-id>1024423</elocation-id><pub-id pub-id-type="doi">10.3389/fendo.2022.1024423</pub-id><pub-id pub-id-type="pmid">36313756</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boudeau</surname><given-names>J</given-names></name><name><surname>Baas</surname><given-names>AF</given-names></name><name><surname>Deak</surname><given-names>M</given-names></name><name><surname>Morrice</surname><given-names>NA</given-names></name><name><surname>Kieloch</surname><given-names>A</given-names></name><name><surname>Schutkowski</surname><given-names>M</given-names></name><name><surname>Prescott</surname><given-names>AR</given-names></name><name><surname>Clevers</surname><given-names>HC</given-names></name><name><surname>Alessi</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>MO25alpha/beta interact with STRADalpha/beta enhancing their ability to bind, activate and localize LKB1 in the cytoplasm</article-title><source>The EMBO Journal</source><volume>22</volume><fpage>5102</fpage><lpage>5114</lpage><pub-id pub-id-type="doi">10.1093/emboj/cdg490</pub-id><pub-id pub-id-type="pmid">14517248</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boudeau</surname><given-names>J</given-names></name><name><surname>Scott</surname><given-names>JW</given-names></name><name><surname>Resta</surname><given-names>N</given-names></name><name><surname>Deak</surname><given-names>M</given-names></name><name><surname>Kieloch</surname><given-names>A</given-names></name><name><surname>Komander</surname><given-names>D</given-names></name><name><surname>Hardie</surname><given-names>DG</given-names></name><name><surname>Prescott</surname><given-names>AR</given-names></name><name><surname>van Aalten</surname><given-names>DMF</given-names></name><name><surname>Alessi</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Analysis of the LKB1-STRAD-MO25 complex</article-title><source>Journal of Cell Science</source><volume>117</volume><fpage>6365</fpage><lpage>6375</lpage><pub-id pub-id-type="doi">10.1242/jcs.01571</pub-id><pub-id pub-id-type="pmid">15561763</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boudeau</surname><given-names>J</given-names></name><name><surname>Miranda-Saavedra</surname><given-names>D</given-names></name><name><surname>Barton</surname><given-names>GJ</given-names></name><name><surname>Alessi</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Emerging roles of pseudokinases</article-title><source>Trends in Cell Biology</source><volume>16</volume><fpage>443</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2006.07.003</pub-id><pub-id pub-id-type="pmid">16879967</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capra</surname><given-names>M</given-names></name><name><surname>Nuciforo</surname><given-names>PG</given-names></name><name><surname>Confalonieri</surname><given-names>S</given-names></name><name><surname>Quarto</surname><given-names>M</given-names></name><name><surname>Bianchi</surname><given-names>M</given-names></name><name><surname>Nebuloni</surname><given-names>M</given-names></name><name><surname>Boldorini</surname><given-names>R</given-names></name><name><surname>Pallotti</surname><given-names>F</given-names></name><name><surname>Viale</surname><given-names>G</given-names></name><name><surname>Gishizky</surname><given-names>ML</given-names></name><name><surname>Draetta</surname><given-names>GF</given-names></name><name><surname>Di Fiore</surname><given-names>PP</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Frequent alterations in the expression of serine/threonine kinases in human cancers</article-title><source>Cancer Research</source><volume>66</volume><fpage>8147</fpage><lpage>8154</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-3489</pub-id><pub-id pub-id-type="pmid">16912193</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>IS</given-names></name><name><surname>Ginsburg</surname><given-names>GS</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Personalized medicine: progress and promise</article-title><source>Annual Review of Genomics and Human Genetics</source><volume>12</volume><fpage>217</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1146/annurev-genom-082410-101446</pub-id><pub-id pub-id-type="pmid">21721939</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>CY</given-names></name><name><surname>Georgiev</surname><given-names>I</given-names></name><name><surname>Anderson</surname><given-names>AC</given-names></name><name><surname>Donald</surname><given-names>BR</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Computational structure-based redesign of enzyme activity</article-title><source>PNAS</source><volume>106</volume><fpage>3764</fpage><lpage>3769</lpage><pub-id pub-id-type="doi">10.1073/pnas.0900266106</pub-id><pub-id pub-id-type="pmid">19228942</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>Y</given-names></name><name><surname>McQuade</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Chan</surname><given-names>FKM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>RIP1-dependent and independent effects of necrostatin-1 in necrosis and T cell activation</article-title><source>PLOS ONE</source><volume>6</volume><elocation-id>e23209</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0023209</pub-id><pub-id pub-id-type="pmid">21853090</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>YJ</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Hydbring</surname><given-names>P</given-names></name><name><surname>Sanda</surname><given-names>T</given-names></name><name><surname>Stefano</surname><given-names>J</given-names></name><name><surname>Christie</surname><given-names>AL</given-names></name><name><surname>Signoretti</surname><given-names>S</given-names></name><name><surname>Look</surname><given-names>AT</given-names></name><name><surname>Kung</surname><given-names>AL</given-names></name><name><surname>von Boehmer</surname><given-names>H</given-names></name><name><surname>Sicinski</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The requirement for cyclin D function in tumor maintenance</article-title><source>Cancer Cell</source><volume>22</volume><fpage>438</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2012.09.015</pub-id><pub-id pub-id-type="pmid">23079655</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>KC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Progresses in predicting post-translational modification</article-title><source>International Journal of Peptide Research and Therapeutics</source><volume>26</volume><fpage>873</fpage><lpage>888</lpage><pub-id pub-id-type="doi">10.1007/s10989-019-09893-5</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christofferson</surname><given-names>DE</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Hitomi</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Upperman</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Gerber</surname><given-names>SA</given-names></name><name><surname>Gygi</surname><given-names>S</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A novel role for RIP1 kinase in mediating TNFα production</article-title><source>Cell Death &amp; Disease</source><volume>3</volume><elocation-id>e320</elocation-id><pub-id pub-id-type="doi">10.1038/cddis.2012.64</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cicenas</surname><given-names>J</given-names></name><name><surname>Zalyte</surname><given-names>E</given-names></name><name><surname>Bairoch</surname><given-names>A</given-names></name><name><surname>Gaudet</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Kinases and cancer</article-title><source>Cancers</source><volume>10</volume><elocation-id>63</elocation-id><pub-id pub-id-type="doi">10.3390/cancers10030063</pub-id><pub-id pub-id-type="pmid">29494549</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clucas</surname><given-names>J</given-names></name><name><surname>Meier</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Roles of RIPK1 as a stress sentinel coordinating cell survival and immunogenic cell death</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>24</volume><fpage>835</fpage><lpage>852</lpage><pub-id pub-id-type="doi">10.1038/s41580-023-00623-w</pub-id><pub-id pub-id-type="pmid">37568036</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The regulation of protein function by multisite phosphorylation--a 25 year update</article-title><source>Trends in Biochemical Sciences</source><volume>25</volume><fpage>596</fpage><lpage>601</lpage><pub-id pub-id-type="doi">10.1016/s0968-0004(00)01712-6</pub-id><pub-id pub-id-type="pmid">11116185</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Croce</surname><given-names>L</given-names></name><name><surname>Coperchini</surname><given-names>F</given-names></name><name><surname>Magri</surname><given-names>F</given-names></name><name><surname>Chiovato</surname><given-names>L</given-names></name><name><surname>Rotondi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The multifaceted anti-cancer effects of BRAF-inhibitors</article-title><source>Oncotarget</source><volume>10</volume><fpage>6623</fpage><lpage>6640</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.27304</pub-id><pub-id pub-id-type="pmid">31762942</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>H</given-names></name><name><surname>Bignell</surname><given-names>GR</given-names></name><name><surname>Cox</surname><given-names>C</given-names></name><name><surname>Stephens</surname><given-names>P</given-names></name><name><surname>Edkins</surname><given-names>S</given-names></name><name><surname>Clegg</surname><given-names>S</given-names></name><name><surname>Teague</surname><given-names>J</given-names></name><name><surname>Woffendin</surname><given-names>H</given-names></name><name><surname>Garnett</surname><given-names>MJ</given-names></name><name><surname>Bottomley</surname><given-names>W</given-names></name><name><surname>Davis</surname><given-names>N</given-names></name><name><surname>Dicks</surname><given-names>E</given-names></name><name><surname>Ewing</surname><given-names>R</given-names></name><name><surname>Floyd</surname><given-names>Y</given-names></name><name><surname>Gray</surname><given-names>K</given-names></name><name><surname>Hall</surname><given-names>S</given-names></name><name><surname>Hawes</surname><given-names>R</given-names></name><name><surname>Hughes</surname><given-names>J</given-names></name><name><surname>Kosmidou</surname><given-names>V</given-names></name><name><surname>Menzies</surname><given-names>A</given-names></name><name><surname>Mould</surname><given-names>C</given-names></name><name><surname>Parker</surname><given-names>A</given-names></name><name><surname>Stevens</surname><given-names>C</given-names></name><name><surname>Watt</surname><given-names>S</given-names></name><name><surname>Hooper</surname><given-names>S</given-names></name><name><surname>Wilson</surname><given-names>R</given-names></name><name><surname>Jayatilake</surname><given-names>H</given-names></name><name><surname>Gusterson</surname><given-names>BA</given-names></name><name><surname>Cooper</surname><given-names>C</given-names></name><name><surname>Shipley</surname><given-names>J</given-names></name><name><surname>Hargrave</surname><given-names>D</given-names></name><name><surname>Pritchard-Jones</surname><given-names>K</given-names></name><name><surname>Maitland</surname><given-names>N</given-names></name><name><surname>Chenevix-Trench</surname><given-names>G</given-names></name><name><surname>Riggins</surname><given-names>GJ</given-names></name><name><surname>Bigner</surname><given-names>DD</given-names></name><name><surname>Palmieri</surname><given-names>G</given-names></name><name><surname>Cossu</surname><given-names>A</given-names></name><name><surname>Flanagan</surname><given-names>A</given-names></name><name><surname>Nicholson</surname><given-names>A</given-names></name><name><surname>Ho</surname><given-names>JWC</given-names></name><name><surname>Leung</surname><given-names>SY</given-names></name><name><surname>Yuen</surname><given-names>ST</given-names></name><name><surname>Weber</surname><given-names>BL</given-names></name><name><surname>Seigler</surname><given-names>HF</given-names></name><name><surname>Darrow</surname><given-names>TL</given-names></name><name><surname>Paterson</surname><given-names>H</given-names></name><name><surname>Marais</surname><given-names>R</given-names></name><name><surname>Marshall</surname><given-names>CJ</given-names></name><name><surname>Wooster</surname><given-names>R</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Mutations of the BRAF gene in human cancer</article-title><source>Nature</source><volume>417</volume><fpage>949</fpage><lpage>954</lpage><pub-id pub-id-type="doi">10.1038/nature00766</pub-id><pub-id pub-id-type="pmid">12068308</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Degterev</surname><given-names>A</given-names></name><name><surname>Ofengeim</surname><given-names>D</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Targeting RIPK1 for the treatment of human diseases</article-title><source>PNAS</source><volume>116</volume><fpage>9714</fpage><lpage>9722</lpage><pub-id pub-id-type="doi">10.1073/pnas.1901179116</pub-id><pub-id pub-id-type="pmid">31048504</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deribe</surname><given-names>YL</given-names></name><name><surname>Pawson</surname><given-names>T</given-names></name><name><surname>Dikic</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Post-translational modifications in signal integration</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>17</volume><fpage>666</fpage><lpage>672</lpage><pub-id pub-id-type="doi">10.1038/nsmb.1842</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dondelinger</surname><given-names>Y</given-names></name><name><surname>Delanghe</surname><given-names>T</given-names></name><name><surname>Priem</surname><given-names>D</given-names></name><name><surname>Wynosky-Dolfi</surname><given-names>MA</given-names></name><name><surname>Sorobetea</surname><given-names>D</given-names></name><name><surname>Rojas-Rivera</surname><given-names>D</given-names></name><name><surname>Giansanti</surname><given-names>P</given-names></name><name><surname>Roelandt</surname><given-names>R</given-names></name><name><surname>Gropengiesser</surname><given-names>J</given-names></name><name><surname>Ruckdeschel</surname><given-names>K</given-names></name><name><surname>Savvides</surname><given-names>SN</given-names></name><name><surname>Heck</surname><given-names>AJR</given-names></name><name><surname>Vandenabeele</surname><given-names>P</given-names></name><name><surname>Brodsky</surname><given-names>IE</given-names></name><name><surname>Bertrand</surname><given-names>MJM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Serine 25 phosphorylation inhibits RIPK1 kinase-dependent cell death in models of infection and inflammation</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>1729</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-09690-0</pub-id><pub-id pub-id-type="pmid">30988283</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eferl</surname><given-names>R</given-names></name><name><surname>Wagner</surname><given-names>EF</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>AP-1: a double-edged sword in tumorigenesis</article-title><source>Nature Reviews. Cancer</source><volume>3</volume><fpage>859</fpage><lpage>868</lpage><pub-id pub-id-type="doi">10.1038/nrc1209</pub-id><pub-id pub-id-type="pmid">14668816</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Enzler</surname><given-names>F</given-names></name><name><surname>Tschaikner</surname><given-names>P</given-names></name><name><surname>Schneider</surname><given-names>R</given-names></name><name><surname>Stefan</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>KinCon: cell-based recording of full-length kinase conformations</article-title><source>IUBMB Life</source><volume>72</volume><fpage>1168</fpage><lpage>1174</lpage><pub-id pub-id-type="doi">10.1002/iub.2241</pub-id><pub-id pub-id-type="pmid">32027084</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fabbro</surname><given-names>D</given-names></name><name><surname>Cowan-Jacob</surname><given-names>SW</given-names></name><name><surname>Moebitz</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Ten things you should know about protein kinases: IUPHAR Review 14</article-title><source>British Journal of Pharmacology</source><volume>172</volume><fpage>2675</fpage><lpage>2700</lpage><pub-id pub-id-type="doi">10.1111/bph.13096</pub-id><pub-id pub-id-type="pmid">25630872</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fassl</surname><given-names>A</given-names></name><name><surname>Geng</surname><given-names>Y</given-names></name><name><surname>Sicinski</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>CDK4 and CDK6 kinases: from basic science to cancer therapy</article-title><source>Science</source><volume>375</volume><elocation-id>eabc1495</elocation-id><pub-id pub-id-type="doi">10.1126/science.abc1495</pub-id><pub-id pub-id-type="pmid">35025636</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feichtner</surname><given-names>A</given-names></name><name><surname>Kugler</surname><given-names>V</given-names></name><name><surname>Schwaighofer</surname><given-names>S</given-names></name><name><surname>Nuener</surname><given-names>T</given-names></name><name><surname>Fleischmann</surname><given-names>J</given-names></name><name><surname>Stefan</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Tracking mutation and drug-driven alterations of oncokinase conformations</article-title><source>Memo</source><volume>15</volume><fpage>137</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1007/s12254-021-00790-6</pub-id><pub-id pub-id-type="pmid">35677701</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferguson</surname><given-names>FM</given-names></name><name><surname>Gray</surname><given-names>NS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Kinase inhibitors: the road ahead</article-title><source>Nature Reviews. Drug Discovery</source><volume>17</volume><fpage>353</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1038/nrd.2018.21</pub-id><pub-id pub-id-type="pmid">29545548</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Festjens</surname><given-names>N</given-names></name><name><surname>Vanden Berghe</surname><given-names>T</given-names></name><name><surname>Cornelis</surname><given-names>S</given-names></name><name><surname>Vandenabeele</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>RIP1, a kinase on the crossroads of a cell’s decision to live or die</article-title><source>Cell Death &amp; Differentiation</source><volume>14</volume><fpage>400</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1038/sj.cdd.4402085</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleischmann</surname><given-names>J</given-names></name><name><surname>Feichtner</surname><given-names>A</given-names></name><name><surname>DeFalco</surname><given-names>L</given-names></name><name><surname>Kugler</surname><given-names>V</given-names></name><name><surname>Schwaighofer</surname><given-names>S</given-names></name><name><surname>Huber</surname><given-names>RG</given-names></name><name><surname>Stefan</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Allosteric kinase inhibitors reshape MEK1 kinase activity conformations in cells and in silico</article-title><source>Biomolecules</source><volume>11</volume><elocation-id>518</elocation-id><pub-id pub-id-type="doi">10.3390/biom11040518</pub-id><pub-id pub-id-type="pmid">33808483</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleischmann</surname><given-names>J</given-names></name><name><surname>Schwaighofer</surname><given-names>S</given-names></name><name><surname>De Falco</surname><given-names>L</given-names></name><name><surname>Enzler</surname><given-names>F</given-names></name><name><surname>Feichtner</surname><given-names>A</given-names></name><name><surname>Kugler</surname><given-names>V</given-names></name><name><surname>Tschaikner</surname><given-names>P</given-names></name><name><surname>Huber</surname><given-names>RG</given-names></name><name><surname>Stefan</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Tracking and blocking interdependencies of cellular BRAF-MEK oncokinase activities</article-title><source>PNAS Nexus</source><volume>2</volume><elocation-id>gad185</elocation-id><pub-id pub-id-type="doi">10.1093/pnasnexus/pgad185</pub-id><pub-id pub-id-type="pmid">37325027</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gainza</surname><given-names>P</given-names></name><name><surname>Roberts</surname><given-names>KE</given-names></name><name><surname>Georgiev</surname><given-names>I</given-names></name><name><surname>Lilien</surname><given-names>RH</given-names></name><name><surname>Keedy</surname><given-names>DA</given-names></name><name><surname>Chen</surname><given-names>C-Y</given-names></name><name><surname>Reza</surname><given-names>F</given-names></name><name><surname>Anderson</surname><given-names>AC</given-names></name><name><surname>Richardson</surname><given-names>DC</given-names></name><name><surname>Richardson</surname><given-names>JS</given-names></name><name><surname>Donald</surname><given-names>BR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>OSPREY: protein design with ensembles, flexibility, and provable algorithms</article-title><source>Methods in Enzymology</source><volume>523</volume><fpage>87</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-394292-0.00005-9</pub-id><pub-id pub-id-type="pmid">23422427</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giacinti</surname><given-names>C</given-names></name><name><surname>Giordano</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>RB and cell cycle progression</article-title><source>Oncogene</source><volume>25</volume><fpage>5220</fpage><lpage>5227</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1209615</pub-id><pub-id pub-id-type="pmid">16936740</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goel</surname><given-names>S</given-names></name><name><surname>DeCristo</surname><given-names>MJ</given-names></name><name><surname>McAllister</surname><given-names>SS</given-names></name><name><surname>Zhao</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>CDK4/6 inhibition in cancer: beyond cell cycle arrest</article-title><source>Trends in Cell Biology</source><volume>28</volume><fpage>911</fpage><lpage>925</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2018.07.002</pub-id><pub-id pub-id-type="pmid">30061045</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goetz</surname><given-names>LH</given-names></name><name><surname>Schork</surname><given-names>NJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Personalized medicine: motivation, challenges, and progress</article-title><source>Fertility and Sterility</source><volume>109</volume><fpage>952</fpage><lpage>963</lpage><pub-id pub-id-type="doi">10.1016/j.fertnstert.2018.05.006</pub-id><pub-id pub-id-type="pmid">29935653</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>YJ</given-names></name><name><surname>Pan</surname><given-names>WW</given-names></name><name><surname>Liu</surname><given-names>SB</given-names></name><name><surname>Shen</surname><given-names>ZF</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>LL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>ERK/MAPK signalling pathway and tumorigenesis</article-title><source>Experimental and Therapeutic Medicine</source><volume>19</volume><fpage>1997</fpage><lpage>2007</lpage><pub-id pub-id-type="doi">10.3892/etm.2020.8454</pub-id><pub-id pub-id-type="pmid">32104259</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huse</surname><given-names>M</given-names></name><name><surname>Kuriyan</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The conformational plasticity of protein kinases</article-title><source>Cell</source><volume>109</volume><fpage>275</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(02)00741-9</pub-id><pub-id pub-id-type="pmid">12015977</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Islam</surname><given-names>MJ</given-names></name><name><surname>Khan</surname><given-names>AM</given-names></name><name><surname>Parves</surname><given-names>MR</given-names></name><name><surname>Hossain</surname><given-names>MN</given-names></name><name><surname>Halim</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Prediction of deleterious non-synonymous SNPs of Human STK11 gene by combining algorithms, molecular docking, and molecular dynamics simulation</article-title><source>Scientific Reports</source><volume>9</volume><elocation-id>16426</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-52308-0</pub-id><pub-id pub-id-type="pmid">31712642</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaco</surname><given-names>I</given-names></name><name><surname>Annibaldi</surname><given-names>A</given-names></name><name><surname>Lalaoui</surname><given-names>N</given-names></name><name><surname>Wilson</surname><given-names>R</given-names></name><name><surname>Tenev</surname><given-names>T</given-names></name><name><surname>Laurien</surname><given-names>L</given-names></name><name><surname>Kim</surname><given-names>C</given-names></name><name><surname>Jamal</surname><given-names>K</given-names></name><name><surname>Wicky John</surname><given-names>S</given-names></name><name><surname>Liccardi</surname><given-names>G</given-names></name><name><surname>Chau</surname><given-names>D</given-names></name><name><surname>Murphy</surname><given-names>JM</given-names></name><name><surname>Brumatti</surname><given-names>G</given-names></name><name><surname>Feltham</surname><given-names>R</given-names></name><name><surname>Pasparakis</surname><given-names>M</given-names></name><name><surname>Silke</surname><given-names>J</given-names></name><name><surname>Meier</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>MK2 phosphorylates RIPK1 to prevent TNF-induced cell death</article-title><source>Molecular Cell</source><volume>66</volume><fpage>698</fpage><lpage>710</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2017.05.003</pub-id><pub-id pub-id-type="pmid">28506461</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>James</surname><given-names>MK</given-names></name><name><surname>Ray</surname><given-names>A</given-names></name><name><surname>Leznova</surname><given-names>D</given-names></name><name><surname>Blain</surname><given-names>SW</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Differential modification of p27Kip1 controls its cyclin D-cdk4 inhibitory activity</article-title><source>Molecular and Cellular Biology</source><volume>28</volume><fpage>498</fpage><lpage>510</lpage><pub-id pub-id-type="doi">10.1128/MCB.02171-06</pub-id><pub-id pub-id-type="pmid">17908796</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karoulia</surname><given-names>Z</given-names></name><name><surname>Gavathiotis</surname><given-names>E</given-names></name><name><surname>Poulikakos</surname><given-names>PI</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>New perspectives for targeting RAF kinase in human cancer</article-title><source>Nature Reviews. Cancer</source><volume>17</volume><fpage>676</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.1038/nrc.2017.79</pub-id><pub-id pub-id-type="pmid">28984291</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasai</surname><given-names>H</given-names></name><name><surname>Petersen</surname><given-names>OH</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Spatial dynamics of second messengers: IP3 and cAMP as long-range and associative messengers</article-title><source>Trends in Neurosciences</source><volume>17</volume><fpage>95</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/0166-2236(94)90112-0</pub-id><pub-id pub-id-type="pmid">7515531</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaserer</surname><given-names>T</given-names></name><name><surname>Blagg</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Combining mutational signatures, clonal fitness, and drug affinity to define drug-specific resistance mutations in cancer</article-title><source>Cell Chemical Biology</source><volume>25</volume><fpage>1359</fpage><lpage>1371</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2018.07.013</pub-id><pub-id pub-id-type="pmid">30146241</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kemp</surname><given-names>BE</given-names></name><name><surname>Parker</surname><given-names>MW</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Tiganis</surname><given-names>T</given-names></name><name><surname>House</surname><given-names>C</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Substrate and pseudosubstrate interactions with protein kinases: determinants of specificity</article-title><source>Trends in Biochemical Sciences</source><volume>19</volume><fpage>440</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1016/0968-0004(94)90126-0</pub-id><pub-id pub-id-type="pmid">7855883</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitajima</surname><given-names>S</given-names></name><name><surname>Ivanova</surname><given-names>E</given-names></name><name><surname>Guo</surname><given-names>S</given-names></name><name><surname>Yoshida</surname><given-names>R</given-names></name><name><surname>Campisi</surname><given-names>M</given-names></name><name><surname>Sundararaman</surname><given-names>SK</given-names></name><name><surname>Tange</surname><given-names>S</given-names></name><name><surname>Mitsuishi</surname><given-names>Y</given-names></name><name><surname>Thai</surname><given-names>TC</given-names></name><name><surname>Masuda</surname><given-names>S</given-names></name><name><surname>Piel</surname><given-names>BP</given-names></name><name><surname>Sholl</surname><given-names>LM</given-names></name><name><surname>Kirschmeier</surname><given-names>PT</given-names></name><name><surname>Paweletz</surname><given-names>CP</given-names></name><name><surname>Watanabe</surname><given-names>H</given-names></name><name><surname>Yajima</surname><given-names>M</given-names></name><name><surname>Barbie</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Suppression of STING associated with LKB1 Loss in KRAS-driven lung cancer</article-title><source>Cancer Discovery</source><volume>9</volume><fpage>34</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-18-0689</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klaeger</surname><given-names>S</given-names></name><name><surname>Heinzlmeir</surname><given-names>S</given-names></name><name><surname>Wilhelm</surname><given-names>M</given-names></name><name><surname>Polzer</surname><given-names>H</given-names></name><name><surname>Vick</surname><given-names>B</given-names></name><name><surname>Koenig</surname><given-names>PA</given-names></name><name><surname>Reinecke</surname><given-names>M</given-names></name><name><surname>Ruprecht</surname><given-names>B</given-names></name><name><surname>Petzoldt</surname><given-names>S</given-names></name><name><surname>Meng</surname><given-names>C</given-names></name><name><surname>Zecha</surname><given-names>J</given-names></name><name><surname>Reiter</surname><given-names>K</given-names></name><name><surname>Qiao</surname><given-names>H</given-names></name><name><surname>Helm</surname><given-names>D</given-names></name><name><surname>Koch</surname><given-names>H</given-names></name><name><surname>Schoof</surname><given-names>M</given-names></name><name><surname>Canevari</surname><given-names>G</given-names></name><name><surname>Casale</surname><given-names>E</given-names></name><name><surname>Depaolini</surname><given-names>SR</given-names></name><name><surname>Feuchtinger</surname><given-names>A</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Schmidt</surname><given-names>T</given-names></name><name><surname>Rueckert</surname><given-names>L</given-names></name><name><surname>Becker</surname><given-names>W</given-names></name><name><surname>Huenges</surname><given-names>J</given-names></name><name><surname>Garz</surname><given-names>AK</given-names></name><name><surname>Gohlke</surname><given-names>BO</given-names></name><name><surname>Zolg</surname><given-names>DP</given-names></name><name><surname>Kayser</surname><given-names>G</given-names></name><name><surname>Vooder</surname><given-names>T</given-names></name><name><surname>Preissner</surname><given-names>R</given-names></name><name><surname>Hahne</surname><given-names>H</given-names></name><name><surname>Tõnisson</surname><given-names>N</given-names></name><name><surname>Kramer</surname><given-names>K</given-names></name><name><surname>Götze</surname><given-names>K</given-names></name><name><surname>Bassermann</surname><given-names>F</given-names></name><name><surname>Schlegl</surname><given-names>J</given-names></name><name><surname>Ehrlich</surname><given-names>HC</given-names></name><name><surname>Aiche</surname><given-names>S</given-names></name><name><surname>Walch</surname><given-names>A</given-names></name><name><surname>Greif</surname><given-names>PA</given-names></name><name><surname>Schneider</surname><given-names>S</given-names></name><name><surname>Felder</surname><given-names>ER</given-names></name><name><surname>Ruland</surname><given-names>J</given-names></name><name><surname>Médard</surname><given-names>G</given-names></name><name><surname>Jeremias</surname><given-names>I</given-names></name><name><surname>Spiekermann</surname><given-names>K</given-names></name><name><surname>Kuster</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The target landscape of clinical kinase drugs</article-title><source>Science</source><volume>358</volume><elocation-id>aan4368</elocation-id><pub-id pub-id-type="doi">10.1126/science.aan4368</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knudsen</surname><given-names>ES</given-names></name><name><surname>Witkiewicz</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The Strange Case of CDK4/6 Inhibitors: mechanisms, resistance, and combination strategies</article-title><source>Trends in Cancer</source><volume>3</volume><fpage>39</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2016.11.006</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kollmann</surname><given-names>K</given-names></name><name><surname>Heller</surname><given-names>G</given-names></name><name><surname>Schneckenleithner</surname><given-names>C</given-names></name><name><surname>Warsch</surname><given-names>W</given-names></name><name><surname>Scheicher</surname><given-names>R</given-names></name><name><surname>Ott</surname><given-names>RG</given-names></name><name><surname>Schäfer</surname><given-names>M</given-names></name><name><surname>Fajmann</surname><given-names>S</given-names></name><name><surname>Schlederer</surname><given-names>M</given-names></name><name><surname>Schiefer</surname><given-names>A-I</given-names></name><name><surname>Reichart</surname><given-names>U</given-names></name><name><surname>Mayerhofer</surname><given-names>M</given-names></name><name><surname>Hoeller</surname><given-names>C</given-names></name><name><surname>Zöchbauer-Müller</surname><given-names>S</given-names></name><name><surname>Kerjaschki</surname><given-names>D</given-names></name><name><surname>Bock</surname><given-names>C</given-names></name><name><surname>Kenner</surname><given-names>L</given-names></name><name><surname>Hoefler</surname><given-names>G</given-names></name><name><surname>Freissmuth</surname><given-names>M</given-names></name><name><surname>Green</surname><given-names>AR</given-names></name><name><surname>Moriggl</surname><given-names>R</given-names></name><name><surname>Busslinger</surname><given-names>M</given-names></name><name><surname>Malumbres</surname><given-names>M</given-names></name><name><surname>Sexl</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis</article-title><source>Cancer Cell</source><volume>24</volume><fpage>167</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2013.07.012</pub-id><pub-id pub-id-type="pmid">23948297</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kollmann</surname><given-names>K</given-names></name><name><surname>Sexl</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>CDK6 and p16INK4A in lymphoid malignancies</article-title><source>Oncotarget</source><volume>4</volume><fpage>1858</fpage><lpage>1859</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.1541</pub-id><pub-id pub-id-type="pmid">24161991</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kornev</surname><given-names>AP</given-names></name><name><surname>Taylor</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Defining the conserved internal architecture of a protein kinase</article-title><source>Biochimica et Biophysica Acta</source><volume>1804</volume><fpage>440</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1016/j.bbapap.2009.10.017</pub-id><pub-id pub-id-type="pmid">19879387</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Köstler</surname><given-names>WJ</given-names></name><name><surname>Zielinski</surname><given-names>CC</given-names></name></person-group><year iso-8601-date="2015">2015</year><chapter-title>Targeting receptor tyrosine kinases in cancer</chapter-title><person-group person-group-type="editor"><name><surname>Wheeler</surname><given-names>D</given-names></name><name><surname>Yarden</surname><given-names>Y</given-names></name></person-group><source>Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease</source><publisher-name>Springer</publisher-name><fpage>225</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-2053-2_10</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kung</surname><given-names>JE</given-names></name><name><surname>Jura</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Prospects for pharmacological targeting of pseudokinases</article-title><source>Nature Reviews. Drug Discovery</source><volume>18</volume><fpage>501</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1038/s41573-019-0018-3</pub-id><pub-id pub-id-type="pmid">30850748</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lahiry</surname><given-names>P</given-names></name><name><surname>Torkamani</surname><given-names>A</given-names></name><name><surname>Schork</surname><given-names>NJ</given-names></name><name><surname>Hegele</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Kinase mutations in human disease: interpreting genotype-phenotype relationships</article-title><source>Nature Reviews. Genetics</source><volume>11</volume><fpage>60</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1038/nrg2707</pub-id><pub-id pub-id-type="pmid">20019687</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lalaoui</surname><given-names>N</given-names></name><name><surname>Boyden</surname><given-names>SE</given-names></name><name><surname>Oda</surname><given-names>H</given-names></name><name><surname>Wood</surname><given-names>GM</given-names></name><name><surname>Stone</surname><given-names>DL</given-names></name><name><surname>Chau</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Stoffels</surname><given-names>M</given-names></name><name><surname>Kratina</surname><given-names>T</given-names></name><name><surname>Lawlor</surname><given-names>KE</given-names></name><name><surname>Zaal</surname><given-names>KJM</given-names></name><name><surname>Hoffmann</surname><given-names>PM</given-names></name><name><surname>Etemadi</surname><given-names>N</given-names></name><name><surname>Shield-Artin</surname><given-names>K</given-names></name><name><surname>Biben</surname><given-names>C</given-names></name><name><surname>Tsai</surname><given-names>WL</given-names></name><name><surname>Blake</surname><given-names>MD</given-names></name><name><surname>Kuehn</surname><given-names>HS</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Anderton</surname><given-names>H</given-names></name><name><surname>Silke</surname><given-names>N</given-names></name><name><surname>Wachsmuth</surname><given-names>L</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Moura</surname><given-names>NS</given-names></name><name><surname>Beck</surname><given-names>DB</given-names></name><name><surname>Gutierrez-Cruz</surname><given-names>G</given-names></name><name><surname>Ombrello</surname><given-names>AK</given-names></name><name><surname>Pinto-Patarroyo</surname><given-names>GP</given-names></name><name><surname>Kueh</surname><given-names>AJ</given-names></name><name><surname>Herold</surname><given-names>MJ</given-names></name><name><surname>Hall</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Chae</surname><given-names>JJ</given-names></name><name><surname>Dmitrieva</surname><given-names>NI</given-names></name><name><surname>McKenzie</surname><given-names>M</given-names></name><name><surname>Light</surname><given-names>A</given-names></name><name><surname>Barham</surname><given-names>BK</given-names></name><name><surname>Jones</surname><given-names>A</given-names></name><name><surname>Romeo</surname><given-names>TM</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Aksentijevich</surname><given-names>I</given-names></name><name><surname>Mullikin</surname><given-names>JC</given-names></name><name><surname>Gross</surname><given-names>AJ</given-names></name><name><surname>Shum</surname><given-names>AK</given-names></name><name><surname>Hawkins</surname><given-names>ED</given-names></name><name><surname>Masters</surname><given-names>SL</given-names></name><name><surname>Lenardo</surname><given-names>MJ</given-names></name><name><surname>Boehm</surname><given-names>M</given-names></name><name><surname>Rosenzweig</surname><given-names>SD</given-names></name><name><surname>Pasparakis</surname><given-names>M</given-names></name><name><surname>Voss</surname><given-names>AK</given-names></name><name><surname>Gadina</surname><given-names>M</given-names></name><name><surname>Kastner</surname><given-names>DL</given-names></name><name><surname>Silke</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory disease</article-title><source>Nature</source><volume>577</volume><fpage>103</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1828-5</pub-id><pub-id pub-id-type="pmid">31827281</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Launonen</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Mutations in the human LKB1/STK11 gene</article-title><source>Human Mutation</source><volume>26</volume><fpage>291</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1002/humu.20222</pub-id><pub-id pub-id-type="pmid">16110486</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laurien</surname><given-names>L</given-names></name><name><surname>Nagata</surname><given-names>M</given-names></name><name><surname>Schünke</surname><given-names>H</given-names></name><name><surname>Delanghe</surname><given-names>T</given-names></name><name><surname>Wiederstein</surname><given-names>JL</given-names></name><name><surname>Kumari</surname><given-names>S</given-names></name><name><surname>Schwarzer</surname><given-names>R</given-names></name><name><surname>Corona</surname><given-names>T</given-names></name><name><surname>Krüger</surname><given-names>M</given-names></name><name><surname>Bertrand</surname><given-names>MJM</given-names></name><name><surname>Kondylis</surname><given-names>V</given-names></name><name><surname>Pasparakis</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Autophosphorylation at serine 166 regulates RIP kinase 1-mediated cell death and inflammation</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>1747</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-15466-8</pub-id><pub-id pub-id-type="pmid">32269263</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavoie</surname><given-names>H</given-names></name><name><surname>Gagnon</surname><given-names>J</given-names></name><name><surname>Therrien</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>ERK signalling: a master regulator of cell behaviour, life and fate</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>21</volume><fpage>607</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1038/s41580-020-0255-7</pub-id><pub-id pub-id-type="pmid">32576977</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Giacalone</surname><given-names>NJ</given-names></name><name><surname>Torossian</surname><given-names>A</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Niu</surname><given-names>K</given-names></name><name><surname>Lin-Tsai</surname><given-names>O</given-names></name><name><surname>Lu</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>BV6, an IAP antagonist, activates apoptosis and enhances radiosensitization of non-small cell lung carcinoma in vitro</article-title><source>Journal of Thoracic Oncology</source><volume>6</volume><fpage>1801</fpage><lpage>1809</lpage><pub-id pub-id-type="doi">10.1097/JTO.0b013e318226b4a6</pub-id><pub-id pub-id-type="pmid">21760551</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Führer</surname><given-names>M</given-names></name><name><surname>Bahrami</surname><given-names>E</given-names></name><name><surname>Socha</surname><given-names>P</given-names></name><name><surname>Klaudel-Dreszler</surname><given-names>M</given-names></name><name><surname>Bouzidi</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Lehle</surname><given-names>AS</given-names></name><name><surname>Magg</surname><given-names>T</given-names></name><name><surname>Hollizeck</surname><given-names>S</given-names></name><name><surname>Rohlfs</surname><given-names>M</given-names></name><name><surname>Conca</surname><given-names>R</given-names></name><name><surname>Field</surname><given-names>M</given-names></name><name><surname>Warner</surname><given-names>N</given-names></name><name><surname>Mordechai</surname><given-names>S</given-names></name><name><surname>Shteyer</surname><given-names>E</given-names></name><name><surname>Turner</surname><given-names>D</given-names></name><name><surname>Boukari</surname><given-names>R</given-names></name><name><surname>Belbouab</surname><given-names>R</given-names></name><name><surname>Walz</surname><given-names>C</given-names></name><name><surname>Gaidt</surname><given-names>MM</given-names></name><name><surname>Hornung</surname><given-names>V</given-names></name><name><surname>Baumann</surname><given-names>B</given-names></name><name><surname>Pannicke</surname><given-names>U</given-names></name><name><surname>Al Idrissi</surname><given-names>E</given-names></name><name><surname>Ali Alghamdi</surname><given-names>H</given-names></name><name><surname>Sepulveda</surname><given-names>FE</given-names></name><name><surname>Gil</surname><given-names>M</given-names></name><name><surname>de Saint Basile</surname><given-names>G</given-names></name><name><surname>Hönig</surname><given-names>M</given-names></name><name><surname>Koletzko</surname><given-names>S</given-names></name><name><surname>Muise</surname><given-names>AM</given-names></name><name><surname>Snapper</surname><given-names>SB</given-names></name><name><surname>Schwarz</surname><given-names>K</given-names></name><name><surname>Klein</surname><given-names>C</given-names></name><name><surname>Kotlarz</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Human RIPK1 deficiency causes combined immunodeficiency and inflammatory bowel diseases</article-title><source>PNAS</source><volume>116</volume><fpage>970</fpage><lpage>975</lpage><pub-id pub-id-type="doi">10.1073/pnas.1813582116</pub-id><pub-id pub-id-type="pmid">30591564</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liggett</surname><given-names>WH</given-names><suffix>Jr</suffix></name><name><surname>Sidransky</surname><given-names>D</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Role of the p16 tumor suppressor gene in cancer</article-title><source>Journal of Clinical Oncology</source><volume>16</volume><fpage>1197</fpage><lpage>1206</lpage><pub-id pub-id-type="doi">10.1200/JCO.1998.16.3.1197</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Jinno</surname><given-names>S</given-names></name><name><surname>Okayama</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Cdk6-cyclin D3 complex evades inhibition by inhibitor proteins and uniquely controls cell’s proliferation competence</article-title><source>Oncogene</source><volume>20</volume><fpage>2000</fpage><lpage>2009</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1204375</pub-id><pub-id pub-id-type="pmid">11360184</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lito</surname><given-names>P</given-names></name><name><surname>Rosen</surname><given-names>N</given-names></name><name><surname>Solit</surname><given-names>DB</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Tumor adaptation and resistance to RAF inhibitors</article-title><source>Nature Medicine</source><volume>19</volume><fpage>1401</fpage><lpage>1409</lpage><pub-id pub-id-type="doi">10.1038/nm.3392</pub-id><pub-id pub-id-type="pmid">24202393</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Longley</surname><given-names>DB</given-names></name><name><surname>Johnston</surname><given-names>PG</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Molecular mechanisms of drug resistance</article-title><source>The Journal of Pathology</source><volume>205</volume><fpage>275</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1002/path.1706</pub-id><pub-id pub-id-type="pmid">15641020</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez</surname><given-names>ED</given-names></name><name><surname>Burastero</surname><given-names>O</given-names></name><name><surname>Arcon</surname><given-names>JP</given-names></name><name><surname>Defelipe</surname><given-names>LA</given-names></name><name><surname>Ahn</surname><given-names>NG</given-names></name><name><surname>Marti</surname><given-names>MA</given-names></name><name><surname>Turjanski</surname><given-names>AG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Kinase activation by small conformational changes</article-title><source>Journal of Chemical Information and Modeling</source><volume>60</volume><fpage>821</fpage><lpage>832</lpage><pub-id pub-id-type="doi">10.1021/acs.jcim.9b00782</pub-id><pub-id pub-id-type="pmid">31714778</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madhavi Sastry</surname><given-names>G</given-names></name><name><surname>Adzhigirey</surname><given-names>M</given-names></name><name><surname>Day</surname><given-names>T</given-names></name><name><surname>Annabhimoju</surname><given-names>R</given-names></name><name><surname>Sherman</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments</article-title><source>Journal of Computer-Aided Molecular Design</source><volume>27</volume><fpage>221</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1007/s10822-013-9644-8</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manning</surname><given-names>G</given-names></name><name><surname>Whyte</surname><given-names>DB</given-names></name><name><surname>Martinez</surname><given-names>R</given-names></name><name><surname>Hunter</surname><given-names>T</given-names></name><name><surname>Sudarsanam</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The protein kinase complement of the human genome</article-title><source>Science</source><volume>298</volume><fpage>1912</fpage><lpage>1934</lpage><pub-id pub-id-type="doi">10.1126/science.1075762</pub-id><pub-id pub-id-type="pmid">12471243</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manning</surname><given-names>BD</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Challenges and opportunities in defining the essential cancer kinome</article-title><source>Science Signaling</source><volume>2</volume><elocation-id>pe15</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.263pe15</pub-id><pub-id pub-id-type="pmid">19318621</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martens</surname><given-names>S</given-names></name><name><surname>Hofmans</surname><given-names>S</given-names></name><name><surname>Declercq</surname><given-names>W</given-names></name><name><surname>Augustyns</surname><given-names>K</given-names></name><name><surname>Vandenabeele</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Inhibitors targeting RIPK1/RIPK3: old and new drugs</article-title><source>Trends in Pharmacological Sciences</source><volume>41</volume><fpage>209</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2020.01.002</pub-id><pub-id pub-id-type="pmid">32035657</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayrhofer</surname><given-names>JE</given-names></name><name><surname>Enzler</surname><given-names>F</given-names></name><name><surname>Feichtner</surname><given-names>A</given-names></name><name><surname>Röck</surname><given-names>R</given-names></name><name><surname>Fleischmann</surname><given-names>J</given-names></name><name><surname>Raffeiner</surname><given-names>A</given-names></name><name><surname>Tschaikner</surname><given-names>P</given-names></name><name><surname>Ogris</surname><given-names>E</given-names></name><name><surname>Huber</surname><given-names>RG</given-names></name><name><surname>Hartl</surname><given-names>M</given-names></name><name><surname>Schneider</surname><given-names>R</given-names></name><name><surname>Troppmair</surname><given-names>J</given-names></name><name><surname>Torres-Quesada</surname><given-names>O</given-names></name><name><surname>Stefan</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mutation-oriented profiling of autoinhibitory kinase conformations predicts RAF inhibitor efficacies</article-title><source>PNAS</source><volume>117</volume><fpage>31105</fpage><lpage>31113</lpage><pub-id pub-id-type="doi">10.1073/pnas.2012150117</pub-id><pub-id pub-id-type="pmid">33229534</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meharena</surname><given-names>HS</given-names></name><name><surname>Fan</surname><given-names>X</given-names></name><name><surname>Ahuja</surname><given-names>LG</given-names></name><name><surname>Keshwani</surname><given-names>MM</given-names></name><name><surname>McClendon</surname><given-names>CL</given-names></name><name><surname>Chen</surname><given-names>AM</given-names></name><name><surname>Adams</surname><given-names>JA</given-names></name><name><surname>Taylor</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Decoding the interactions regulating the active state mechanics of eukaryotic protein kinases</article-title><source>PLOS Biology</source><volume>14</volume><elocation-id>e2000127</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.2000127</pub-id><pub-id pub-id-type="pmid">27902690</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehenni</surname><given-names>H</given-names></name><name><surname>Gehrig</surname><given-names>C</given-names></name><name><surname>Nezu</surname><given-names>J</given-names></name><name><surname>Oku</surname><given-names>A</given-names></name><name><surname>Shimane</surname><given-names>M</given-names></name><name><surname>Rossier</surname><given-names>C</given-names></name><name><surname>Guex</surname><given-names>N</given-names></name><name><surname>Blouin</surname><given-names>JL</given-names></name><name><surname>Scott</surname><given-names>HS</given-names></name><name><surname>Antonarakis</surname><given-names>SE</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Loss of LKB1 kinase activity in Peutz-Jeghers syndrome, and evidence for allelic and locus heterogeneity</article-title><source>American Journal of Human Genetics</source><volume>63</volume><fpage>1641</fpage><lpage>1650</lpage><pub-id pub-id-type="doi">10.1086/302159</pub-id><pub-id pub-id-type="pmid">9837816</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meylan</surname><given-names>E</given-names></name><name><surname>Burns</surname><given-names>K</given-names></name><name><surname>Hofmann</surname><given-names>K</given-names></name><name><surname>Blancheteau</surname><given-names>V</given-names></name><name><surname>Martinon</surname><given-names>F</given-names></name><name><surname>Kelliher</surname><given-names>M</given-names></name><name><surname>Tschopp</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappa B activation</article-title><source>Nature Immunology</source><volume>5</volume><fpage>503</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1038/ni1061</pub-id><pub-id pub-id-type="pmid">15064760</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molaei</surname><given-names>A</given-names></name><name><surname>Molaei</surname><given-names>E</given-names></name><name><surname>Sadeghnia</surname><given-names>H</given-names></name><name><surname>Hayes</surname><given-names>AW</given-names></name><name><surname>Karimi</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>LKB1: An emerging therapeutic target for cardiovascular diseases</article-title><source>Life Sciences</source><volume>306</volume><elocation-id>120844</elocation-id><pub-id pub-id-type="doi">10.1016/j.lfs.2022.120844</pub-id><pub-id pub-id-type="pmid">35907495</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrison</surname><given-names>DK</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>KSR: a MAPK scaffold of the ras pathway?</article-title><source>Journal of Cell Science</source><volume>114</volume><fpage>1609</fpage><lpage>1612</lpage><pub-id pub-id-type="doi">10.1242/jcs.114.9.1609</pub-id><pub-id pub-id-type="pmid">11309192</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrison</surname><given-names>DK</given-names></name><name><surname>Davis</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Regulation of MAP kinase signaling modules by scaffold proteins in mammals</article-title><source>Annual Review of Cell and Developmental Biology</source><volume>19</volume><fpage>91</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1146/annurev.cellbio.19.111401.091942</pub-id><pub-id pub-id-type="pmid">14570565</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moynagh</surname><given-names>PN</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The NF-κB pathway</article-title><source>Journal of Cell Science</source><volume>118</volume><fpage>4589</fpage><lpage>4592</lpage><pub-id pub-id-type="doi">10.1242/jcs.02579</pub-id><pub-id pub-id-type="pmid">16219681</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narbonne</surname><given-names>P</given-names></name><name><surname>Hyenne</surname><given-names>V</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Labbé</surname><given-names>JC</given-names></name><name><surname>Roy</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Differential requirements for STRAD in LKB1-dependent functions in <italic>C. elegans</italic></article-title><source>Development</source><volume>137</volume><fpage>661</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1242/dev.042044</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ndembe</surname><given-names>G</given-names></name><name><surname>Intini</surname><given-names>I</given-names></name><name><surname>Perin</surname><given-names>E</given-names></name><name><surname>Marabese</surname><given-names>M</given-names></name><name><surname>Caiola</surname><given-names>E</given-names></name><name><surname>Mendogni</surname><given-names>P</given-names></name><name><surname>Rosso</surname><given-names>L</given-names></name><name><surname>Broggini</surname><given-names>M</given-names></name><name><surname>Colombo</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>LKB1: can we target an hidden target? focus on NSCLC</article-title><source>Frontiers in Oncology</source><volume>12</volume><elocation-id>889826</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2022.889826</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nebenfuehr</surname><given-names>S</given-names></name><name><surname>Kollmann</surname><given-names>K</given-names></name><name><surname>Sexl</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The role of CDK6 in cancer</article-title><source>International Journal of Cancer</source><volume>147</volume><fpage>2988</fpage><lpage>2995</lpage><pub-id pub-id-type="doi">10.1002/ijc.33054</pub-id><pub-id pub-id-type="pmid">32406095</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newton</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Protein kinase C: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions</article-title><source>Chemical Reviews</source><volume>101</volume><fpage>2353</fpage><lpage>2364</lpage><pub-id pub-id-type="doi">10.1021/cr0002801</pub-id><pub-id pub-id-type="pmid">11749377</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newton</surname><given-names>AC</given-names></name><name><surname>Bootman</surname><given-names>MD</given-names></name><name><surname>Scott</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Second messengers</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>8</volume><elocation-id>a005926</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a005926</pub-id><pub-id pub-id-type="pmid">27481708</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ochoa</surname><given-names>D</given-names></name><name><surname>Bradley</surname><given-names>D</given-names></name><name><surname>Beltrao</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Evolution, dynamics and dysregulation of kinase signalling</article-title><source>Current Opinion in Structural Biology</source><volume>48</volume><fpage>133</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/j.sbi.2017.12.008</pub-id><pub-id pub-id-type="pmid">29316484</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ortega</surname><given-names>S</given-names></name><name><surname>Malumbres</surname><given-names>M</given-names></name><name><surname>Barbacid</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Cyclin D-dependent kinases, INK4 inhibitors and cancer</article-title><source>Biochimica et Biophysica Acta</source><volume>1602</volume><fpage>73</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/S0304-419X(02)00037-9</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otto</surname><given-names>T</given-names></name><name><surname>Sicinski</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Cell cycle proteins as promising targets in cancer therapy</article-title><source>Nature Reviews. Cancer</source><volume>17</volume><fpage>93</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1038/nrc.2016.138</pub-id><pub-id pub-id-type="pmid">28127048</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>X</given-names></name><name><surname>Heitman</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Protein kinase A operates A molecular switch that governs yeast pseudohyphal differentiation</article-title><source>Molecular and Cellular Biology</source><volume>22</volume><fpage>3981</fpage><lpage>3993</lpage><pub-id pub-id-type="doi">10.1128/MCB.22.12.3981-3993.2002</pub-id><pub-id pub-id-type="pmid">12024012</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Partanen</surname><given-names>JI</given-names></name><name><surname>Tervonen</surname><given-names>TA</given-names></name><name><surname>Myllynen</surname><given-names>M</given-names></name><name><surname>Lind</surname><given-names>E</given-names></name><name><surname>Imai</surname><given-names>M</given-names></name><name><surname>Katajisto</surname><given-names>P</given-names></name><name><surname>Dijkgraaf</surname><given-names>GJP</given-names></name><name><surname>Kovanen</surname><given-names>PE</given-names></name><name><surname>Mäkelä</surname><given-names>TP</given-names></name><name><surname>Werb</surname><given-names>Z</given-names></name><name><surname>Klefström</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Tumor suppressor function of Liver kinase B1 (Lkb1) is linked to regulation of epithelial integrity</article-title><source>PNAS</source><volume>109</volume><fpage>E388</fpage><lpage>E397</lpage><pub-id pub-id-type="doi">10.1073/pnas.1120421109</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pellegrini</surname><given-names>E</given-names></name><name><surname>Signor</surname><given-names>L</given-names></name><name><surname>Singh</surname><given-names>S</given-names></name><name><surname>Boeri Erba</surname><given-names>E</given-names></name><name><surname>Cusack</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Structures of the inactive and active states of RIP2 kinase inform on the mechanism of activation</article-title><source>PLOS ONE</source><volume>12</volume><elocation-id>e0177161</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0177161</pub-id><pub-id pub-id-type="pmid">28545134</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Politi</surname><given-names>K</given-names></name><name><surname>Ayeni</surname><given-names>D</given-names></name><name><surname>Lynch</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The next wave of EGFR tyrosine kinase inhibitors enter the clinic</article-title><source>Cancer Cell</source><volume>27</volume><fpage>751</fpage><lpage>753</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2015.05.012</pub-id><pub-id pub-id-type="pmid">26058074</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pouysségur</surname><given-names>J</given-names></name><name><surname>Volmat</surname><given-names>V</given-names></name><name><surname>Lenormand</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling</article-title><source>Biochemical Pharmacology</source><volume>64</volume><fpage>755</fpage><lpage>763</lpage><pub-id pub-id-type="doi">10.1016/s0006-2952(02)01135-8</pub-id><pub-id pub-id-type="pmid">12213567</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pufall</surname><given-names>MA</given-names></name><name><surname>Graves</surname><given-names>BJ</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Autoinhibitory domains: modular effectors of cellular regulation</article-title><source>Annual Review of Cell and Developmental Biology</source><volume>18</volume><fpage>421</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1146/annurev.cellbio.18.031502.133614</pub-id><pub-id pub-id-type="pmid">12142282</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puylaert</surname><given-names>P</given-names></name><name><surname>Coornaert</surname><given-names>I</given-names></name><name><surname>Neutel</surname><given-names>CHG</given-names></name><name><surname>Dondelinger</surname><given-names>Y</given-names></name><name><surname>Delanghe</surname><given-names>T</given-names></name><name><surname>Bertrand</surname><given-names>MJM</given-names></name><name><surname>Guns</surname><given-names>PJ</given-names></name><name><surname>De Meyer</surname><given-names>GRY</given-names></name><name><surname>Martinet</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The Impact of RIPK1 kinase inhibition on atherogenesis: a genetic and a pharmacological approach</article-title><source>Biomedicines</source><volume>10</volume><elocation-id>1016</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines10051016</pub-id><pub-id pub-id-type="pmid">35625752</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qing</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Mitchell</surname><given-names>DC</given-names></name><name><surname>Beresis</surname><given-names>RT</given-names></name><name><surname>Gordan</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Methods to assess small molecule allosteric modulators of the STRAD pseudokinase</article-title><source>Methods in Enzymology</source><volume>667</volume><fpage>427</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.1016/bs.mie.2022.03.041</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quelle</surname><given-names>DE</given-names></name><name><surname>Cheng</surname><given-names>M</given-names></name><name><surname>Ashmun</surname><given-names>RA</given-names></name><name><surname>Sherr</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF</article-title><source>PNAS</source><volume>94</volume><fpage>669</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1073/pnas.94.2.669</pub-id><pub-id pub-id-type="pmid">9012842</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajakulendran</surname><given-names>T</given-names></name><name><surname>Sicheri</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Allosteric protein kinase regulation by pseudokinases: insights from STRAD</article-title><source>Science Signaling</source><volume>3</volume><elocation-id>pe8</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.3111pe8</pub-id><pub-id pub-id-type="pmid">20197543</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raju</surname><given-names>S</given-names></name><name><surname>Whalen</surname><given-names>DM</given-names></name><name><surname>Mengistu</surname><given-names>M</given-names></name><name><surname>Swanson</surname><given-names>C</given-names></name><name><surname>Quinn</surname><given-names>JG</given-names></name><name><surname>Taylor</surname><given-names>SS</given-names></name><name><surname>Webster</surname><given-names>JD</given-names></name><name><surname>Newton</surname><given-names>K</given-names></name><name><surname>Shaw</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Kinase domain dimerization drives RIPK3-dependent necroptosis</article-title><source>Science Signaling</source><volume>11</volume><elocation-id>aar2188</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.aar2188</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramms</surname><given-names>DJ</given-names></name><name><surname>Raimondi</surname><given-names>F</given-names></name><name><surname>Arang</surname><given-names>N</given-names></name><name><surname>Herberg</surname><given-names>FW</given-names></name><name><surname>Taylor</surname><given-names>SS</given-names></name><name><surname>Gutkind</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>G<italic>α</italic>s-Protein Kinase A (PKA) Pathway Signalopathies: the emerging genetic landscape and therapeutic potential of human diseases driven by Aberrant G<italic>α</italic>s-PKA Signaling</article-title><source>Pharmacological Reviews</source><volume>73</volume><fpage>155</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1124/pharmrev.120.000269</pub-id><pub-id pub-id-type="pmid">34663687</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reiterer</surname><given-names>V</given-names></name><name><surname>Eyers</surname><given-names>PA</given-names></name><name><surname>Farhan</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Day of the dead: pseudokinases and pseudophosphatases in physiology and disease</article-title><source>Trends in Cell Biology</source><volume>24</volume><fpage>489</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2014.03.008</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Röck</surname><given-names>R</given-names></name><name><surname>Mayrhofer</surname><given-names>JE</given-names></name><name><surname>Torres-Quesada</surname><given-names>O</given-names></name><name><surname>Enzler</surname><given-names>F</given-names></name><name><surname>Raffeiner</surname><given-names>A</given-names></name><name><surname>Raffeiner</surname><given-names>P</given-names></name><name><surname>Feichtner</surname><given-names>A</given-names></name><name><surname>Huber</surname><given-names>RG</given-names></name><name><surname>Koide</surname><given-names>S</given-names></name><name><surname>Taylor</surname><given-names>SS</given-names></name><name><surname>Troppmair</surname><given-names>J</given-names></name><name><surname>Stefan</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>BRAF inhibitors promote intermediate BRAF(V600E) conformations and binary interactions with activated RAS</article-title><source>Science Advances</source><volume>5</volume><elocation-id>eaav8463</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.aav8463</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodríguez</surname><given-names>C</given-names></name><name><surname>Muñoz</surname><given-names>M</given-names></name><name><surname>Contreras</surname><given-names>C</given-names></name><name><surname>Prieto</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>AMPK, metabolism, and vascular function</article-title><source>The FEBS Journal</source><volume>288</volume><fpage>3746</fpage><lpage>3771</lpage><pub-id pub-id-type="doi">10.1111/febs.15863</pub-id><pub-id pub-id-type="pmid">33825330</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodríguez-Díez</surname><given-names>E</given-names></name><name><surname>Quereda</surname><given-names>V</given-names></name><name><surname>Bellutti</surname><given-names>F</given-names></name><name><surname>Prchal-Murphy</surname><given-names>M</given-names></name><name><surname>Partida</surname><given-names>D</given-names></name><name><surname>Eguren</surname><given-names>M</given-names></name><name><surname>Kollmann</surname><given-names>K</given-names></name><name><surname>Gómez de Cedrón</surname><given-names>M</given-names></name><name><surname>Dubus</surname><given-names>P</given-names></name><name><surname>Cañamero</surname><given-names>M</given-names></name><name><surname>Martínez</surname><given-names>D</given-names></name><name><surname>Sexl</surname><given-names>V</given-names></name><name><surname>Malumbres</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Cdk4 and Cdk6 cooperate in counteracting the INK4 family of inhibitors during murine leukemogenesis</article-title><source>Blood</source><volume>124</volume><fpage>2380</fpage><lpage>2390</lpage><pub-id pub-id-type="doi">10.1182/blood-2014-02-555292</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romagosa</surname><given-names>C</given-names></name><name><surname>Simonetti</surname><given-names>S</given-names></name><name><surname>López-Vicente</surname><given-names>L</given-names></name><name><surname>Mazo</surname><given-names>A</given-names></name><name><surname>Lleonart</surname><given-names>ME</given-names></name><name><surname>Castellvi</surname><given-names>J</given-names></name><name><surname>Ramon y Cajal</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>p16Ink4a overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors</article-title><source>Oncogene</source><volume>30</volume><fpage>2087</fpage><lpage>2097</lpage><pub-id pub-id-type="doi">10.1038/onc.2010.614</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russo</surname><given-names>AA</given-names></name><name><surname>Tong</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>J-O</given-names></name><name><surname>Jeffrey</surname><given-names>PD</given-names></name><name><surname>Pavletich</surname><given-names>NP</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a</article-title><source>Nature</source><volume>395</volume><fpage>237</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1038/26155</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez-Cespedes</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>A role for LKB1 gene in human cancer beyond the Peutz–Jeghers syndrome</article-title><source>Oncogene</source><volume>26</volume><fpage>7825</fpage><lpage>7832</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1210594</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheiblecker</surname><given-names>L</given-names></name><name><surname>Kollmann</surname><given-names>K</given-names></name><name><surname>Sexl</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>CDK4/6 and MAPK-crosstalk as opportunity for cancer treatment</article-title><source>Pharmaceuticals</source><volume>13</volume><elocation-id>418</elocation-id><pub-id pub-id-type="doi">10.3390/ph13120418</pub-id><pub-id pub-id-type="pmid">33255177</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheicher</surname><given-names>R</given-names></name><name><surname>Hoelbl-Kovacic</surname><given-names>A</given-names></name><name><surname>Bellutti</surname><given-names>F</given-names></name><name><surname>Tigan</surname><given-names>A-S</given-names></name><name><surname>Prchal-Murphy</surname><given-names>M</given-names></name><name><surname>Heller</surname><given-names>G</given-names></name><name><surname>Schneckenleithner</surname><given-names>C</given-names></name><name><surname>Salazar-Roa</surname><given-names>M</given-names></name><name><surname>Zöchbauer-Müller</surname><given-names>S</given-names></name><name><surname>Zuber</surname><given-names>J</given-names></name><name><surname>Malumbres</surname><given-names>M</given-names></name><name><surname>Kollmann</surname><given-names>K</given-names></name><name><surname>Sexl</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>CDK6 as a key regulator of hematopoietic and leukemic stem cell activation</article-title><source>Blood</source><volume>125</volume><fpage>90</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1182/blood-2014-06-584417</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitt</surname><given-names>DL</given-names></name><name><surname>Mehta</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Study of spatiotemporal regulation of kinase signaling using genetically encodable molecular tools</article-title><source>Current Opinion in Chemical Biology</source><volume>71</volume><elocation-id>102224</elocation-id><pub-id pub-id-type="doi">10.1016/j.cbpa.2022.102224</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Schrödinger</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><source>Schrödinger release 2019-4: protein preparation wizard; epik; impact; prime; glide; ligprep; induced fit docking protocol</source><publisher-name>Schrödinger</publisher-name></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Semczuk</surname><given-names>A</given-names></name><name><surname>Jakowicki</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Alterations of pRb1-cyclin D1-cdk4/6-p16INK4A pathway in endometrial carcinogenesis</article-title><source>Cancer Letters</source><volume>203</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2003.09.012</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shackelford</surname><given-names>DB</given-names></name><name><surname>Shaw</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The LKB1-AMPK pathway: metabolism and growth control in tumour suppression</article-title><source>Nature Reviews. Cancer</source><volume>9</volume><fpage>563</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1038/nrc2676</pub-id><pub-id pub-id-type="pmid">19629071</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shchemelinin</surname><given-names>I</given-names></name><name><surname>Sefc</surname><given-names>L</given-names></name><name><surname>Necas</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Protein kinases, their function and implication in cancer and other diseases</article-title><source>Folia Biologica</source><volume>52</volume><fpage>81</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">17089919</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shrestha</surname><given-names>S</given-names></name><name><surname>Byrne</surname><given-names>DP</given-names></name><name><surname>Harris</surname><given-names>JA</given-names></name><name><surname>Kannan</surname><given-names>N</given-names></name><name><surname>Eyers</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cataloguing the dead: breathing new life into pseudokinase research</article-title><source>The FEBS Journal</source><volume>287</volume><fpage>4150</fpage><lpage>4169</lpage><pub-id pub-id-type="doi">10.1111/febs.15246</pub-id><pub-id pub-id-type="pmid">32053275</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shutinoski</surname><given-names>B</given-names></name><name><surname>Alturki</surname><given-names>NA</given-names></name><name><surname>Rijal</surname><given-names>D</given-names></name><name><surname>Bertin</surname><given-names>J</given-names></name><name><surname>Gough</surname><given-names>PJ</given-names></name><name><surname>Schlossmacher</surname><given-names>MG</given-names></name><name><surname>Sad</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>K45A mutation of RIPK1 results in poor necroptosis and cytokine signaling in macrophages, which impacts inflammatory responses in vivo</article-title><source>Cell Death &amp; Differentiation</source><volume>23</volume><fpage>1628</fpage><lpage>1637</lpage><pub-id pub-id-type="doi">10.1038/cdd.2016.51</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silke</surname><given-names>J</given-names></name><name><surname>Meier</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Inhibitor of apoptosis (IAP) proteins-modulators of cell death and inflammation</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>5</volume><elocation-id>a008730</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a008730</pub-id><pub-id pub-id-type="pmid">23378585</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Southekal</surname><given-names>S</given-names></name><name><surname>Mishra</surname><given-names>NK</given-names></name><name><surname>Guda</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Pan-cancer analysis of human kinome gene expression and promoter DNA methylation identifies dark kinase biomarkers in multiple cancers</article-title><source>Cancers</source><volume>13</volume><elocation-id>1189</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13061189</pub-id><pub-id pub-id-type="pmid">33801837</pub-id></element-citation></ref><ref id="bib121"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Speir</surname><given-names>M</given-names></name><name><surname>Djajawi</surname><given-names>TM</given-names></name><name><surname>Conos</surname><given-names>SA</given-names></name><name><surname>Tye</surname><given-names>H</given-names></name><name><surname>Lawlor</surname><given-names>KE</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Targeting RIP kinases in chronic inflammatory disease</article-title><source>Biomolecules</source><volume>11</volume><elocation-id>646</elocation-id><pub-id pub-id-type="doi">10.3390/biom11050646</pub-id></element-citation></ref><ref id="bib122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stefan</surname><given-names>E</given-names></name><name><surname>Aquin</surname><given-names>S</given-names></name><name><surname>Berger</surname><given-names>N</given-names></name><name><surname>Landry</surname><given-names>CR</given-names></name><name><surname>Nyfeler</surname><given-names>B</given-names></name><name><surname>Bouvier</surname><given-names>M</given-names></name><name><surname>Michnick</surname><given-names>SW</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Quantification of dynamic protein complexes using <italic>Renilla</italic>luciferase fragment complementation applied to protein kinase A activities<italic>in vivo</italic></article-title><source>PNAS</source><volume>104</volume><fpage>16916</fpage><lpage>16921</lpage><pub-id pub-id-type="doi">10.1073/pnas.0704257104</pub-id></element-citation></ref><ref id="bib123"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname><given-names>P</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Pan</surname><given-names>H</given-names></name><name><surname>Bai</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>PY</given-names></name><name><surname>Ying</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Hou</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Sun</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Fang</surname><given-names>R</given-names></name><name><surname>Han</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Deuitch</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Dissanayake</surname><given-names>D</given-names></name><name><surname>Haude</surname><given-names>K</given-names></name><name><surname>McWalter</surname><given-names>K</given-names></name><name><surname>Roadhouse</surname><given-names>C</given-names></name><name><surname>MacKenzie</surname><given-names>JJ</given-names></name><name><surname>Laxer</surname><given-names>RM</given-names></name><name><surname>Aksentijevich</surname><given-names>I</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A dominant autoinflammatory disease caused by non-cleavable variants of RIPK1</article-title><source>Nature</source><volume>577</volume><fpage>109</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1830-y</pub-id></element-citation></ref><ref id="bib124"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>SS</given-names></name><name><surname>Kim</surname><given-names>C</given-names></name><name><surname>Vigil</surname><given-names>D</given-names></name><name><surname>Haste</surname><given-names>NM</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Anand</surname><given-names>GS</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Dynamics of signaling by PKA</article-title><source>Biochimica et Biophysica Acta</source><volume>1754</volume><fpage>25</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.bbapap.2005.08.024</pub-id></element-citation></ref><ref id="bib125"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>SS</given-names></name><name><surname>Ilouz</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Kornev</surname><given-names>AP</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Assembly of allosteric macromolecular switches: lessons from PKA</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>13</volume><fpage>646</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.1038/nrm3432</pub-id><pub-id pub-id-type="pmid">22992589</pub-id></element-citation></ref><ref id="bib126"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>SS</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Steichen</surname><given-names>JM</given-names></name><name><surname>Keshwani</surname><given-names>MM</given-names></name><name><surname>Kornev</surname><given-names>AP</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>PKA: lessons learned after twenty years</article-title><source>Biochimica et Biophysica Acta</source><volume>1834</volume><fpage>1271</fpage><lpage>1278</lpage><pub-id pub-id-type="doi">10.1016/j.bbapap.2013.03.007</pub-id><pub-id pub-id-type="pmid">23535202</pub-id></element-citation></ref><ref id="bib127"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>SS</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Bruystens</surname><given-names>JGH</given-names></name><name><surname>Del Rio</surname><given-names>JC</given-names></name><name><surname>Lu</surname><given-names>TW</given-names></name><name><surname>Kornev</surname><given-names>AP</given-names></name><name><surname>Ten Eyck</surname><given-names>LF</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>From structure to the dynamic regulation of A molecular switch: a journey over 3decades</article-title><source>Journal of Biological Chemistry</source><volume>296</volume><elocation-id>100746</elocation-id><pub-id pub-id-type="doi">10.1016/j.jbc.2021.100746</pub-id></element-citation></ref><ref id="bib128"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ui</surname><given-names>A</given-names></name><name><surname>Ogiwara</surname><given-names>H</given-names></name><name><surname>Nakajima</surname><given-names>S</given-names></name><name><surname>Kanno</surname><given-names>S</given-names></name><name><surname>Watanabe</surname><given-names>R</given-names></name><name><surname>Harata</surname><given-names>M</given-names></name><name><surname>Okayama</surname><given-names>H</given-names></name><name><surname>Harris</surname><given-names>CC</given-names></name><name><surname>Yokota</surname><given-names>J</given-names></name><name><surname>Yasui</surname><given-names>A</given-names></name><name><surname>Kohno</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Possible involvement of LKB1-AMPK signaling in non-homologous end joining</article-title><source>Oncogene</source><volume>33</volume><fpage>1640</fpage><lpage>1648</lpage><pub-id pub-id-type="doi">10.1038/onc.2013.125</pub-id><pub-id pub-id-type="pmid">23584481</pub-id></element-citation></ref><ref id="bib129"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van</surname><given-names>AAN</given-names></name><name><surname>Kunkel</surname><given-names>MT</given-names></name><name><surname>Baffi</surname><given-names>TR</given-names></name><name><surname>Lordén</surname><given-names>G</given-names></name><name><surname>Antal</surname><given-names>CE</given-names></name><name><surname>Banerjee</surname><given-names>S</given-names></name><name><surname>Newton</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Protein kinase C fusion proteins are paradoxically loss of function in cancer</article-title><source>The Journal of Biological Chemistry</source><volume>296</volume><elocation-id>100445</elocation-id><pub-id pub-id-type="doi">10.1016/j.jbc.2021.100445</pub-id><pub-id pub-id-type="pmid">33617877</pub-id></element-citation></ref><ref id="bib130"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>VanArsdale</surname><given-names>T</given-names></name><name><surname>Boshoff</surname><given-names>C</given-names></name><name><surname>Arndt</surname><given-names>KT</given-names></name><name><surname>Abraham</surname><given-names>RT</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Molecular pathways: targeting the cyclin D–CDK4/6 axis for cancer treatment</article-title><source>Clinical Cancer Research</source><volume>21</volume><fpage>2905</fpage><lpage>2910</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-0816</pub-id></element-citation></ref><ref id="bib131"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Marinis</surname><given-names>JM</given-names></name><name><surname>Beal</surname><given-names>AM</given-names></name><name><surname>Savadkar</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Khan</surname><given-names>M</given-names></name><name><surname>Taunk</surname><given-names>PS</given-names></name><name><surname>Wu</surname><given-names>N</given-names></name><name><surname>Su</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Ahsan</surname><given-names>A</given-names></name><name><surname>Kurz</surname><given-names>E</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Yaboh</surname><given-names>I</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Gutierrez</surname><given-names>J</given-names></name><name><surname>Diskin</surname><given-names>B</given-names></name><name><surname>Hundeyin</surname><given-names>M</given-names></name><name><surname>Reilly</surname><given-names>M</given-names></name><name><surname>Lich</surname><given-names>JD</given-names></name><name><surname>Harris</surname><given-names>PA</given-names></name><name><surname>Mahajan</surname><given-names>MK</given-names></name><name><surname>Thorpe</surname><given-names>JH</given-names></name><name><surname>Nassau</surname><given-names>P</given-names></name><name><surname>Mosley</surname><given-names>JE</given-names></name><name><surname>Leinwand</surname><given-names>J</given-names></name><name><surname>Kochen Rossi</surname><given-names>JA</given-names></name><name><surname>Mishra</surname><given-names>A</given-names></name><name><surname>Aykut</surname><given-names>B</given-names></name><name><surname>Glacken</surname><given-names>M</given-names></name><name><surname>Ochi</surname><given-names>A</given-names></name><name><surname>Verma</surname><given-names>N</given-names></name><name><surname>Kim</surname><given-names>JI</given-names></name><name><surname>Vasudevaraja</surname><given-names>V</given-names></name><name><surname>Adeegbe</surname><given-names>D</given-names></name><name><surname>Almonte</surname><given-names>C</given-names></name><name><surname>Bagdatlioglu</surname><given-names>E</given-names></name><name><surname>Cohen</surname><given-names>DJ</given-names></name><name><surname>Wong</surname><given-names>KK</given-names></name><name><surname>Bertin</surname><given-names>J</given-names></name><name><surname>Miller</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>RIP1 kinase drives macrophage-mediated adaptive immune tolerance in pancreatic cancer</article-title><source>Cancer Cell</source><volume>34</volume><fpage>757</fpage><lpage>774</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2018.10.006</pub-id><pub-id pub-id-type="pmid">30423296</pub-id></element-citation></ref><ref id="bib132"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Fan</surname><given-names>D</given-names></name><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Ye</surname><given-names>Q</given-names></name><name><surname>Xi</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Xiao</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The latest information on the RIPK1 post-translational modifications and functions</article-title><source>Biomedicine &amp; Pharmacotherapy</source><volume>142</volume><elocation-id>112082</elocation-id><pub-id pub-id-type="doi">10.1016/j.biopha.2021.112082</pub-id></element-citation></ref><ref id="bib133"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinlich</surname><given-names>R</given-names></name><name><surname>Green</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The two faces of receptor interacting protein kinase-1</article-title><source>Molecular Cell</source><volume>56</volume><fpage>469</fpage><lpage>480</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2014.11.001</pub-id><pub-id pub-id-type="pmid">25459879</pub-id></element-citation></ref><ref id="bib134"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wingo</surname><given-names>SN</given-names></name><name><surname>Gallardo</surname><given-names>TD</given-names></name><name><surname>Akbay</surname><given-names>EA</given-names></name><name><surname>Liang</surname><given-names>M-C</given-names></name><name><surname>Contreras</surname><given-names>CM</given-names></name><name><surname>Boren</surname><given-names>T</given-names></name><name><surname>Shimamura</surname><given-names>T</given-names></name><name><surname>Miller</surname><given-names>DS</given-names></name><name><surname>Sharpless</surname><given-names>NE</given-names></name><name><surname>Bardeesy</surname><given-names>N</given-names></name><name><surname>Kwiatkowski</surname><given-names>DJ</given-names></name><name><surname>Schorge</surname><given-names>JO</given-names></name><name><surname>Wong</surname><given-names>K-K</given-names></name><name><surname>Castrillon</surname><given-names>DH</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Somatic LKB1 mutations promote cervical cancer progression</article-title><source>PLOS ONE</source><volume>4</volume><elocation-id>e5137</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0005137</pub-id><pub-id pub-id-type="pmid">19340305</pub-id></element-citation></ref><ref id="bib135"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>P</given-names></name><name><surname>Clausen</surname><given-names>MH</given-names></name><name><surname>Nielsen</surname><given-names>TE</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Allosteric small-molecule kinase inhibitors</article-title><source>Pharmacology &amp; Therapeutics</source><volume>156</volume><fpage>59</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2015.10.002</pub-id></element-citation></ref><ref id="bib136"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Min</surname><given-names>X</given-names></name><name><surname>Stippec</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>B-H</given-names></name><name><surname>Goldsmith</surname><given-names>EJ</given-names></name><name><surname>Cobb</surname><given-names>MH</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Regulation of WNK1 by an autoinhibitory domain and autophosphorylation</article-title><source>Journal of Biological Chemistry</source><volume>277</volume><fpage>48456</fpage><lpage>48462</lpage><pub-id pub-id-type="doi">10.1074/jbc.M207917200</pub-id></element-citation></ref><ref id="bib137"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Jin</surname><given-names>T</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Ofengeim</surname><given-names>D</given-names></name><name><surname>Zou</surname><given-names>C</given-names></name><name><surname>Mifflin</surname><given-names>L</given-names></name><name><surname>Pan</surname><given-names>L</given-names></name><name><surname>Amin</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Shan</surname><given-names>B</given-names></name><name><surname>Naito</surname><given-names>MG</given-names></name><name><surname>Meng</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Pan</surname><given-names>H</given-names></name><name><surname>Aron</surname><given-names>L</given-names></name><name><surname>Adiconis</surname><given-names>X</given-names></name><name><surname>Levin</surname><given-names>JZ</given-names></name><name><surname>Yankner</surname><given-names>BA</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>TBK1 Suppresses RIPK1-driven apoptosis and inflammation during development and in aging</article-title><source>Cell</source><volume>174</volume><fpage>1477</fpage><lpage>1491</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.07.041</pub-id><pub-id pub-id-type="pmid">30146158</pub-id></element-citation></ref><ref id="bib138"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yam</surname><given-names>C</given-names></name><name><surname>Hung</surname><given-names>MC</given-names></name><name><surname>Hortobagyi</surname><given-names>GN</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>CDK4/6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: Are we at the finish line?</article-title><source>Oncotarget</source><volume>9</volume><fpage>34193</fpage><lpage>34195</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.26134</pub-id><pub-id pub-id-type="pmid">30344934</pub-id></element-citation></ref><ref id="bib139"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamaguchi</surname><given-names>H</given-names></name><name><surname>Hendrickson</surname><given-names>WA</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation</article-title><source>Nature</source><volume>384</volume><fpage>484</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1038/384484a0</pub-id><pub-id pub-id-type="pmid">8945479</pub-id></element-citation></ref><ref id="bib140"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Bhatt</surname><given-names>T</given-names></name><name><surname>Dickler</surname><given-names>M</given-names></name><name><surname>Giri</surname><given-names>D</given-names></name><name><surname>Scaltriti</surname><given-names>M</given-names></name><name><surname>Baselga</surname><given-names>J</given-names></name><name><surname>Rosen</surname><given-names>N</given-names></name><name><surname>Chandarlapaty</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence</article-title><source>Oncogene</source><volume>36</volume><fpage>2255</fpage><lpage>2264</lpage><pub-id pub-id-type="doi">10.1038/onc.2016.379</pub-id><pub-id pub-id-type="pmid">27748766</pub-id></element-citation></ref><ref id="bib141"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>SW</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Ni</surname><given-names>W</given-names></name><name><surname>Fu</surname><given-names>DA</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Kaye</surname><given-names>FJ</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Role of INSL4 signaling in sustaining the growth and viability of LKB1-inactivated lung cancer</article-title><source>JNCI</source><volume>111</volume><fpage>664</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1093/jnci/djy166</pub-id></element-citation></ref><ref id="bib142"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>Z</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Su</surname><given-names>W</given-names></name><name><surname>Yaeger</surname><given-names>R</given-names></name><name><surname>Tao</surname><given-names>J</given-names></name><name><surname>Na</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Rymar</surname><given-names>A</given-names></name><name><surname>Tao</surname><given-names>A</given-names></name><name><surname>Timaul</surname><given-names>NM</given-names></name><name><surname>Mcgriskin</surname><given-names>R</given-names></name><name><surname>Outmezguine</surname><given-names>NA</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Chang</surname><given-names>Q</given-names></name><name><surname>Qeriqi</surname><given-names>B</given-names></name><name><surname>Barbacid</surname><given-names>M</given-names></name><name><surname>de Stanchina</surname><given-names>E</given-names></name><name><surname>Hyman</surname><given-names>DM</given-names></name><name><surname>Bollag</surname><given-names>G</given-names></name><name><surname>Rosen</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling</article-title><source>Nature Medicine</source><volume>25</volume><fpage>284</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1038/s41591-018-0274-5</pub-id></element-citation></ref><ref id="bib143"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yarbrough</surname><given-names>WG</given-names></name><name><surname>Buckmire</surname><given-names>RA</given-names></name><name><surname>Bessho</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>ET</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Biologic and biochemical analyses of p16INK4a mutations from primary tumors</article-title><source>JNCI Journal of the National Cancer Institute</source><volume>91</volume><fpage>1569</fpage><lpage>1574</lpage><pub-id pub-id-type="doi">10.1093/jnci/91.18.1569</pub-id></element-citation></ref><ref id="bib144"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeon</surname><given-names>JH</given-names></name><name><surname>Heinkel</surname><given-names>F</given-names></name><name><surname>Sung</surname><given-names>M</given-names></name><name><surname>Na</surname><given-names>D</given-names></name><name><surname>Gsponer</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Systems-wide identification of cis-regulatory elements in proteins</article-title><source>Cell Systems</source><volume>2</volume><fpage>89</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/j.cels.2016.02.004</pub-id><pub-id pub-id-type="pmid">27135163</pub-id></element-citation></ref><ref id="bib145"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>Q</given-names></name><name><surname>Sicinska</surname><given-names>E</given-names></name><name><surname>Geng</surname><given-names>Y</given-names></name><name><surname>Ahnström</surname><given-names>M</given-names></name><name><surname>Zagozdzon</surname><given-names>A</given-names></name><name><surname>Kong</surname><given-names>Y</given-names></name><name><surname>Gardner</surname><given-names>H</given-names></name><name><surname>Kiyokawa</surname><given-names>H</given-names></name><name><surname>Harris</surname><given-names>LN</given-names></name><name><surname>Stål</surname><given-names>O</given-names></name><name><surname>Sicinski</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Requirement for CDK4 kinase function in breast cancer</article-title><source>Cancer Cell</source><volume>9</volume><fpage>23</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2005.12.012</pub-id></element-citation></ref><ref id="bib146"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeqiraj</surname><given-names>E</given-names></name><name><surname>Filippi</surname><given-names>BM</given-names></name><name><surname>Deak</surname><given-names>M</given-names></name><name><surname>Alessi</surname><given-names>DR</given-names></name><name><surname>van Aalten</surname><given-names>DMF</given-names></name></person-group><year iso-8601-date="2009">2009a</year><article-title>Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation</article-title><source>Science</source><volume>326</volume><fpage>1707</fpage><lpage>1711</lpage><pub-id pub-id-type="doi">10.1126/science.1178377</pub-id><pub-id pub-id-type="pmid">19892943</pub-id></element-citation></ref><ref id="bib147"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeqiraj</surname><given-names>E</given-names></name><name><surname>Filippi</surname><given-names>BM</given-names></name><name><surname>Goldie</surname><given-names>S</given-names></name><name><surname>Navratilova</surname><given-names>I</given-names></name><name><surname>Boudeau</surname><given-names>J</given-names></name><name><surname>Deak</surname><given-names>M</given-names></name><name><surname>Alessi</surname><given-names>DR</given-names></name><name><surname>van Aalten</surname><given-names>DMF</given-names></name></person-group><year iso-8601-date="2009">2009b</year><article-title>ATP and MO25alpha regulate the conformational state of the STRADalpha pseudokinase and activation of the LKB1 tumour suppressor</article-title><source>PLOS Biology</source><volume>7</volume><elocation-id>e1000126</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.1000126</pub-id><pub-id pub-id-type="pmid">19513107</pub-id></element-citation></ref><ref id="bib148"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>PL</given-names></name><name><surname>Gray</surname><given-names>NS</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Targeting cancer with small molecule kinase inhibitors</article-title><source>Nature Reviews Cancer</source><volume>9</volume><fpage>28</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1038/nrc2559</pub-id></element-citation></ref><ref id="bib149"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>JZ</given-names></name><name><surname>Lu</surname><given-names>T-W</given-names></name><name><surname>Stolerman</surname><given-names>LM</given-names></name><name><surname>Tenner</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>JR</given-names></name><name><surname>Zhang</surname><given-names>J-F</given-names></name><name><surname>Falcke</surname><given-names>M</given-names></name><name><surname>Rangamani</surname><given-names>P</given-names></name><name><surname>Taylor</surname><given-names>SS</given-names></name><name><surname>Mehta</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Phase Separation of a PKA regulatory subunit controls cAMP compartmentation and oncogenic signaling</article-title><source>Cell</source><volume>182</volume><fpage>1531</fpage><lpage>1544</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.07.043</pub-id></element-citation></ref><ref id="bib150"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Maloney</surname><given-names>R</given-names></name><name><surname>Jang</surname><given-names>H</given-names></name><name><surname>Nussinov</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The mechanism of Raf activation through dimerization</article-title><source>Chemical Science</source><volume>12</volume><fpage>15609</fpage><lpage>15619</lpage><pub-id pub-id-type="doi">10.1039/D1SC03444H</pub-id></element-citation></ref><ref id="bib151"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zubiete-Franco</surname><given-names>I</given-names></name><name><surname>García-Rodríguez</surname><given-names>JL</given-names></name><name><surname>Lopitz-Otsoa</surname><given-names>F</given-names></name><name><surname>Serrano-Macia</surname><given-names>M</given-names></name><name><surname>Simon</surname><given-names>J</given-names></name><name><surname>Fernández-Tussy</surname><given-names>P</given-names></name><name><surname>Barbier-Torres</surname><given-names>L</given-names></name><name><surname>Fernández-Ramos</surname><given-names>D</given-names></name><name><surname>Gutiérrez-de-Juan</surname><given-names>V</given-names></name><name><surname>López de Davalillo</surname><given-names>S</given-names></name><name><surname>Carlevaris</surname><given-names>O</given-names></name><name><surname>Beguiristain Gómez</surname><given-names>A</given-names></name><name><surname>Villa</surname><given-names>E</given-names></name><name><surname>Calvisi</surname><given-names>D</given-names></name><name><surname>Martín</surname><given-names>C</given-names></name><name><surname>Berra</surname><given-names>E</given-names></name><name><surname>Aspichueta</surname><given-names>P</given-names></name><name><surname>Beraza</surname><given-names>N</given-names></name><name><surname>Varela-Rey</surname><given-names>M</given-names></name><name><surname>Ávila</surname><given-names>M</given-names></name><name><surname>Rodríguez</surname><given-names>MS</given-names></name><name><surname>Mato</surname><given-names>JM</given-names></name><name><surname>Díaz-Moreno</surname><given-names>I</given-names></name><name><surname>Díaz-Quintana</surname><given-names>A</given-names></name><name><surname>Delgado</surname><given-names>TC</given-names></name><name><surname>Martínez-Chantar</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>SUMOylation regulates LKB1 localization and its oncogenic activity in liver cancer</article-title><source>EBioMedicine</source><volume>40</volume><fpage>406</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2018.12.031</pub-id><pub-id pub-id-type="pmid">30594553</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.94755.3.sa0</article-id><title-group><article-title>eLife assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Dötsch</surname><given-names>Volker</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Goethe University</institution><country>Germany</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group></front-stub><body><p>This article reports an <bold>important</bold> bioluminescence-based reporter system to evaluate kinase conformations. This assay is applied to four different kinases that have unique, very special regulatory features, thereby indicating that the assay can be used to provide <bold>convincing</bold> evidence on the conformational state of a large number of kinases. This paper will be of interest to researchers working on kinases and their conformational states.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.94755.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>This technical report by Kugler at al., expands the application of a fluorescence-based reporter to study the conformational state of various kinases. This reporter, named KinCon (Kinase Conformation), interrogates the conformational state of a kinase (i.e., active vs. inactive) based on engineering complementary fusion proteins that fluoresce upon interaction. This assay has several advantages as it allows studying full-length kinases, that is, the kinase domain and regulatory domains, inside the cell and under various experimental conditions such as the presence of inhibitors or activator proteins, and in wildtype and mutants involved in disease states.</p><p>Strengths:</p><p>One major strength of this study is that it is quite comprehensive. The authors use KinCon for four different kinases, BRAF, LKB1, RIP and CDK4/6. These kinases have very different regulatory elements and associated proteins, which the authors explore to study their conformational state. Moreover, they use small molecule inhibitors or mutations to further dissect how the conformational state of the kinase in disease states. The collective set of results strongly suggests that KinCon is a versatile tool that can be used to study many kinases of biomedical and fundamental importance. Given that kinases are extensively studied by researchers in academia or industry, KinCon could have a broad impact as well.</p><p>Weaknesses:</p><p>This manuscript, however, also has several weaknesses that I outline below. These weaknesses decrease the overall level of impact on the manuscript, as is.</p><p>• The manuscript is exceedingly long. For instance, the introduction provides background information for each kinase that is further expanded in the results section. I think the background information for each kinase in the Introduction and Results sections can be significantly reduced to highlight the major points. Otherwise, not only does the manuscript become too long, but also the main points get diluted.</p><p>• Similarly, the figure legends are very long, providing information that is already in the main text or in Methods. The authors should provide the essential information to understand the figure.</p><p>• A major concern throughout the manuscript is the use of the word &quot;dynamics,&quot; which is used in the text in various contexts. The authors should clarify what they understand for dynamics of conformation. Are they measuring how the time-dependent process by which the kinase is interconverting between active and inactive states? It seems to me that the assays in this report evaluate a population of kinases that are in an open or close conformation (i.e., a particular state in each experimental condition) but there is not direct information how the kinase goes from one state to the other. In that sense, the use of dynamics is unclear. Also, the use of dynamics in different sentences in ambiguous. Here are a few examples but this should be revised throughout the manuscript:</p><p>- Line 27: dynamics of full-length protein kinases. Is this referred to dynamics of conformational interconversion between inactive and active states?</p><p>- Line 138: dynamic functioning of kinases. No clear what that means.</p><p>- Line 276: ... alters KinCon dynamics. Not clear if they are measuring time-dependent process or a single point.</p><p>- Figure legend 4F: dynamics of CDK4/6 reporters. Again, not clear how the assay is measuring dynamics.</p><p>Nonetheless, in my opinion the authors use proper terminology that describes their assay in which the term dynamics is not used: Title (... impact of protein and small molecule interactions on kinase conformations) and Line 89 (... reporter can be used to track conformational changes of kinases...)</p><p>• The authors use the phrase that KinCon has predictive capabilities (abstract and line 142). What do the authors refer to this?</p><p>• The authors indicate that KinCon is a highly sensitive assay. Can the authors elaborate on what high sensitivity means? For example, can they discuss how other fluorescence-based approaches that are less sensitive would not be able to accomplish the same type of results or derive similar conclusions? Can they provide a resolution metric both in space and time? Given that the authors state that this is a technical report, this information is of relevance.</p><p>• The authors nicely describe how KinCon works in Figure 1B and part of 1C. I do think that the bottom of panel 1C needs to be revised, as well as the text describing the potential scenarios of potency, efficacy and synergism.</p><p>- One issue with this part of Figure 1C is that it is not clear what the x-axis in the 3 plots refer to. Is this time? Is this concentration of a small molecule, inhibitor or binding partner? This was confusing also in the context of the term dynamics used throughout the text. The terms potency, efficacy and synergism should be subtitles or the panels and the x-axis should be better defined, especially for a non-specialized reader.</p><p>- Related to this part of Figure 1C is the text. The authors mention potency, effectiveness and synergy (Line 195). Can the authors use more fundamental terminology related to these three scenarios, for example, changes in activation constant, percent of protein activates? Also, why synergy is only related to effectiveness? Can synergy also be associated to potency?</p><p>- Lastly, the use of these three cartoons gives the impression that the experimental results to come will follow a similar representation. Instead, the results are presented in bar plots for many different conditions. I think this will lead to confusion for a broad audience.</p><p>• For a non-expert reader, can the authors clarify the use of tracking basal conformations vs. transient over-expression of the various KinCon constructs? Moreover, the authors use the term transient over-expression for 10, 16, 24 and 48 h (Line 203). This, to a non-expert reader, seems not transient.</p><p>• Regarding Figure 1E and similar graphical representations: Why is the signal (RLU) non-linear with time? If the fluorescence of the KinCon construct is linearly related with its expression or concentration inside the cell, one would expect a linear increase. Have the authors plotted RLU/Expression band intensity to account for changes in protein concentration? For instance, some of the results within Figure 3 are normalized to concentration on the reporter expression level.</p><p>• For the results with LKB1, the authors claim that intermediate fold change in fluorescence (Figure 2E) is due to a partially closed intermediate state (Line 262). Can the authors discard the possibility by which there is a change in populations of active and inactive that on average give intermediate values?</p><p>• The authors claim in Line 274 that mutations located at the interface of the LKB1/STRADalkpha complex affect interactions and hypothesize that allosteric communication between LKB1 and STRADalpha is essential for function. Given that this mutations are at the interaction interface, why would the authors postulate an allosteric mechanism that evokes an effect distant to the interaction/active site? Could it be that function requires surface contacts alone that are disrupted by the mutations?</p><p>• I was unable to find text to explain the following: Figure 2I shows the mutation R74A as n.s., but in the text only W308C is mentioned to not change fluorescence. Could the authors clarify why R74A is not discussed in the text? Maybe this reviewer missed the text in which it was discussed. Similarly, the author states in line 326 that the study included an analysis of RIPK2. However, I was unable to find results, graphs or additional text discussing RIPK2.</p><p>• Some figures of RLU use absolute values, percentages and fold change. Is there a reason why the authors use different Y-axis values? These should be explained and justified in Methods. Similarly, bars for wt in Figures 3D, G, or 4D, E,F show no errors. How are the authors normalizing the data and repeats so that there is no error, and are they treating the rest of the data (i.e., mutants and/or treated with small molecules) in the same way?</p><p>• Lastly, the section starting in Line 472 reads more like a discussion of results from different type of inhibitors used in this study that results on its own. The authors should consider a new subtitle as results or make this section a discussion.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.94755.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>Protein kinases have been very successfully targeted with small molecules for several decades, with many compounds (including clinical drugs) bringing about conformational changes that are also relevant to broader interactions with the cellular signaling networks that they control. The authors set out to develop a targeted biosensor approach to evaluate distinct kinase conformations in cells for multiple kinases in the context of incoming signals, other proteins and small molecule binding, with a broad goal of using the KinCon assay to confirm (and perhaps predict) how drug binding or signal perception changes conformations and outputs in the presence of cellular complexes; this work will likely impact on the field with cellular reporters of kinase conformations a useful addition to the toolbox.</p><p>Strengths:</p><p>The KinCon reporter platform has previously been validated for well-known kinases; in this study, the team evaluate how to employ a full-length kinase (often containing a known pathological mutation). The sensitive detection method is based on a Renilla luciferase (RLuc)protein fragment complementation assay, where individual RLuc fragments are present at the N and the C terminus of the kinase. This report, which is both technical and practical in nature, co-expresses the kinase with known interactors (at low levels) in a high throughput format and then performs pharmacological evaluation with known small molecule kinase modulators. This is explained nicely in Figure 1, as are the signaling pathways that are being evaluated. Data demonstrate that V600E BRAF iexposed to vemurafenib is converted to the inactive conformation, as expected. In contrast, the more closed STRADα and LKB1 KinCon conformations appear to represent the more active state of the complexed kinase, and a W308C mutation (evaluated alongside others) reverses this effect. The authors then evaluated necroptotic signaling in the context of RIPK1/3 under conditions where RIPK1 and RIPK3 are active, confirming that the reporters highlight the active states of both kinases. Exposure to compounds that are known to engage with the RIPK1 arm of the pathway induce bioluminescence changes consistent with the opening (inactivation) of the kinase. Finally, the authors move to an important drug target for which clinical drugs have arrived relatively recently; the CDK4/6 complexes. These are of additional importance because kinase-independent functions also exist for CDK6, and the effects of drugs in cells usually relies on a downstream marker, rather than demonstration of direct protein complex engagement. The data presented are interpreted as the formation of complexes with the CDK inhibitor p16INK4a; reducing the affinity of the interaction through mutations drives an inactive conformation, whilst the application of CDK4/6 inhibitors does not, implying binding to the active conformation.</p><p>Weaknesses:</p><p>(1) The work is very solid, and uses examples from the literature and also extends into new experimental space. An obvious weakness is mentioned by the authors for the CKDK data, in that measurements with Cyclin D (the activating subunit) are not characterised, although Cyclin D might be assumed to be present?</p><p>(2) The work with the trimeric LKB1 complex involves pseudokinase, STRADalpha, whose conformation is also examined as a function of LKB1 status; since STRAD is an activator of LKB1, a future goal should be the evaluation of the complex in the presence of STRAD inhibitory/activating small molecules.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.94755.3.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kugler</surname><given-names>Valentina</given-names></name><role specific-use="author">Author</role><aff><institution>University of Innsbruck</institution><addr-line><named-content content-type="city">Innsbruck</named-content></addr-line><country>Austria</country></aff></contrib><contrib contrib-type="author"><name><surname>Schwaighofer</surname><given-names>Selina</given-names></name><role specific-use="author">Author</role><aff><institution>University of Innsbruck</institution><addr-line><named-content content-type="city">Innsbruck</named-content></addr-line><country>Austria</country></aff></contrib><contrib contrib-type="author"><name><surname>Feichtner</surname><given-names>Andreas</given-names></name><role specific-use="author">Author</role><aff><institution>University of Innsbruck</institution><addr-line><named-content content-type="city">Innsbruck</named-content></addr-line><country>Austria</country></aff></contrib><contrib contrib-type="author"><name><surname>Enzler</surname><given-names>Florian</given-names></name><role specific-use="author">Author</role><aff><institution>Innsbruck Medical University</institution><addr-line><named-content content-type="city">Innsbruck</named-content></addr-line><country>Austria</country></aff></contrib><contrib contrib-type="author"><name><surname>Fleischmann</surname><given-names>Jakob</given-names></name><role specific-use="author">Author</role><aff><institution>Tyrolean Cancer Research Institute</institution><addr-line><named-content content-type="city">Innsbruck</named-content></addr-line><country>Austria</country></aff></contrib><contrib contrib-type="author"><name><surname>Strich</surname><given-names>Sophie</given-names></name><role specific-use="author">Author</role><aff><institution>University of Innsbruck</institution><addr-line><named-content content-type="city">Innsbruck</named-content></addr-line><country>Austria</country></aff></contrib><contrib contrib-type="author"><name><surname>Schwarz</surname><given-names>Sarah</given-names></name><role specific-use="author">Author</role><aff><institution>Tyrolean Cancer Research Institute</institution><addr-line><named-content content-type="city">Innsbruck</named-content></addr-line><country>Austria</country></aff></contrib><contrib contrib-type="author"><name><surname>Wilson</surname><given-names>Rebecca</given-names></name><role specific-use="author">Author</role><aff><institution>Institute of Cancer Research</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Tschaikner</surname><given-names>Philipp</given-names></name><role specific-use="author">Author</role><aff><institution>Tyrolean Cancer Research Institute</institution><addr-line><named-content content-type="city">Innsbruck</named-content></addr-line><country>Austria</country></aff></contrib><contrib contrib-type="author"><name><surname>Troppmair</surname><given-names>Jakob</given-names></name><role specific-use="author">Author</role><aff><institution>Innsbruck Medical University</institution><addr-line><named-content content-type="city">Innsbruck</named-content></addr-line><country>Austria</country></aff></contrib><contrib contrib-type="author"><name><surname>Sexl</surname><given-names>Veronika</given-names></name><role specific-use="author">Author</role><aff><institution>University of Innsbruck</institution><addr-line><named-content content-type="city">Innsbruck</named-content></addr-line><country>Austria</country></aff></contrib><contrib contrib-type="author"><name><surname>Meier</surname><given-names>Pascal</given-names></name><role specific-use="author">Author</role><aff><institution>The Institute of Cancer Research</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Kaserer</surname><given-names>Teresa</given-names></name><role specific-use="author">Author</role><aff><institution>University of Innsbruck</institution><addr-line><named-content content-type="city">Innsbruck</named-content></addr-line><country>Austria</country></aff></contrib><contrib contrib-type="author"><name><surname>Stefan</surname><given-names>Eduard</given-names></name><role specific-use="author">Author</role><aff><institution>University of Innsbruck</institution><addr-line><named-content content-type="city">Innsbruck</named-content></addr-line><country>Austria</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><p>We would like to thank you and the two Reviewers for the thoughtful evaluation of the manuscript and the support for publication. We have addressed all points raised by the two Reviewers.</p><p>- We have extensively streamlined the manuscript. Repetitive passages regarding the respective kinase cascades have been removed.</p><p>- We improved the presentation of the main Figures (mainly labeling and font size):</p><p>- Figure 1: C, D, E, F o Figure 2: C, E, F, G, I, o Figure 3: D o Figure 4: F</p><p>- Figure 5: A, B, C, D, E</p><p>- We integrated new SI-data related to kinase functions, expression and the ‘cell-type comparisons’ of the KinCon reporter system (Figure Supplement 4, 5).</p><p>Below you will find a detailed point-by-point response.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Recommendations For The Authors):</bold></p><p>Regarding the issue of the use of the word &quot;dynamics,&quot; as described in the public review, here are a few examples of ambiguous use in different sentences: o Line 27: dynamics of full-length protein kinases. Is this referring to the dynamics of conformational interconversion between inactive and active states?</p><p>- Line 138: dynamic functioning of kinases. It is not clear what this means. o Line 276: ... alters KinCon dynamics. Not clear if they are measuring time-dependent process or a single point.</p><p>- Figure legend 4F: dynamics of CDK4/6 reporters. Again, not clear how the assay is measuring dynamics.</p><p>In my opinion, the authors use proper terminology that describes their assay in which the term dynamics is not used: Title: &quot;... impact of protein and small molecule interactions on kinase conformations&quot; and Line 89 &quot;... reporter can be used to track conformational changes of kinases...&quot;.</p></disp-quote><p>We have replaced the “dynamics” sections.</p><p>- Line 27: The understanding of the structural dynamics of…</p><p>- Line 91: This reporter can be used to track dynamic changes of kinases conformations…</p><p>- Line 139: Conventional methods often fall short in capturing the dynamics of kinases within their native cellular environments…</p><p>- Line 146: Such insights into the molecular structure dynamics of kinases in intact cells…</p><p>- Line 199: In order to enhance our understanding of kinase structure dynamics…</p><p>- Line 276: These findings underline that indeed the trimeric complex formation alters….</p><p>- Figure Legend 4F: Quantification of alterations of CDK4/6 KinCon reporter bioluminescence signals…</p><disp-quote content-type="editor-comment"><p>The authors state that KinCon has predictive capabilities (abstract and line 142). What do the authors mean by this?</p></disp-quote><p>Previously we have benchmarked the suitability of the KinCon reporter for target engagement assays of wt and mutated kinase activities. With this we determined specificities of melanoma drugs for mutated BRAF variants (Mayrhofer 2020, PNAS).</p><disp-quote content-type="editor-comment"><p>The authors indicate that KinCon is a highly sensitive assay. Can the authors elaborate on what high sensitivity means?</p></disp-quote><p>With sensitivity we mean that we can detect conformation dynamics of the reporter at low expression levels of the hybrid protein expressed in the cell line of choice.</p><p>- Line 209: Immunoblotting of cell lysates following luminescence measurements showed expression levels of the reporters in the range and below the endogenous expressed kinases (Figure 1E). …</p><p>- Line 219: Using this readout, we showed that at expression levels of the BRAF KinCon reporter below the immunoblotting detection limit, one hour of drug exposure exclusively converted BRAF-V600E to the more closed conformation (Figure 1F, G, Figure Supplement 1B).</p><p>- Line 221: These data underline that at expression levels far below the endogenous kinase, protein activity conformations can be tracked in intact cells. …</p><disp-quote content-type="editor-comment"><p>For example, can they discuss how other fluorescence-based approaches that are less sensitive would not be able to accomplish the same type of results or derive similar conclusions? Can they provide a resolution metric both in space and time? Given that the authors state that this is a technical report, this information is of relevance.</p></disp-quote><p>We highlight the key pros &amp; cons of the KinCon reporter technology in following sections:</p><p>-Line 529: The KinCon technology, introduced here, seeks to address the previously mentioned challenges. It has the potential to become a valuable asset for tracking kinase functions in living cells which are hard to measure solely via phosphotransferase activities. Overall, it offers an innovative solution for understanding kinase activity conformations, which could pave the way for more novel intervention strategies for kinase entities with limited pharmaceutical targeting potential. So far, this relates to the tracking of kinase-scaffold and pseudo-kinase functions.</p><p>- Line 535: Key advantages of the KinCon reporter technology is the robustness of the system to track kinase conformations at varying expression levels. However, in contrast to fluorescence-based reporter read-outs subcellular analysis and cell sorting are still challenging due to comparable low levels of light emission</p><disp-quote content-type="editor-comment"><p>The authors nicely describe how KinCon works in Figure 1B and part of 1C. I do think that the bottom of panel 1C needs to be revised, as well as the text describing the potential scenarios of potency, efficacy, and synergism.</p><p>One issue with this part of Figure 1C is that it is not clear what the x-axis in the 3 plots refers to. Is this time? Is this concentration of a small molecule, inhibitor, or binding partner? This was confusing also in the context of the term dynamics used throughout the text. The terms potency, efficacy, and synergism should be subtitles, or the panels and the x-axis should be better defined, especially for a non-specialized reader.</p><p>Related to this part of Figure 1C is the text. The authors mention potency, effectiveness, and synergy (Line 195). Can the authors use more fundamental terminology related to these three scenarios, for example, changes in activation constant, and percent of protein activates? Also, why synergy is only related to effectiveness? Can synergy also be associated with potency?</p></disp-quote><p>Thank you for bringing this up, we have revised Figure 1C to better reflect the mentioned effects of potency. To avoid confusion, we removed the illustration for drug synergism. Accordingly, we have integrated the axis descriptions for the presented dose-response curves.</p><p>Thus, we have further streamlined the text in the introduction – examples are shown below:</p><p>- Line 195: Light recordings and subsequent calculations of time-dependent dosage variations of bioluminescence signatures of parallel implemented KinCon configurations aid in establishing dose-response curves. These curves are used for discerning pharmacological characteristics such as drug potency, effectiveness of drug candidates, and potential drug synergies (Figure 1C)</p><p>- Figure 1C: Shown is the workflow for the KinCon reporter construct engineering and analyses using KinCon technology. The kinase gene of interest is inserted into the multiple cloning site of a mammalian expression vector which is flanked by respective PCA fragments (-F[1], -F[2]) and separated with interjacent flexible linkers. Expression of the genetically encoded reporter in indicated multi-well formats allows to vary expression levels and define a coherent drug treatment plan. Moreover, it is possible to alter the kinase sequence (mutations) or to co-express or knock-down the respective endogenous kinase, interlinked kinases or proteinogenic regulators of the respective pathway. After systematic administration of pathway modulating drugs or drug candidates, analyses of KinCon structure dynamics may reveal alterations in potency, efficacy, and potential synergistic effects of the tested bioactive small molecules (schematic dose response curves are depicted)</p><disp-quote content-type="editor-comment"><p>Lastly, the use of these three cartoons gives the impression that the experimental results to come will follow a similar representation. Instead, the results are presented in bar plots for many different conditions. I think this will lead to confusion for a broad audience.</p></disp-quote><p>The bottom panel of Figure 1C is not the depiction of real experiments but rather an illustration of fitted dose-response curves. We would like to present previous demonstrations of doseresponse curves using BRAF KinCon data and ERK phosphorylation (Röck 2019, Sci. Advances)</p><p>We further agree with the reviewer and have therefore added a new part in the methods section addressing the evaluation of data extensively.</p><p>- Line 668: In Figure 1 E and F, a representative experiment of n=4 independent experiments is shown. In these cases, absolute bioluminescence values without any normalization are shown. Otherwise, data was indicated as RLU (relative light unit) fold change. This means the data was normalized on the indicated control condition either with normalization of the western blot or without; as indicated.</p><disp-quote content-type="editor-comment"><p>For a non-expert reader, can the authors clarify the use of tracking basal conformations vs. transient over-expression of the various KinCon constructs? Moreover, the authors use the term transient over-expression for 10, 16, 24, and 48 h (Line 203). This, to a non-expert reader, does not seem transient.</p></disp-quote><p>We have revised the manuscript to clarify it:</p><p>- Line 207: We showed that transient over-expression of these KinCon reporters for a time frame of 10h, 16h, 24h or 48h in HEK293T cells delivers consistently increasing signals for all KinCon reporters (Figure 1E, Figure Supplement 1A).</p><p>- Figure 1E Representative KinCon experiments of time-dependent expressions of indicated KinCon reporter constructs in HEK293T cells are shown (mean ± SEM). Indicated KinCon reporters were transiently over-expressed in 24-well format in HEK293T cells for 10h, 16h, 24h and 48h each.</p><disp-quote content-type="editor-comment"><p>Regarding Figure 1E and similar graphical representations: Why is the signal (RLU) nonlinear with time? If the fluorescence of the KinCon construct is linearly related to its expression or concentration inside the cell, one would expect a linear increase. Have the authors plotted RLU/Expression band intensity to account for changes in protein concentration? For instance, some of the results within Figure 3 are normalized to concentration on reporter expression level.</p></disp-quote><p>Out intention was to show that varying expression levels can be used for the illustrated target engagement assays.Indeed, the represented elevations of RLU might be due to factors such as:</p><p>- Doubling times of cells</p><p>- Cell density</p><p>- Media composition (which changes over time)</p><p>- Reporter protein stabilities</p><p>- Abundance of interactors of kinases</p><disp-quote content-type="editor-comment"><p>For the results with LKB1, the authors claim that intermediate fold change in fluorescence (Figure 2E) is due to a partially closed intermediate state (Line 262). Can the authors discard the possibility by which there is a change in populations of active and inactive that on average give intermediate values?</p></disp-quote><p>Based on our experience with KinCon reporter conformation states of kinases we tested so far, we assume that the presented data reflects an intermediate state. We agree that it needs further validation. We have changed the text accordingly:</p><p>- Line 264: Upon interaction with LKB1 this conformation shifts to a partially closed intermediate state.</p><disp-quote content-type="editor-comment"><p>The authors claim in Line 274 that mutations located at the interface of the LKB1/STRADalpha complex affect interactions and hypothesize that allosteric communication between LKB1 and STRADalpha is essential for function. Given that these mutations are at the interaction interface, why would the authors postulate an allosteric mechanism that evokes an effect distant from the interaction/active site? Could it be that function requires surface contacts alone that are disrupted by the mutations?</p></disp-quote><p>We agree with the reviewer and changed our argumentation for this point:</p><p>- Line 276: These findings underline that indeed the trimeric complex formation alters the opening and closing of the tested full-length kinase structures using the applied KinCon reporter read out</p><disp-quote content-type="editor-comment"><p>I was unable to find text to explain the following: Figure 2I shows the mutation R74A as n.s., but in the text, only W308C is mentioned to not change fluorescence. Could the authors clarify why R74A is not discussed in the text? Maybe this reviewer missed the text in which it was discussed.</p></disp-quote><p>We adapted the manuscript and include the R74A mutation as followed:</p><p>- Line 296: Among these mutations, only the W308C and R74A mutation prevented significant closing of the LKB1 conformation when co-expressed with STRADα and MO25 (Figure 2I).</p><p>In Figure 2I where the individual measurements of the LKB1-R74A KinCon are highlighted in red to better emphasize the deviations. In the case of the R74A mutation the effect seen might be due to the high deviation between the experiments (Highlighted in red). These deviations are much higher when compared to either the wt or the W308 mutant, and can also be seen in the LKB1-R74A-KinCon only condition (white). Even though no significant closing of the LKB1 conformation could be observed in the case of R74A, we believe, since the trend of the conformation closing upon complex formation is still visible that the effect is still there. Further replicates would be necessary to validate this theory.</p><disp-quote content-type="editor-comment"><p>Similarly, the authors state in line 326 that the study included an analysis of RIPK2. However, I was unable to find results, graphs, or additional text discussing RIPK2.</p></disp-quote><p>The RIPK2 conformation was analyzed in Figure 3C (page 12).</p><disp-quote content-type="editor-comment"><p>Some figures of RLU use absolute values, percentages, and fold change. Is there are reason why the authors use different Y-axis values? These should be explained and justified in Methods. Similarly, bars for wt in Figures 3D, G, or 4D, E, F show no errors. How are the authors normalizing the data and repeats so that there is no error, and are they treating the rest of the data (i.e., mutants and/or treated with small molecules) in the same way?</p></disp-quote><p>We have changed the Y-axis values. Now, throughout the manuscript we show that there is a RLU fold-change. Except are selected experiments when solely absolute RLU values are shown (such as Figure 1E, F). We have also decided to integrate a paragraph into the methods section (Line 655). Figure 3D was changed as well.</p><p>- Line 668: In Figure 1 E and F, a representative experiment of n=4 independent experiments is shown. In these cases absolute bioluminescence values without any normalisation are shown. Otherwise, data was indicated as RLU fold change. This means the data was normalized on the indicated control condition (either with normalization of the western blot or without; as indicated).</p><p>The data is generally normalized on wt or untreated conditions, when the cells were treated with small molecules for target engagement assays.</p><disp-quote content-type="editor-comment"><p>Lastly, the section starting in Line 472 reads more like a discussion of results from different types of inhibitors used in this study that results on its own. The authors should consider a new subtitle such as results or make this section a discussion.</p></disp-quote><p>We agree with the reviewer and this part of the results was split into a new section of the result:</p><p>- Line 455: “Effect of different kinase inhibitor types on the KinCon reporter system”.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p><p>I have a few suggestions, since the paper is a distillation of a vast amount of work and tells a useful story.</p><p>(1) The work is very solid, uses examples from the literature, and also extends into new experimental space. An obvious weakness is mentioned by the authors for the CKD data, in that measurements with Cyclin D (the activating subunit) are not characterized, although Cyclin D might be assumed to be present.</p></disp-quote><p>We performed experiments with the CDK4/6 KinCon reporters and co-expressed CyclinD with a ratio of 1:3 (HEK293T cells, expression for 48h). However, in the context of inhibitor treatments we could not track conformation changes in these initial experiments. The cells were treated with the indicated CDK4/6i [1µM] for 3h. This seems to not impact the conformation of CDK4/6 wt or mutated KinCon reporters. There is a tendency that CyclinD co-expression promotes CDK4/6 conformation opening (data not shown).</p><fig id="sa3fig1" position="float"><label>Author response image 1.</label><caption><title>Bioluminescence signal of CDK4/6 KinCon reporters with co-expressed CyclinD3 (HEK293T, expression for 48h) upon exposure to indicated CDK4/6i [1µM] or DMSO for 3h (mean ± SEM, n=3 ind. experiments).</title><p>No significant changes using the current setting.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-94755-sa3-fig1-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>(2) The work with the trimeric LKB1 complex involves pseudokinase, STRADalpha, whose conformation is also examined as a function of LKB1 status; since STRAD is an activator of LKB1. A future goal should be the evaluation of the complex in the presence of STRAD inhibitory/activating small molecules.</p></disp-quote><p>Thank you for this great idea, we are currently compiling a FWF grant application to get support for such a R&amp;D project.</p><disp-quote content-type="editor-comment"><p>Minor points</p><p>• Have any of the data been repeated in a different cell background? This came to mind because HeLa cells lack LKB1, which might be a useful place to test the LKB1 data in a different context.</p></disp-quote><p>This experiment was performed and we show it in Figure Supplement 5. Further, we followed the advice of the reviewer and performed suggested experiments. We integrated the colon cancer cell line SW480 into the experimental setup. Overall, three cell settings showed the same pattern of KinCon reporter analyses for LKB1-STRADα-MO25 complex formation utilizing the LKB1- and STRADα-KinCon reporters.</p><disp-quote content-type="editor-comment"><p>• The study picks up the PKA Cushings Syndrome field, which makes sense, and data are presented for L206R. PMID 35830806 explains how different patient mutations drive different signaling outcomes through distinct complex formations, and it would be interesting to discuss how mutations in KinCon complexes, especially those with mutations, could affect sub-cellular localization. Could the authors explain if this was done for any of the proteins, whose low experimental expression is a clear advantage, but is presumably hard to maintain across experiments?</p></disp-quote><p>The feedback of the reviewer motivated us to perform subcellular fractionation experiments. They were performed with PKAc wt and L206R KinCon reporters as well as BRAF wt and V600E reporters. We were not able to see major differences between the wt and mutated reporter constructs in respect to their nucleus: cytoplasm localizations (Figure Supplement 4). For your information, in a R+D project with the mitochondrial kinase PINK1 we see localization of the reporter as expected almost exclusively at the mitochondria fraction.</p><p>- Line 495: In this context of activating kinase mutations we showed that using PKAc (wt and L206R) and BRAF (wt and V600E) reporters as example we could not track alterations of cytoplasmic and nuclear localization (Figure Supplement 4). Furthermore, subcellular localization of PKAc KinCon reporters did not change when L206R mutant was introduced (Figure Supplement 4). As a control BRAF wt and V600E KinCon reporters were used and also no changes in localization was observed.</p><disp-quote content-type="editor-comment"><p>• I suggest changing PMs (Figure 2 and others) simply to mutation, I read this as plasma membrane constantly.</p></disp-quote><p>We agree and we have changed it to “patient mutation” in Figure 2C, Figure 3E, Figure 4B.</p></body></sub-article></article>